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Abstract  
Rotavirus is the major enteric pathogen that is responsible for more than 500,000 deaths of children 
worldwide annually. The use of live-attenuated oral rotavirus vaccines has significantly reduced 
child mortality rate in developed countries. However, the situation still remains unacceptably worse 
in most developing countries due to low efficacy of the vaccines in the region. The vaccines often 
do not reach the developing countries due to financial and logistic challenges.   
A high burden of rotavirus disease and the unresolved challenges with the current rotavirus 
vaccines, particularly in developing countries, have ignited efforts to develop next-generation low-
cost, effective and safe vaccine candidates. Virus-like particles (VLPs) have come into focus for 
their promising application in vaccination because of their unique and attractive set of properties 
including safety, self-adjuvanticity, developability, economy and the ability to be formulated for 
stability without a cold chain. Their impact on human health is already evident through 
commercialization of VLP vaccines against hepatitis B virus infection, human papillomavirus-
induced cervical cancer and hepatitis E virus infection. Rotavirus-like particles (RLPs) with proven 
preclinical immunogenicity and protective efficacy are considered as safe and effective vaccine 
candidates. While RLPs comprising multiple viral proteins can be difficult to process, modular 
VLPs presenting rotavirus antigenic modules are promising approaches in reducing process 
complexity and cost. Depending on the physicochemical properties, size and /or surface density of 
modules, modularization may affect production of stable VLP forming subunits, termed 
capsomeres, and prevent VLP assembly. This thesis demonstrates a multipronged approach for a 
low-cost production of  stable bacterially-produced modular murine polyomavirus  capsomeres and 
in vitro assembled VLPs presenting a rotavirus highly conserved peptide epitope (RV10) and a 
conformational and a virus neutralizing 18 kDa antigen (VP8*), separately. The experimental works 
in this thesis were carried out to address challenges associated with the adverse effects of inserted 
module’s physicochemical properties, size and density on the production of modular capsomeres 
and VLPs. Particularly, the expression and purification of stable modular capsomeres for in vitro 
modular VLP assembly and the enhancement of module-specific immune response were 
investigated. The outcomes of the work in this thesis are: (i) a rapid and simple high-throughput 
screening method based on dynamic light scattering measurements was developed to identify 
additives for enhanced stability of modular capsomeres; (ii) using synthetic biology designs, the 
hydrophobicity of RV10 modules was engineered for enhanced stability of modular capsomeres; 
(iii) in vitro assembled modular VLPs displaying RV10 modules were obtained via a module 
titration approach using Escherichia coli protein co-expression strategy; and (iv) highly stable and 
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immunogenic modular VLPs displaying conformational VP8* were produced using a combination 
of Escherichia coli protein co-expression, simplified modular capsomere purification steps and cell-
free in vitro VLP assembly. The outcomes of this thesis expand the potential and plasticity of the 
murine polyomavirus VLP platform for presentation of antigenic modules regardless of their 
adverse physicochemical properties and large size. This work introduces, to the best of our 
knowledge, the first bacterially-produced capsomeres and in vitro assembled VLPs displaying either 
hydrophobic RV10 peptide modules or 18 kDa rotavirus VP8* large antigens. The modular 
capsomeres (CapVP8*) and modular VLPs (VLP-VP8*) induced high levels of VP8*-specific 
antibodies in mice. The high immunogenicity of CapVP8* and VLP-VP8*likely indicates 
protective efficacy and makes them a more viable vaccine candidate for further development to 
prevent rotavirus in the developing world at affordable cost. The strategies developed in this thesis 
potentially provides a cost-effective production route for modular capsomere and VLPs presenting 
other antigenic modules from rotavirus and other target pathogens, highly suitable to manufacturing 
economics for the developing world. 
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Chapter 1 
Project overview 
Children under the age of five years are at an increased risk for factors that cause diseases, deaths 
and disabilities [1,2]. The health of this population age group is a major challenge worldwide 
because it is highly dependent on provision of good health care and proper nutrition [3], and the use 
of safe and effective vaccines [4]. There often remain significant disparities in minimizing risk 
factors and promoting healthy conditions between countries with different levels of  socio-economic 
development [3]. In 2000, the United Nations Millennium Development Goal 4 (MDG4) called for 
reduction of under-five mortality rate by two-thirds between 1990 and 2015 via eradicating diseases 
and promoting health [3,5,6]. Although the world has made substantial progress, childhood 
mortality still remains unacceptably high particularly in developing countries in Africa and South 
Asia (Fig. 1-1) [5,6]. It is estimated that 5.9 million children died globally before age 5 years in 
2015 [6] of which more than 50% died of infectious causes, particularly in low-income developing 
countries in Africa [5,6].  
Diarrhoeal diseases associated with gastrointestinal infections resulting from oral-faecal 
contamination are the second leading cause of childhood mortality worldwide next to pneumonia. 
They caused 9% of the total under-five deaths in 2013 [5,6]. Among the various enteric pathogens, 
rotavirus (RV) was the main causes of diarrhoeal death in children under five in 2013 [7]. It has 
caused nearly 500,000 deaths worldwide in children under 5 years of age every year [5,8]. The 
situation is significantly worse in developing countries in sub-Sahara Africa and South-east Asia 
where more than 80% of the globally recorded deaths in 2008 occurred in the region [8]. 
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Figure 1-1.  Under-five mortality rate and under-five deaths by country. The highest national under-five mortality rates 
are found in sub-Sahara Africa. The figure was adapted from UNICEF´s Progress report 2015 [6]. 
The treatment option for RV infection is limited to oral rehydration therapy to restore and maintain 
hydration until the infection resolves [9]. The availability of limited information on therapeutic 
targets has impeded efforts for RV-specific antiviral drug discovery and development [10].  
Investigators in the field have tried to identify possible targets involved in the replication cycle and 
pathogenesis of different RV strains [10-14]. These targets have been used for in vitro and/or in 
vivo screening of different molecules for RV-specific antiviral activity [10,12-14]. Although the 
results obtained from in vitro antiviral screening using cell culture techniques have been 
encouraging, no chemotherapeutic agent is available to date for treatment of RV infection [11]. 
Thus, vaccination remains the major and primary prophylactic strategy to reduce the morbidity and 
mortality from RV diseases [15-17]. 
The story of RV vaccine development has been a story of starts and stops, of missteps and 
advances, of great success followed by huge disappointments. RotaShieldTM was the first 
multivalent live-attenuated oral reassortant vaccine against RV. It was introduced into the United 
States immunization program in 1998 and then withdrawn immediately as it was associated with 
high risk of intussusception in vaccinated children [15,18]. The experience gained from 
commercialization of RotaShieldTM has broadened understanding of the scientific communities and 
ignited their efforts to discover and develop safe and effective vaccines. In 2006, two live-
attenuated oral RV vaccines, RotaTeq® (Merck) and RotarixTM (GlaxoSmithKline), were licenced 
in most developed countries [16]. The introduction of these vaccines has reduced childhood 
mortality and demonstrated good safety and efficacy profiles in most developed countries [16,18]. 
However, their efficacy in selected low- and middle-income countries was low during clinical trials 
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and post-licensure studies [19]. Moreover, the vaccines often could not reach the developing world 
due to the unresolved financial and logistic challenges [20].  
In consideration of these unresolved challenges and the high demand of RV vaccines in the  
developing world, many investigators are looking for alternative strategies to develop next- 
generation vaccine candidates to address the difficulties including cost of existing vaccine 
preparations. These new vaccine candidates can be developed based on rational design and with 
detailed knowledge of the T-cell and B-cell epitopes [16] and aim to provide an effective weapon 
against RV. Such vaccines may range from recombinant peptides, recombinant fusion and soluble 
proteins, and virus-like particles (VLPs).  Particularly, VLPs have evolved to become a widely 
accepted tool for vaccination because of their high safety and efficacy profile [21], their self-
adjuvanting property, their ability to present foreign epitopes on their surface, their particulate and 
multivalent nature [22,23] and their ability to be formulated for stability without a cold chain [24]. 
Their impact on human health is already evident through the use of marketed VLP vaccines against 
hepatitis B virus infection, human papillomavirus-induced cervical cancer and hepatitis E virus 
infection [25,26].  
Rotavirus-like particles (RLPs), which are synthetic mimics of the virus, can be a safe and effective 
alternative vaccine candidate class to marketed live-attenuated oral vaccines [27]. They induced a 
high immune response and protection in animal studies against challenge with live virus [27,28]. 
However, a highly complex and expensive bioprocessing of RLPs by recombinant techniques 
within cells [29] remains one of the major challenges for commercialization of these vaccine 
candidates for use in the developing world. Therefore, distinct strategies are required to develop 
safe, effective and cheap next-generation RV vaccines that can reach the developing world. 
During the past decade, Professor Anton Middelberg and Dr Linda Lua, and their groups, have 
developed a low-cost and easily scalable transformational microbial platform technology for 
manufacturing viral capsomeres and VLPs. The technology uses Escherichia coli (E. coli) for 
production of murine polyomavirus VP1 capsomeres that can be assembled into VLPs in vitro in 
cell-free bioreactors [30,31]. VP1 capsomeres and VLPs have also become important platforms for 
presentation of foreign epitopes in a modular architecture (Fig. 1-2) [32], allowing vaccines to be 
made in a less complex way for the developing world. Insertion of group A streptococcus J8-
peptide epitope at a surface-exposed loop of VP1 has resulted in production of stable modular 
capsomeres in E. coli and in vitro assembled modular VLPs [32,33]. Insertion of influenza A M2e-
peptide module at the surface-exposed loop or at N- and C-termini of truncated VP1 has also 
resulted in stable modular capsomeres that do not assemble into VLPs [32,34]. Modularization of 
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M2e- and J8-peptide modules did not affect the stability of VP1 capsomere and VLP structures. 
Moreover, the modular capsomeres and VLPs showed clear immunogenicity and protective efficacy 
in a mouse model [32-34]. However, depending on the physicochemical properties and size of 
foreign antigenic module, modularization may adversely affect the stability of modular capsomeres, 
the in vitro assembly of modular capsomeres to form modular VLPs and/or the stability of in vitro 
assembled modular VLPs.  In this PhD thesis, the development of modular capsomeres and VLPs as 
novel next-generation RV vaccine candidates was introduced to address a high global burden of RV 
diseases and the unresolved challenges with the marketed vaccines.  
 
 
 
 
Figure 1-2. Murine polyomavirus VP1 VLP platform for display of foreign antigenic modules in a modular 
architecture. A relevant target antigen from a target pathogen (red) is inserted at surface exposed engineered insertion 
site of VP1 at the genetic level. The modular VP1 containing the relevant target antigen is expressed in E. coli as 
pentameric modular VLP subunits, termed as capsomeres. Then highly purified 72 capsomeres subunits assemble in 
vitro to form a VLP. The figure was made based on the information available in Middelberg et al.[32]. 
1.1. Burden of rotavirus 
RV is a large and complex virus in the family of Reovirdae [35]. It is a non-enveloped and 
icosahedral viral particle containing 11 segments of double stranded RNAs within its three-layered 
capsid architecture [36]. The virus shows unusual aspects of structural complexity and has a unique 
replication cycle. Its triple layer capsid is highly stable for its success as a gastrointestinal tract 
pathogen and structured properly to protect its genome and deliver it successfully into host cells for 
viral replication [36,37].  
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RV strains are classified into seven serogroups (group A-G) based on the genetic variations of the 
major structural protein VP6 of the virion [38]. Groups A, B and C cause infection in humans. 
Particularly, RV strains from group A are the most prevalent pathogens associated with diseases in 
humans, domestic and laboratory animals [39]. These viral strains are the major enteric pathogens 
causing gastroenteritis and diarrhoea in infants and children under five years of age.   They cause 
about 111 million episodes of gastroenteritis for which health care is not sought and are responsible 
for 25 million clinic visits, more than 2 million hospital admissions and 500,000 annual deaths in 
children under 5 years of age worldwide every year [8]. More than 80% of the deaths occur in 
developing countries. For example, most countries in sub-Saharan Africa have a higher burden of 
disease and deaths than the rest of the world. There was an estimated 300,000 deaths due to RV 
diseases in the region in the year 2009 [40]. Children in developing countries of South Asia also 
bear the greatest burden of deaths primarily due to malnutrition and lack of access to rehydration 
therapy [41]. A study on the burden of diarrhoeal diseases estimated that RV accounts for close to 
40% diarrhoea-related hospitalizations and is responsible for 13% all deaths in children under 5 
years of age and kills approximately 150,000 children annually in India [41,42]. 
RV-related diseases are common in the Middle East and North Africa, which are associated with 
significant morbidity, mortality and cost [43]. RV is also estimated to cause approximately 40% of 
all diarrhoea hospitalizations and deaths and a quarter of ambulatory visits for diarrhoea  in Latin 
America and the Caribbean region, resulting in approximately 10 million episodes of diarrhoea 
annually, two million seeking care in a clinic, 75,000 hospitalizations and 15,000 deaths annually 
[44,45]. Despite low mortality rate  in developed countries of North America, Europe, East Asia 
and Australia, still there is high incidence of RV disease, imposing a considerable burden upon their 
health systems and economies [46]. 
1.2. The current vaccine paradigm  
Children under five years of age have experienced one or more RV infections regardless of where 
they live or their socioeconomic status. The improvements in housing, pure water supply, 
sanitation, personal hygiene, food quality, nutrition, maternal education and the use of oral 
rehydration therapy have significantly reduced hospitalizations from bacterial and parasitic 
diarrheal disease but they are unlikely to reduce the overall incidence of RV infection [46,47]. 
Consequently, vaccination remains the most effective public health strategy to reduce the global 
burden of diarrhoeal diseases due to RVs. Vaccine preparations against RVs can generate virus 
neutralizing antibodies and/or initiate appropriate virus-specific cellular immune responses prior to 
infection [16,18].  
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The current rotavirus vaccine paradigm uses two live-attenuated oral vaccines, RotarixTM 
(GlaxoSmithKline) and RotaTeq® (Merck), in most developed countries [15-18]. Some developing 
countries have also incorporated the vaccines in their childhood immunization schedules. The 
vaccines are effective and significantly reduced the incidence of severe gastroenteritis in infants in 
high- and middle-income countries [48]. Nevertheless, their efficacy in selected low-income 
countries, where they are needed most, was low during clinical trials and post-licensure studies 
[19,49]. The reasons for their lower efficacy in developing countries may be due to high levels of 
maternal antibodies, mixed infections with various pathogens in the gut, a higher rate of 
malnutrition, regional differences in prevalent RV genotypes and serotypes, and emergence of 
potentially virulent strains via reassortment of RVs between vaccine strains and circulating wild 
type strains [19,47,50]. Their attenuated live nature has raised concerns related to viral shading and 
risk of reversion and transmission [51]. They have also caused intussusception in some vaccinated 
infants [52]. The detection of porcine circovirus type 1 DNA in RotarixTM vaccine and fragments of 
DNA of porcine circovirus type 1 and type 2 in Rota Teq® as potential contaminants has raised 
questions with regard to the quality and safety of the vaccines [53]. Moreover, live-attenuated 
vaccines are often produced using cell culture technology that demands high cost and strict 
conditions of production, storage, transportation and distribution. This often causes financial and 
logistic challenges for introducing the vaccines into the developing world [20].  
1.3. Next-generation rotavirus vaccines 
A high global burden of RV and the unresolved challenges with the marketed live-attenuated oral 
RV vaccines have ignited efforts to develop next-generation vaccine candidates. The design of the 
new RV vaccine candidates based on detailed knowledge of T-cell and B-cell epitopes would result 
in novel new vaccines to address the difficulties of the marketed vaccine preparations (Table 1-1). 
Such vaccines may range from recombinant peptides, recombinant fusion or soluble proteins [54-
56] and RLPs [27].  Particularly, RLPs have gained promising potential as safe and effective 
alternative vaccine candidates to oral live-attenuated vaccines. They induced a strong immune 
response and protective efficacy in different animal models against direct challenge with a live virus 
[27,28].  
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Table 1-1: Comparison of marketed live-attenuated oral RV vaccines and next-generation VLP-based RV vaccine 
candidates. The Table was prepared based the information available in [19,20,24,29,32,49,57]. 
Parameters Rotavirus vaccines 
 Marketed live-attenuated 
vaccines 
Rotavirus-like particles 
(RLPs) 
Modular rotavirus VLPs 
Cost Expensive for low-income 
countries (US$ 2.5-3.5 
per dose 
Expensive due to high 
manufacturing cost from 
eukaryotic expression 
system 
Affordable for low-
income countries (at a 
calculation cost of less 
than 1cent per dose) 
Distribution/Logistics Challenging and 
prohibitive for low-
income developing 
countries 
Easy, particularly, freeze-
dried RLPs 
Easy, particularly, freeze-
dried VLPs 
Thermal stability Unstable and needs a 
cold chain system 
Can be stabilized and do 
not need a cold chain 
Can be stabilized and do 
not need a cold chain 
Efficacy Low efficacy in 
developing countries 
Showed pre-clinical 
protective efficacy  
Pre-clinical and clinical 
efficacy have not yet 
tested 
Risk of reversion High risk of reversion No risk No risk 
Risk of intussusception Risk of intussusception 
was observed in 
vaccinated children 
No risk No risk 
RLPs are non-replicating synthetic mimics of the virus that are made by recombinant techniques 
within the expression host cells [29,58]. As rotavirus is very complex, the RLPs made inside the 
cell are also complex, and typically contain unassembled proteins, single layered (assembled VP2), 
double layered (VLP2/6), and triple layered (VLP2/6/7) RLPs, with or without the VP4 spikes (Fig. 
1-3) [29,59]. Production of RLPs inside the cell often involves highly complex, inefficient and 
expensive bioprocessing steps and suffers from the limitations of yield and scalability [29,58,59]. 
Simplifying the overall bioprocessing steps, improving efficiency of VLP formation and feasibility 
for large scale production, and reduction of manufacturing cost have been the focus of many 
developments to enable the developing world to use the final product with affordable cost.  
The ability to manufacture VLPs and their subunits, termed capsomeres, using a transformational 
microbial viral capsomere and VLP platforms suggests huge potential for cost reduction [57]. Using 
this technology, the murine polyomavirus capsid protein, VP1, is produced in high yields using a 
low-cost prokaryotic expression system and scalable chromatographic and non-chromatographic 
techniques are used for purification of its capsomeres and followed by in vitro assembly of 
capsomeres into VLPs in a cell-free bioreactors [30,31]. The capsomeres and VLPs can also serve 
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as platforms for display of foreign epitopes in a modular architecture (Fig. 1-2) [32,34]. Insertion of 
immunologically relevant peptide epitopes or vaccine antigens from influenza A and group A 
streptococcus  to the surface loops of murine polyomavirus capsid protein, VP1, at genetic level 
through polymerase chain reaction or gene construction have resulted in  modular capsomeres and 
VLPs [32,34,60]. The modular capsomeres and VLPs showed clear immunogenicity and protective 
efficacy in mice [33,61]. Most importantly, modularization of M2e-and J8-peptide modules can be 
well tolerated and did not affect the stability and in vitro assembly of capsomeres to form VLPs 
[32,34].   
 
 
Figure 1-3. Simultaneous expression of four RV structural proteins results in the formation of single-layered RLP 
(sLRLP), double-layered RLP (dIRLP), triple-layered RLP (tIRLP) and complete RLP (cRLP).The steps followed for 
assembly of cRPL are unknown. This figure was adapted from Palomares et al.[29]. 
However, depending on the physicochemical properties and size of modules, modularization may 
affect the stability and in vitro assembly of capsomeres to form VLPs. So far, murine polyomavirus 
VP1 capsomeres and VLPs have served as a platform for presentation of small (less than 10 kDa) 
and hydrophilic peptides [32-34,62]. There are some B-cell epitopes, such as the RV peptide 
epitopes from VP8 subunit domain [63], and many T cell epitopes [64-66], which are hydrophobic 
peptides. Presentation of these peptides using a capsomere and/or VLP platform may result in 
modular vaccine candidates that induce protective immunity against RV. It may be also essential to 
present large antigens in a capsomere and/or VLP platform instead of small peptides to maintain the 
conformational structure of the immunogenic domains of the antigens for effective binding to B-cell 
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receptors, antibodies or other arms of the immune system. More recently, Lua et al. [60] 
demonstrated the modularization and presentation of an 18 kDa RV VP8* large antigen on the 
surface of VP1 VLP, but using a baculovirus-insect cell expression platform for VLP assembly in 
vivo. Thus, the need to use the VP1 capsomere and VLP vaccine platforms for production of next-
generation RV vaccine candidates using a low-cost bacterial expression system leads to the general 
question that this research addresses: are VP1 capsomere and VLP platforms suitable for 
presentation of hydrophobic peptide epitopes? Can stable modular capsomeres presenting an 18 
kDa RV VP8* large antigen be produced using a prokaryotic microbial host for subsequent VLP 
assembly in vitro? If they can be proved to be suitable, the VP1 capsomere and VLP platforms will 
demonstrate their potential and plasticity for low-cost manufacturing of modular capsomeres and 
VLPs presenting various heterologous modules regardless of the size and the physicochemical 
properties of modules.   
1.4. Research objectives 
The aim of this PhD project is to contribute towards the design and bioprocessing of modular virus-
like particles and capsomeres, using E. coli, to present a RV cross-reactive and hydrophobic peptide 
epitope (RV10) and an 18 kDa RV large antigen (VP8*) as next-generation vaccine candidates 
against RV. 
The research covered in this thesis was guided by four main objectives. 
(i) to produce in E. coli modular capsomeres presenting a RV peptide module  and to identify 
optimum processing conditions for purification of stable modular capsomeres; 
(ii) to address the effect of inserting RV hydrophobic peptide modules on protein expression, 
capsomere stability and in vitro VLP assembly using synthetic biology design strategies; 
(iii) to develop a simplified bioprocessing route for manufacturing of modular capsomeres and 
VLPs presenting  a RV VP8* large antigen; and 
(iv) to assess the immunogenicity of potential modular capsomere and VLP vaccine candidates 
developed from (ii) and (iii) in vivo in mice. 
The rationale behind each of these research objectives is explained in the following sections. 
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1.4.1. Enhancing the stability of modular capsomeres  
The stability of modular capsomeres is very crucial, particularly for their application in vaccination, 
where lower efficacy can be a result of poor vaccine stability [67]. Moreover, production of 
modular VLPs via in vitro assembly in a cell-free reactor often needs highly stable and pure 
capsomeres, which are stabilized against aggregation. Modularization of capsomeres can be well 
tolerated [32,34]; however results can be dependent on the physicochemical properties of modules. 
Insertion of modules may alter protein characteristics. It may also affect the structural features of 
protein-protein interfaces and the nature of their interactions, and the interaction of amino acid 
residues and subdomains of proteins with solvent molecules. Alteration of protein characteristics or 
structural features may lead to formation of insoluble and/or soluble aggregates during downstream 
processing of modular capsomeres. Thus, depending on the physicochemical properties of modules, 
modularization may require tailoring of the processing conditions specific to each module to 
maintain protein colloidal stability.  
The nature of the environment surrounding the proteins can be tailored to each protein by adjusting 
the pH and ionic strength of processing solutions [68,69] or by adding stabilizing additives [69]. 
Several additives have been studied for their potential to stabilize proteins at different stages of 
processing, formulation or upon storage. However, identification of the most effective additive from 
a large experimental space for each target protein is laborious and time-consuming using analytical 
methods with low-throughput capacity [70]. Therefore, the use of high-throughput screening (HTS) 
techniques may provide opportunities for simple and rapid screening for the most effective 
additives. For example, dynamic light scattering (DLS) measurement with high-throughput capacity 
provides in situ analysis within short time periods using small amounts of protein [24]. DLS can be 
suitable and effective for HTS of protein processing conditions, particularly in cases when the size 
difference between different species, such as between capsomeres and soluble aggregates, is high.  
Due to its high-throughput capacity, simplicity and suitability [24], a DLS-based analysis was used 
to develop a rapid, simple and effective HTS method to identify optimal processing conditions for 
enhancing the stability of modular capsomeres (Chapter 3). The developed DLS-based HTS method 
was able to screen 54 processing conditions in the presence of various additives for their potential to 
enhance stability of RvVP1 capsomeres.  Eight conditions were successfully identified as effective 
stabilisers, from which the additives, 0.1% (v/v) triton x-100 (TX-100), 0.05% (v/v) TX-100, 
tween-80 (TW-80) and tween-20 (TW-20) were able to increase stability of RvVP1 modular 
capsomeres. The potential of these additives in stabilizing RvVP1 capsomeres was further 
confirmed with high-resolution size exclusion chromatography (SEC) (Chapter 3). 
11 
 
1.4.2. Synthetic biology design strategies for modules 
It is clear from Section 1.4.1 that tailoring the nature of the environment surrounding the proteins by 
adding stabilizing additives can enhance the stability of modular capsomeres.  Non-ionic detergents 
are very mild chemical compounds that do not denature proteins and they increase stability of 
proteins by inhibiting hydrophobic interactions between proteins or by coating interfaces to 
modulate adsorption loss and aggregation [71]. However, these additives   may be unwanted and 
have to be removed to use the modular capsomeres for in vivo application or to assembly them into 
modular VLPs in vitro in a cell-free reactor. Modular RvVP1 capsomeres did not form modular 
VLPs when assembled in vitro in the presence of non-ionic detergents (Appendix A). Removal of 
detergents from protein solutions is tedious and not efficient [72]. Their removal often results in re-
aggregation of target proteins during further downstream processing or upon storage. Moreover, 
their efficiency in stabilizing modular capsomeres during downstream processing and the 
purification yield may depend on the physicochemical properties and size of modules. Particularly, 
modular capsomeres displaying a hydrophobic peptide module will rarely perform well during 
upstream as well as downstream processing even under optimized protein expression and 
processing conditions (Chapter 4). Modularization may also cause structural perturbation of 
capsomeres or prevent modular VLP formation via in vitro assembly from modular capsomeres due 
to steric hindrance [60].  
Synthetic biology has the potential to solve various problems in vaccine development and 
manufacturing [73]. Low expression level of proteins, poor stability during downstream processing, 
or low purification yield can be avoided through redesign of the constructs or modules using 
synthetic biology. Addition of polar and/or charged amino acids into the module sequence would 
reduce the overall hydrophobicity of the module by providing additional charges or hydrogen bonds 
and favours expression of soluble and stable proteins in E. coli.  Insertion of ionic linker sequences 
into the hydrophobic module sequence can also reduce the hydrophobicity of the peptide module. 
Linkers showed profound impact on the stability of fusion proteins during expression, processing 
and storage [74]. They can also separate different moieties of fusion proteins spatially in order to 
alleviate structural perturbation of moieties, which often compromises the stability and activity of 
fusion proteins [75]. Previous study demonstrated presentation of an 18 kDa RV large antigen, 
VP8*, on the surface of VLP using linkers and by reducing the number of antigenic modules on the 
VLP surface sufficiently below the maximum [60]. The study revealed that longer linkers ensured 
structural separation and independence between VP8* and the VLP, and a reduction in number of 
antigenic domains on the VLP surface did avoid a steric hindrance to VLP formation in vivo using 
the insect cell-baculovirus expression system.  
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In consideration of this successful work in VLP formation in vivo, different synthetic biology 
design strategies were used in this thesis to address the effect of inserting hydrophobic peptide 
modules on protein expression, stability of modular capsomeres and in vitro assembly of modular 
VLPs (Chapter 4). Insertion of linkers flanking the antigenic module and titration of number of 
antigenic module on each capsomere via co-expression strategy of unmodified VP1 and modular 
VP1 in E. coli resulted in stable modular capsomeres presenting a RV cross-reactive hydrophobic 
peptide epitope (RV10) on the murine polyomavirus capsid protein VP1. The modular capsomeres 
(CapRV10) formed modular VLPs, RV10VLP in vitro in a cell-free reactor. RV10VLP is the first 
bacterially-produced in vitro assembled VLPs displaying RV10 (Chapter 4). The developed 
synthetic biology design strategies enabled the production of CapRV10 and RV10VLP vaccine 
candidates using a low-cost bacterial co-expression system. The production of RV10-specific 
antibody against CapRV10 and RV10VLP was also assessed in this thesis.  The mice immunized 
with adjuvanted CapRV10 and non-adjuvanted RV10VLP induced production of comparable (P = 
0.2236) and low RV10-specific IgG titres (~102.5 and 103.5 for CapRV10 and RV10VLP, 
respectively) (Appendix B).    
1.4.3. Molecular and bioprocess engineering for simplified production of modular VLPs 
presenting large antigens 
As mentioned in Section 1.4.2, CapRV10 and RV10VLP induced production of low titres of RV10-
specific antibodies. The specific causes for low immunogenicity of CapRV10 and RV10VLP are 
unknown. It is speculated that induction of high module-specific immune response can necessitate 
presentation of large conformational antigens on the surface of capsomeres or VLPs.  Previous 
study demonstrated that a modular VLP vaccine containing the protrusion (P) domain of the 
norovirus capsid protein displaying VP8* antigen has shown anti-VP8* specific immune response 
and protective efficacy in mice. However, the total expression level of P particle-VP8* chimera is 
very low in E. coli [76,77]. The limitations of purification yield and scalability may also be the 
challenge of the system as the VLP was made inside an E. coli cell, and then purified using low-
throughput SEC [76]. More recently, Lua et al. [60] has also developed a stable modular murine 
polyomavirus VLP presenting VP8* using a baculovirus-insect cell co-expression system. Low 
expression and purification yield, and expensive bioprocessing steps have made the system 
infeasible for production of VLP-VP8* as vaccines for the developing world. 
An alternative and now-proven approach for VLP assembly via cell-free in vitro processing has 
been developed  for production of highly immunogenic and protective modular VLPs presenting J8 
peptide modules using the murine polyomavirus VP1 VLP vaccine platform [32,33]. Using this 
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approach, soluble GST-tagged capsomeres presenting small peptide modules are produced in 
bacteria and purified using chromatographic techniques, and then assembled into VLPs, under 
engineering control, in a cell-free reactor [31-33]. However,  the use of the GST tag adds 
complexity and cost to the bioprocess due to its multimerization effects, and the demand for affinity 
chromatography purification  and enzyme-mediated tag release steps [78,79]. With the aim to 
develop safe and cost-effective next-generation vaccine candidates against RV for the developing 
world, the bioprocess was simplified using module titration strategy for modularization of 
capsomeres with large VP8* module and expression of non-tagged proteins in E. coli for recovery 
of capsomeres by selective salting-out precipitation that eliminates affinity purification and 
subsequent enzyme-mediated tag release. It was successfully used for production of stable non 
GST-tagged capsomeres presenting a RV 18 kDa VP8* module (CapVP8*) with high purity. 
Modular CapVP8* capsomeres formed modular VLP-VP8* via in vitro assembly (Chapter 5). 
Moreover, the immunogenicity of CapVP8*and VLP-VP8* was assessed in this thesis. The mice 
immunized with adjuvanted CapVP8* and non-adjuvanted VLP-VP8* developed high (~ 105) and 
comparable (P = 0.6730) VP8*-specific IgG titers (Chapter 5). 
1.5. Thesis organization 
This PhD thesis consists of 6 chapters, including this introductory chapter. 
Chapter 2 provides a literature review of key topics in this research. It includes a review of RV 
(structure, classification, replication cycle, infection, pathogenesis and disease burden and immunity 
to rotavirus), live-attenuated oral vaccines, development of next-generation vaccine candidates 
against rotavirus, strategies for production of modular capsomeres and VLPs by microbial 
expression system and assessing the immunogenicity of candidate vaccines in vivo using animal 
models. 
Chapter 3 focuses on developing a HTS method for rapid identification of buffer additives for 
enhancing the stability of modular capsomeres [objective (i)]. 
Synthetic biology design strategies are covered in Chapter 4 [objective (ii)]. The strategies are 
applied for addressing the effect of inserting hydrophobic antigen sequence on the stability of 
modular capsomeres and formation of modular VLPs via in vitro assembly. 
Chapter 5 investigates a combination of molecular and bioprocess engineering approaches for 
simplified production of bacterially-produced modular capsomeres and in vitro assembled VLPs 
presenting VP8*- a RV large antigen. It also investigates the potential of modular capsomere and 
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VLP formulations for production of VP8*-specific neutralizing antibodies. In vivo immunogenicity 
tests in mice were carried out to address objectives (iv). 
Chapter 6 summarizes conclusions from the work accomplished in this thesis and presents 
suggestions for future research. 
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Chapter 2 
Literature review 
2.1. Rotavirus  
RV is a non-enveloped and icosahedral virus that belongs to the family Reoviridae. RV is a large 
virus approximately 100 nm in diameter. RV shows unusual aspects of structural complexity for its 
success as a gastrointestinal pathogen [1,2]. Its genome consists of 11 segments of double stranded 
RNA (dsRNA), ranging in size approximately from 660 (segment 11) to 3,300 (segment 1) base 
pairs. The total genome size is approximately 18,550 base pairs. The genome codes for six 
structural proteins (VP1, VP2, VP3, VP4, VP6 and VP7) and six non-structural proteins (NSP1-
NSP6) and is enclosed by three concentric capsid layers as shown in Fig. 2-1. The inner most capsid 
layer of RV is formed by 60 dimers of the structural protein, VP2. This layer encloses the genomic 
RNA and 12 copies of each of two minor structural proteins VP1 and VP3. VP1 is the RNA-
dependent RNA polymerase whereas VP3 refers to the viral capping enzymes, guanylyltransferase 
and methylase [2,3]. 
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Figure 2-1. The structure of RV virion. This figure  was produced based on the information available in Jayaram et al. 
[4].  
The middle layer of the RV capsid shell is formed by 260 trimers of VP6 [3]. VP6 is the most 
abundant viral structural protein that constitutes approximately 51% of the virion by weight. This 
protein contains 397 amino acids and has an estimated molecular mass of 45 kDa. VP6 is highly 
conserved with more than 87% amino acid sequence similarity between any two mammalian group 
A  RV strains [2,3]. It plays key roles in the replication cycle of RV. It is essential for the immature 
capsid particle to be transcriptionally active and for the budding of the immature capsid particle in 
to the endoplasmic reticulum where final maturation and assembly of the virus takes place [3,5]. It 
is also the most immunogenic viral protein as it contains highly conserved and protective T-cell 
epitopes [5].  
The outer most capsid of RV contains two structural proteins, VP7 and VP4. The smooth external 
surface of the outer capsid is made up of 780 copies of trimers of glycoprotein VP7 (Fig. 2-1) [3]. 
VP7 is the major constituent of the outer capsid with a molecular weight of 37 kDa in its unreduced 
and 41 kDa in its reduced form. VP7 is considered as the key mediator of the calcium driven 
uncoating in RV strains [4]. It is also involved in neutralization of the virus particles [6,7]. It 
determines the G serotype and contains antigenic domains that are highly conserved within the 
same serotype but divergent among different serotypes [7]. The minor constituent of the outer 
capsid shell of RV contains 60 spike-like particles formed by dimers of VP4 (Fig. 2-1). VP4 
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extends approximately from 12 nm from the VP7 surface [3]. VP4 has a molecular weight of 88 
kDa and its cleavage by trypsin in the gut of the host into the C-terminal subunit domain, VP5 (60 
kDa) and the N-terminal subunit domain, VP8 (28 kDa) helps the virus to penetrate the enterocytes. 
VP4 also plays an important role in host cell attachment, haemagglutination, virulence and 
neutralization [3,4]. VP4 determines P-serotype of the virus and contains cross-reactive epitopes.  
Particularly, the VP8 subunit domain contains linear B-cell epitopes [8] and large conformational 
antigenic domains that induce production of virus neutralizing antibodies [9]. 
2.2. Classification of rotaviruses 
RVs are classified into seven serogroups (group A, B, C, D, E, F, and G) on the basis of the 
antigenic properties or the amino acid sequence variations of the major structural protein VP6 of the 
virion [10]. There is a vast diversity of genotypes and serotypes within each group.  Among the 
seven serogroups, only groups A, B and C contain viral strains causing infection in humans. 
Particularly, viral strains from group A are the most prevalent pathogens causing diarrhoea in 
humans, pigs, cattle, laboratory animals, and birds [11]. Group A RV strains are further classified 
into two genotypes based on the molecular characterization of the outer capsid proteins, VP7 and 
VP4. VP7 specifies the G (glycoprotein) genotype whereas VP4 specifies the P (protease-sensitive) 
genotype [11,12]. G-types are classified as serotypes by neutralization assay or as genotypes by the 
nucleotide sequencing of VP7. Both the neutralization assay and nucleotide sequencing yield 
concordant results. Thus, the G-types are referred to by their G serotypes alone or by their G-
genotypes alone that are equivalent [1,11]. Unlike G-types, classification of P-types by 
neutralization and sequencing assays does not always result in concordant results. Consequently, 
there is often a dual system for P-typing. P serotypes are referred to by their serotype numbers (e.g., 
P1, P2, P3, etc.) and P genotypes are denoted in brackets (e.g., P [8], P [4] etc.). P genotyping is the 
most widely used method for classification because of difficulties in standardizing VP4 serotype 
assay [13]. To date, there are at least 27 G (G1-G27) and 35 P (P [1]-P [35]) genotypes with 
different combinations of G and P genotypes.  For example, more than 70 G-P combinations have 
been detected from 12 G types and 15 P types identified in humans [14].  
Despite the vast potential serotype diversity for human RVs,  in nature it does not appear that all G-
P combinations are equally efficient  in competing for a niche in the human gastrointestinal tract 
[1]. Globally, human infection with group A RV mainly caused by G1, G2, G3, G4 and G9 in 
combination with P[4], P[6] and P[8] to form various G-P combinations. Among the different 
combinations, G1P[8], G2P[4], G3P[8], G4P[8], G9P[8] and G12P[8] are responsible for about 90 
% of the infections in humans. More importantly, genotype and serotype distribution of group A 
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RV strains varied between geographical areas [15]. Studies have shown that genotypes G1, G3, G4 
and G9 account for 90 % of all RV infections in North America and Europe; however, they are 
responsible for less than 70% of cases in Africa [16]. Whereas P[8] and P[4]  account for over 90% 
of P types circulating worldwide, their relative frequency seems to be lower in Africa, where P[6] 
accounts for almost a third of all P types detected in Africa [16,17]. In addition, the genotype and 
serotype distribution showed temporal fluctuation. Major changes in one or more dominant 
circulating strain genotypes can occur from one season to another [16].  
Besides the molecular characterization of the outer capsid proteins, the genes for expression of less 
diverse RV proteins have been considered for classification of group A RV strains. To date, the 
complete open reading frame sequences of all 11 genome segments of almost 80 RV strains have 
been determined for viruses isolated from human and animal hosts [12]. The Rotavirus 
Classification Working Group has proposed a classification system based on nucleotide sequence 
percentage identity cut-off values for each of the 11 group A RV genomic RNA segments. The 
nucleotide cut-off values are used to distinguish genotypes for each gene segment based on 
phylogenetic analyses and pairwise sequence identity profiles [12]. This new classification system 
resulted in the identification of  27G (Glycosylated [VP7]), 35P (Protease-sensitive [VP4]), 16I 
(Inner capsid [VP6]), 9R (RNA-dependent RNA polymerase [VP1]), 9C (Core protein [VP2]), 8M 
(Methyltransferase [VP3]), 16A (Interferon antagonist [NSP1]), 9N (NTpase [NSP2]), 12T 
(Translation enhancer [NSP3]), 14E (Enterotoxin [NSP4]) and 11 H (pHosphoprotein [NSP5/6]) 
[12,13]. Such a classification system can allow a more complete analysis of unusual RV strains  that 
might emerge because of accumulation of point mutations, genomic reassortment during mixed 
infections, reassortment between strains of RVs isolated from humans or among strains of human 
and animal origin, gene rearrangement within gene segments or introduction of animal RV genes 
into human RV population via direct virus transmission from an animal to a human host [12,14].  
The vast genotype diversity of human RV strains across the world and emergence of unusual 
pathogenic strains due to continuous evolution of RV strains may have important implications for 
prevention of RV diseases and vaccine development as hetrotypic strains and newly emerging 
global strains can fail to share neutralizing antigens with the existing vaccine preparations. Thus 
continuous identification and characterization of globally, nationally or locally prevalent viral 
strains are very important for the development of vaccines, monitoring vaccine efficacy, and 
epidemiological study of endemic and epidemic rotavirus diseases.   
 
26 
 
2.3. Replication cycle of rotavirus 
RV is a fascinating virus because of its unusual and complex structure, and its unique replication 
features [9]. Its highly stable triple-layered capsid is structured properly to protect the RNA genome 
and to deliver the genetic material into a suitable host cell for its replication and for assembly of the 
viral particles [4].  
The replication of RV takes place in the cytoplasm of matured enterocytes using the host cell 
metabolic machinery [18]. The matured enterocytes express factors required for virus entry, 
efficient infection and/or replication. RV attachment and entry into host cells constitute multistep 
processes. The viral infection involves intestinal protease, two outer capsid proteins, VP4 and VP7, 
and possible cellular receptors [3,4]. Trypsin-like proteases from the gastrointestinal tract cleave the 
VP4 (88 kDa) spike protein into VP8 (28 kDa, aa1-247) and VP5 (60 kDa, aa248-776). Trypsin-
mediated cleavage of VP4 primes the virus to enter into the host cell [4,18].  RV entry into 
enterocytes involves interaction of VP8 with sialic acid containing receptors in the initial cell 
attachment step and interaction of VP5 with integrins such as αvβ3, α4β1, α2β1 during the 
subsequent post attachment steps [3,4]. The heat shock cognate protein 70, some gangliosides and 
the cell molecules that are associated with cholesterol and glycosphingolipid-enriched lipid 
microdomains  can also serve as RV receptors [3,19]. Following RV cell attachments, the three-
layered virus particle is internalized via non-clathrin- or non-caveolin-mediated endocytosis and 
traffics to the early endosome (Fig. 2-2), wherein the low calcium concentration is predicted to 
trigger VP7 disassembly. The dissociation of VP7 trimers mediates virus uncoating, serves as a cue 
for VP5 rearrangement and allows the virion to penetrate the endosomal membrane [20].  
The net result of attachment, uncoating and penetration of the endosomal membrane is the release 
of the VP2-VP6 double-layer particles (DLPs) into the cytosol of the host cell [18]. The DLPs 
contain transcriptionally active viral polymerase complexes (VP1 and VP3). The complexes of the 
polymerases catalyse the synthesis of  11 species of capped,  non-poly (A) viral positive single-
stranded RNAs ((+) RNAs) using the negative sense RNAs ((-)RNAs) of dsRNA genome segments 
as templates [18,20]. The nascent (+) RNAs are extruded from a DLP through channels present at 
each of the 12 vertices of the icosahedral. They serve dual roles during the RV replication cycle, 
acting as mRNAs for synthesis of viral proteins by cellular ribosomes and as templates for genome 
replication [18,20,21]. For a typical group A RVs, translation of (+) RNAs gives rise to six 
structural and six non-structural proteins inside the cytoplasm of the infected host cells (Fig. 2-2).  
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The non-structural proteins have varied roles  in the replication cycle [22]. Some non-structural 
proteins have only indirect roles in the replication of viral genome or virion assembly. For example, 
NSP1 functions as an interferon (INF) antagonist to prevent the effect of INF on the expression of 
viral proteins and production of viral particles [19]. NSP3 is required for the subversion of the host 
translation machinery [21,22]. The other non-structural proteins, NSP2, NSP5 and NSP4 play direct 
roles in gene replication and particle assembly [22-24]. NSP2 is a highly basic protein that exists as 
homo-octamers in the cytoplasm of infected cells [25]. It interacts with another non-structural 
protein, NSP5, early in the replication cycle. The interaction of NSP2 and NSP5 and their co-
localization around transcribing DLPs result in the formation of viroplasms (Fig. 2-2) [25].  
The viroplasms correspond to the electron dense inclusion bodies without lipid membranes. They 
are surrounded by polyribosomes and are localized adjacent to the cell nucleus and near the 
endoplasmic reticulum. Viroplasms serve as putative sites of viral transcription, genome packaging 
and replication, and core assembly [18,21,22]. The numerous self- and partner- specific interactions 
of NSP2 and NSP5 suggest that viroplasms form as large, semi-regular networks designed to 
sequester viral RNAs and capsid proteins for assembly into nascent virions [20]. Viroplasm-
associated (+) RNAs are selectively packaged into assembling VP2 cores. Following encapsidation 
of the 11 (+)RNAs species, core-associated polymerase complexes perform minus strand synthesis, 
thereby reconstituting  the dsRNA genome inside a pre-virion particle. Then, cores generated within 
viroplasms interact with VP6 accumulating at the periphery of viroplasms to form DLPs [21-23]. 
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Figure 2-2. The replication cycle of RV. It involves multistep processes. First, the virus enters into the host cell via to 
cellular receptors and interaction with co-receptors. Following entry, the outer capsid layer, VP7 and VP4, are 
removed from the particle in the cytoplasm to release the DLPs. The mRNA is produced from DLPs and undergone 
translation to express 6 structural and 6 non-structural proteins. Assembly of DLPs containing VP2, VP1, VP3 and 
VP6) and a full complement of 11 ssRNAs is taken place in the viroplasms. Then dsRNAs are synthesised in the precore 
particles and the particles are mature into triple layered particles by NSP4 acting as an intracellular receptor. Finally, 
matured particles are released from the cell via exocytosis or lysis and the virus infects other cells to continue its life 
cycle. The figure was adapted from Trask et al. [20]. 
Newly made DLPs may amplify the replication cycle by supporting secondary rounds of (+) strand 
synthesis or may acquire the outer capsid proteins by interacting with the endoplasmic reticulum 
[21,22]. Budding of DLPs from viroplasms into the endoplasmic reticulum results in transiently-
enveloped particles [1,22]. The budding of DLPs into the endoplasmic reticulum is  mediated by the 
affinity of the VP6 for the cytosolic tail of viral endoplasmic reticulum transmembrane protein, 
NSP4 [22]. The outer capsid proteins, VP4 and VP7, are incorporated into new DLPs during the 
budding process through protein rearrangements that occur as the transient envelope is lost [1,20]. 
The high affinity interactions of NSP4 and DLPs, and NSP4 and VP5 are very critical for assembly 
of VP4 spikes during particle formation in the endoplasmic reticulum before assembly of VP7  
Once mature triple-layered particles form, they are predominantly released from  cells via either cell 
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lysis or by a non-lytic trafficking pathway (or exocytosis) (Fig. 2-2) [18,20]. The release of the viral 
particle from the infected cell exposes the virion to trypsin-like proteases of the gut. Specific 
trypsin-mediated cleavage of VP4 into VP5 and VP8  produces the fully infectious virion that can 
infect host cells and the replication cycle continues within the cytoplasm of the host cells as shown 
in Fig. 2-2 [20].  
2.4. Infection, pathogenesis and disease burden 
RV is a highly contagious enteric pathogen with low viral doses [26]. The virus is highly stable and 
able to persist in the environment for long period of time. The presence of RV in the environment 
carries health risks because of its high stability and its very low infectious viral doses. It is 
transmitted to susceptible individuals mainly by the faecal-oral route from direct contact with 
children and adults with subclinical illness or through contact with contaminated hands, fomites, 
food, water and surfaces [26,27]. The transmission of RVs can also occur from animal to human as 
well as from animal to animal either by direct contact of the virus or by the contribution of one or 
more genes to reassortants [28,29]. RV shedding in large quantities from the stools of vaccinated 
children, or infected individuals and animals can contribute for transmission of the virus between 
intra- and inter-species of animals and exacerbate the risks of infection [26,29].  
RV mainly infects the mature enterocytes in the mid and upper part of the villi of the small intestine 
[30]. The virus uses its two outer capsid proteins, VP4 and VP7,  trypsin-like proteases and cellular 
receptors [19] to infect mature enterocytes. The spike-protein VP4 has also played critical roles  in 
RV virulence and pathogenesis in different animals and humans [28,30]. In addition, virus virulence 
is related to the structural protein, VP3 and the non-structural proteins NSP1, NSP2 and NSP4 [28]. 
Its complex structure with different virulence factors help the virus to cause not only 
gastrointestinal infections but also systemic infections that may result in clinical consequences in 
multiple organs [1,28]. 
An infection of the gastrointestinal tract by RV ultimately leads to diarrhoea without visible organ 
damage [28,30]. Diarrhoea is the main clinical manifestations of RV infections mainly in infants 
and young children. It is also sometimes associated with sporadic outbreaks in elderly and 
immunosuppressed patients [1,31]. RV induced diarrhoea may involve  multifactorial pathogenesis 
mechanisms [32]. One of the pathophysiological mechanisms by which RV induces diarrhoea is 
malabsorption [1,31,32] due to virus-mediated  destruction of absorptive enterocytes, virus-induced 
down regulation of the expression of absorptive enzymes, and  functional changes in tight junctions 
between enterocytes that lead to paracellular leakage [1]. Local villus ischemia leading to vascular 
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damage and diarrhoea [31,32], alterations in transepithelial fluid balance [32], reduction in 
epithelial surface area by replacing the absorptive enterocytes with immature, crypt-like, secretory 
cells [31,33] and the activation of the enteric nervous system [30,31] are some of the proposed 
pathogenesis mechanisms of RV induced diarrhoea.  
The enterotoxic activity of NSP4 represents another mechanism of RV induced diarrhoea (Fig. 2-3) 
[31,33,34]. A secreted cleavage product of NSP4 (NSP4aa112-175 or the extracellular NSP4) binds to 
integrins α1β1 or α2β1 on neighbouring cells and triggers the activation of phospholipase C (PLC) 
that leads to the production of inositol 1,4,5-triphosphate (IP3), IP3 receptor and  IP4. The 
production of IP3 and its receptor mediates calcium release. The calcium activates chloride 
secretion [33-35].  Calcium mobilization may also trigger the release of different mediators such as 
cytokines, amines, prostaglandins, peptides and nitric oxide that activate the enteric nervous system, 
there by stimulating chloride secretion and consequently secretion of water [33,35]. In parallel, 
osmotic diarrhoea is also induced by several lytic viral cycles [33]. Studies demonstrated that the 
secretion of chloride is generally age-dependent, occurring in neonatal mice but not in adult mice 
and leads to diarrhoea [34]. The clinical outcomes of RV infection are affected not only by the viral 
factors but also by the age of the host. Infants at the age of 3 months to 2 years are highly 
susceptible to severe RV induced diarrhoea. Although RV can infect adults, severe symptomatic 
disease is relatively uncommon and can result from infections with unusual virus strain or 
extremely high dose of virus particularly  in case of immunosuppressed individuals [1].  
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Figure 2-3. Mechanisms for RV induced diarrhoea. Synthesis of viral proteins in the cell cytoplasm during replication 
leads to an increase in the concentration of Ca2+ in the endoplasmic reticulum (ER) that induces activation of Ca2+-
dependent enzymes in the cytosol of infected cells. Activated enzymes induce cell lysis and the release of viral proteins 
and viral progeny. NSP4 might act as a viral enterotoxin on as-yet-uninfected cells to induce secretary diarrhoea 
through a) Ca2+-dependent secretion by intestinal cells; b) Ca2+-dependent secretion of peptides and amines to 
stimulate the enteric nervous system (ENS); and c) further activation of epithelial-cell chloride (Cl-1) secretion by the 
ENS. At the same time, released virus infects downstream absorptive cells that lead to a massive cell death, as a 
consequence, reduction of the absorptive surface of the intestinal epithelium and an osmotic component of diarrhoea. 
Various forms of the virus along the RV-maturation pathway are shown: DLP ~ double-layered particles; IMP ~ 
intramembrane particle; TPL ~ triple-layered particle; SERCA ~ sarcoplasmic/endoplasmic-reticulum Ca2+-ATPase. 
The figure was adapted  from Bomsel et al. [33] 
Group A RV strains are the leading causes of gastroenteritis and severe diarrhoea in infants and in 
young children worldwide [1].  They  cause more than 2 million hospital admissions and 500,000 
annual deaths worldwide in 2008 in children under 5 years of age  More than 80% of the deaths 
occur in developing countries in Africa, Asia, Latin America and in other developing regions [36]. 
The disease burden still remains unacceptably worse in most developing countries [37].  
2.5. Immunity to rotavirus 
Multiple RV infections occur in children throughout their childhood. Each natural infection can 
result in the development of protective immunity against severe RV induced acute gastroenteritis 
and recurrent gastroenteritis [38]. The innate immunity to RV infection is acquired after early 
exposure and acting as the first line of defence against subsequent viral infection[1,39]. It uses 
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pathogen recognition receptors (PRRs) as primary sensors for viral infection to confer protection 
against subsequent severe disease through rapid production of cytokines [40]. The interaction of RV 
dsRNA with PRRs during replication leads to the activation of IFN regulatory factor 3 (IRF3) and 
nuclear factor (NF)-ҡβ.  IRF3 and NF-κβ translocate from the cytoplasm to the nucleus and 
stimulate transcription of interferon stimulated genes (ISGs) and type I IFN [41]. Type I IFNs, 
particularly  IFN-α and IFN-β subtypes, are critical for an effective innate immune response against 
RV [42]. 
INF-α4 and INF-β are also secreted and bound to their respective IFN receptors to activate the 
dsRNA-dependent kinases, Jak1 and Tyk2 [38]. The activated kinases phosphorylate and activate 
transcription factors STAT1 and STAT2 to form a heterotrimeric transcription factor complex 
(ISGF3) with a third transcription factor, IRF9. ISGF3 translocates to the nucleus and binds to IFN-
stimulated response elements (ISREs) to induce transcription of hundreds of ISGs. INF and ISG 
transcripts can play a critical role in the innate immune response and interferes with the replication 
of the virus at various stages in the replication cycle [38,42,43]. The role of the non-specific innate 
immunity in modulating RV infection in vitro and in animal models has been known, but the role in 
human beings is not well explored [1]. This wing of the immune system based on type I IFN 
response may not be always efficient in providing protective immunity against RV infections. The 
virus often uses its NSP1 to escape from the type I IFN-mediated immune response [43]. In 
addition, the innate immunity does not prevent the host from reinfection [38].  
The adaptive immune response can be another important wing of the immune system in resolution 
of ongoing RV infection and protection against subsequent infection [44]. It usually appears later 
and protects against reinfection or severe diarrhoea in young children or animals when they are 
reinfected [45]. Some studies in experimental animals and humans suggested that the virus-specific 
antibody- and cell-mediated immune responses are elicited by natural RV infection or RV 
vaccination [44]. The exact immunological mechanism by which the adaptive immunity provides 
protection against RV after natural infection or after immunization is still incompletely understood 
[46]. The mechanisms of the immune responses to RV are very complex and vary depending on the 
animal species studied [39].  
There has been great interest in identifying the correlates of protection using animal models and 
humans after both natural infection and vaccination. The production of both systemic and mucosal 
RV-specific antibodies plays an important role in protection against reinfection. Neutralizing 
antibody to VP4 and VP7 can block enterocyte infection directly when present in the intestine (Fig. 
2-4) [39,46]. However, full correlation of anti-VP4 and anti-VP7 neutralizing antibodies with 
33 
 
protection is still unclear in both animals and humans following natural RV infection and RV 
vaccination [47]. Correlates of protection after vaccination often vary depending on the type of 
immunogen and vaccines. In case of heterologous vaccines, serum antibodies may not provide 
adequate correlates of protection whereas serum IgA may reflect antiviral activity in case of 
homologous vaccines [46]. 
 
Figure 2-4. Potential mechanisms of the adaptive immunity to RV. In step 1, neutralizing antibodies, mainly secretary 
IgA (sIgA), directed against the outer capsid proteins can prevent viral binding and penetration, inducing viral 
exclusion. If the mechanism in step 1 fails the virus will infect the cell and replication will take place in step 2. Viral 
replication can be inhibited by secretary anti-VP6 dimeric IgA during transcytosis across enterocytes as shown in step 
3. In step 4, cytokine-secreting RV-specific T-cells can also inhibit virus replication. If viral replication is not stopped in 
step 4, replicating virus produces NSP4. Antibodies against NSP4 could potentially prevent diarrhoea, which will be 
induced by direct or mediated action of NSP4. This figure was adapted  with slight modification from Angel et al. [39]. 
Besides the neutralizing antibodies against VP4 and VP7, some studies revealed the protective 
immunity of antibodies against VP6 and NSP4 proteins (Fig. 4) [39,48]. Studies using different 
animal models demonstrated induction of VP6-specific antibody of the IgA class [49]. The VP6-
specfic IgAs in the intestine are able to clear RV infections via non-neutralizing or intracellular 
neutralizing immune responses following transcytosis via enterocytes into the gut lumen [5]. 
Studies have also investigated the protective role of antibody produced against NSP4 and NSP4aa114-
135 peptide [47,48]. Antibody to NSP4 can block diarrhoea via its anti-enterotoxin activity, but 
cannot prevent viral infection [50]. For example, mouse dams fed transgenic potato tuber 
expressing cholera toxin-murine RV NSP4aa114-135 peptide fusion protein were found to develop 
NSP4-specific serum and intestinal antibodies. The mouse pups born to such dams were partially 
protected by passively acquired anti-NSP4 antibodies against diarrhoea induced by simian RV 
SA11 [31,48].  
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The cell-mediated immune arms of the adaptive immunity may also play a role in protection of RV 
infections. Experiments in animal models have demonstrated an important role of cell mediated 
immunity in protection from RV shedding [51]. The adoptive transfer of both immune splenic and 
intestinal CD8+ T cells, and splenic CD4+ T cells has shown clearance of chronic RV infection 
using the mouse model [52]. Particularly, different studies have investigated the critical role of 
CD4+ T cells in VP6-induced protection of mice against RV shedding [52,53]. Studies using the 
murine model suggested that T cells can play an important role in antiviral immunity since CD4+ T 
cells contribute to the development of RV-specific IgA by memory B cells and RV specific CD8+ T 
cells accelerate the resolution of primary virus infection [53]. Some studies using animal models 
also demonstrated the role of the cell-mediated immune response in resolution of primary RV 
infection and in providing protective immunity against RV re-infection through production of 
cytokines by activated T cells [52,54]. Particularly, the Th1 cytokines, such as IFN-γ,  play a major 
direct and/or indirect role in the defence against RV infection [55].  
Although the role of cell mediated immune response in humans for protection from RV infection or 
vaccination is not well characterized [52], results from different studies using animal models 
suggested that the cell mediated immune response with its various components is an important wing 
of the adaptive immunity in resolution of primary RV infection and in providing protective 
immunity against RV re-infection. 
2.6. Strategies for control and prevention of rotavirus  
Virtually all children will have experienced RV infection during their childhood independent of the 
socioeconomic status the countries where they live. RV gastroenteritis complicated by dehydration 
remains a major cause of child mortality, morbidity and hospitalization [37]. Hygiene and sanitation 
practices are not sufficient to prevent the spread of RV infection within the community and to 
reduce the burden of the diseases at regional, national and/or global level. The treatment option for 
RV is primarily supportive and consists of rehydration and restoration of electrolyte balance until 
the infection resolves [56]. However, coverage levels of rehydration therapy remain low particularly 
in most developing countries due to inadequate manufacturing capacity and lack of access to good 
health care delivery facilities and infrastructure [57]. Clinical trials have also demonstrated the 
effectiveness of some probiotic preparations in reducing the severity and duration of RV-induced 
diarrhoea in children and adults [58,59]. In addition, some studies have been carried out to identify 
possible therapeutic targets that are involved in the replication cycle and pathogenesis of RVs [60-
62]. Availability of limited information on the therapeutic targets has impeded the discovery and 
development of RV-specific antivirals [62]. More recently, some of the targets have been used for 
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in vitro and/or in vivo screening of different molecules for RV-specific antiviral activity. Although 
the findings from RV-specific in vitro antiviral screening using cell culture techniques have been 
encouraging [61-65], no RV-specific chemotherapeutic agents are available to date for clinical use 
[60]. Thus vaccination remains to be the major and primary prophylactic strategy to reduce the 
morbidity and mortality from RV diseases [39]. Vaccine preparations against RVs can generate 
virus neutralizing antibodies and/or initiate appropriate virus-specific cellular immune responses 
prior to infection [39,66]. The current vaccine paradigm consists of live-attenuated oral RV 
vaccines. In addition, different non-replicating subunit vaccine candidates against RV are under 
development. 
2.6.1. Live-attenuated vaccines 
A live-attenuated tissue-culture-grown RV strains formulated for oral delivery would best mimic 
the natural immunity induced by wild-type RV infection in the intestines [39,66,67]. So far different 
live-attenuated RV oral vaccines have been developed and tried/or used to prevent the burden of 
RV. Bovine RV (RIT 4237) was the first candidate live oral vaccine. This vaccine candidate was 
derived from a bovine strain Nebraska calf diarrhoea virus, P6[1]G6, and named RIT 4237 for use 
in human trials. Its cross-protective efficacy against human RV strains in studies in gnotobiotic pigs 
initiated human trials [68]. A series of human trials were conducted in Finland from 1982 to 1986, 
starting from phase I studies in adults and rapidly progressing to efficacy trials in infants. However, 
the RIT 4237 vaccine failed to show consistent efficacy in trials in developing countries and its 
further development was soon abandoned [67,68]. 
Rhesus RV was introduced as an alternative heterologous RV vaccine candidate to bovine derived 
RIT 4237 [69]. This vaccine candidate multiplied more efficiently in human intestines and showed 
greater immunogenicity compared with RIT 4237. However, Rhesus RV alone did not show 
impressive protective efficacy in Finland and in the USA [67]. Moreover, its protective efficacy was 
likewise inconsistent [69].  
The development of reassortant strains having the attenuation properties of the animal strains and 
individual genes encoding the outer capsid proteins of common human RV strains improved the 
efficacy of monovalent vaccines [66,70]. Reassortment of the Rhesus RV vaccine backbone with 
human RV VP7 proteins representing the G-types G1, G2 and G4 resulted in the human-rhesus RV 
tetravalent vaccine [66,69]. This vaccine candidate showed higher efficacy against severe RV 
gastroenteritis in USA and in Finland and, it was also quite efficacious in Venezuela [67].  It was 
the first multivalent live-attenuated oral reassortant vaccine licensed as RotashieldTM and 
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incorporated into the USA infant immunization program in 1998 against RV [69]. But its 
association with high risk of intussusception in vaccinated children led its withdrawal from the 
program a year after its introduction [66,70].  
In 2006, WHO recommended two live-attenuated oral RV vaccines, RotarixTM and RotaTeq® for 
use in the USA, Australia, many European and Latin American countries where evidence of 
efficacy was demonstrated [39]. The human monovalent RV vaccine was originally developed by 
isolating the viral strain (strain 89-12) infecting a child in Cincinnati and by tissue culture passage 
of a wild type strain using African Green monkey kidney cells [39,66]. This vaccine is a P1A[8]G1 
strain thus represents the most common of the human RV VP7 and VP4 antigens [66,70]. The 
vaccine was prepared based on the rationale that a vaccine containing a human RV G1P[8] strain 
can induce serotype-specific immunity against the most common human G-type and P-type RVs 
[67,70]. It was further developed by Avant Immunotherapeutics and licensed to GlaxoSmithKline 
Biologicals. GlaxoSmithKline Biologicals further modified the vaccine by cloning and tissue 
culture passaging of the parent vaccine strain [66,69]. The resulting vaccine, RIX4414 (RotarixTM) 
(Fig. 2-5), underwent initial trials in Finland and showed safety, immunogenicity and efficacy [66]. 
Clinical trials conducted across Europe, Latin America, Asia with this vaccine also demonstrated 
high efficacy against severe gastroenteritis caused by circulating wild-type RV. Generally, 
RotarixTM was highly efficacious in preventing severe gastroenteritis in infancy in high and middle 
income countries [39,66,67,70].  
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Figure 2-5. Marketed live-attenuated oral RV vaccines. (a) RotarixTM is a monovalent an attenuated human RV vaccine 
made of a tissue-culture-adapted human P1A[8]G1, VP6 subgroup II and NSP4 geno-group B strain. (b) RotaTeq® is a 
bovine (WC3)-human reassortant vaccine composed of the five strains, each containing a human RV gene encoding the 
VP7 neutralizing protein from different serotypes. Notably, in the WI79-9 and SC2-9 viruses (the last was used to create 
the first), genes 3 (VP3) and 9 (VP7) are of human origin. The figure was adapted from Angel et al.[39]. 
The bovine-human pentavalent reassortant RV vaccine [RotaTeq® (Merck and Co., Whitehouse 
station, New Jersey, USA)] is an oral, pentavalent, live-attenuated human-bovine mono-reassortant 
vaccine (Fig. 5) [39]. The backbone of RotaTeq® is the bovine RV strain WC3, which is a low 
passage level isolate of calf RV that was used as a candidate vaccine in the 1980s [67]. The WC3 
strain (G6P7[5]) was reasserted with VP7 surface proteins of human RVs G1, G2, G3 and G4, and 
human VP4 type P1A[8] RV to develop the pentavalent vaccine [67,69]. RotaTeq® was licensed in 
the USA, Australia, and many European and Latin American countries since 2006.  It was safe, 
immunogenic and highly efficacious against RV during clinical trials and significantly reduced the 
incidence of severe gastroenteritis in infants in developed and middle income countries [39].  
Both RotarixTM and RotaTeq® have shown good safe and efficacy profiles  in preventing severe 
diarrhoea among children in middle- and high-income countries [39,66]. However, their efficacy in 
selected low-income countries of Africa, Asia and Central America, where they are needed most, 
was low during clinical trials and post-licensure studies [71,72]. The restricted immunogenicity and 
efficacy of the vaccines in developing regions may be due to host-related aspects, socio-cultural and 
socioeconomic differences, vaccine related characteristics, the higher prevalence of enteric 
infections, presence of other co-morbidities such as HIV/AIDS, tuberculosis, malaria, concomitant 
administration of other oral viral vaccines [71], regional differences in prevalent genotypes and 
serotypes, and reassortment between vaccine strains and circulating wild type strains or among 
vaccine strains [11]. Moreover, potential safety issues with the vaccines are yet to be clarified; the 
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mechanisms by which they induce protection and the molecular basis of their attenuation are not 
well understood [39]. Their live-attenuated nature raised some concerns related to viral shedding, 
reversion to virulent strains and the risk of transmission and intussusception [73]. The detection of  
porcine circovirus type 1 DNA in RotarixTM vaccine and fragments of DNA of porcine circovirus 
type 1 and type 2 in Rota Teq® as potential contaminants has also raised questions with regard to 
the safety and quality of the vaccines [74]. In addition to these challenges, financial and logistic 
obstacles are also limiting the use of the vaccines in developing countries [75]. Because of high cost 
and low efficacy of RotarixTM and RotaTeq®, only few developing countries with the highest RV-
related mortality rates have introduced the vaccines into their routine Expanded Program for 
Immunization schedules with the help of donating organizations [76].   
Another live-attenuated oral rotavirus vaccine, the Lanzhou Lamb RV vaccine, has been licensed in 
China since 2000. This vaccine was developed directly from an ovine animal strain, group A (G10 
P[12]) [77,78]. Administration of one dose of this vaccine conferred partial protection in children 
[78]. Several other live-attenuated RV vaccine candidates are under development: the bovine (UK 
strain)-human reassortant vaccine, the human neonatal RV-3 strain, and the natural bovine-human 
reassortant neonatal 116E strain have progressed to different stages [69,77]. The bovine RV 
pentavalent vaccine contains RV human-bovine (UK) reassortant strains of serotype G1, G2, G3, 
G4 and G9. It has been developed by the serum Institute of India Ltd, in collaboration with the 
National Institute of Allergy and Infectious Diseases, USA. This vaccine candidate was safe and 
immunogenic during toxicity studies in animals and, Phase I and II clinical studies in adults, 
children and infants [79]. The 116E RV strain, which has an unusual G9P[11] genotype, is a 
naturally bovine-human reassortant strain containing one 10 gene segments from a human RV, and 
a single gene encoding spike protein from a bovine strain [80,81]. This live-attenuated vaccine 
candidate was developed recently as part of the Indo-US vaccine action program [81]. Studies 
showed that 116E RV vaccine against severe RV gastroenteritis and severe gastroenteritis of any 
cause was efficacious in Indian infants [82]. However, no complete data for efficacy in the second 
year of life and no results from post-marketing surveillance study available to date. The 116E 
vaccine caused intussusception in few Indian infants during studies for efficacy and safety [81,82]. 
Appaiahgari et al. [80] also demonstrated the interference of maternal antibody on the 
immunogenicity of oral RV 116E vaccine in Indian infants. 
2.6.2. Inactivated vaccines 
Observable progress has been achieved in the last four decades in the accelerated development of 
live-attenuated oral RV vaccines. However, improved vaccines are still needed, particularly in 
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developing countries where the burden of the disease is the highest but where the currently used 
oral vaccines have been the least effective and costly and logistically fragile [75,76]. The use of 
inactivated RV vaccines have been suggested as an alternative to live-attenuated oral vaccines since 
they pose several scientific and administrative advantages to the live-attenuated ones [83].  They 
have greater efficacy for children in developing world and do not cause intussusception and other 
adverse events [83,84]. In different animal models, partial or complete protection has been induced 
using parenteral immunization with inactivated RV. For example, Johansen et al. [85] have 
demonstrated that formalin-inactivated RV given intramuscularly with the adjuvants, MPL® or L3®, 
stimulated a potent immune response with high neutralizing antibody titres and induced protective 
immunity in infant mouse model. Wang et al. [84] demonstrated that a very low dose of thermally 
inactivated RV formulated with aluminium hydroxide was highly immunogenic in mice. However, 
they got significantly lower immunogenicity and less protective immunity of the inactivated human 
strain CDC-9(G1P[8]) vaccine formulated with aluminium phosphate against RV infection in 
gnotobiotic piglets [84]. Inactivated RV vaccine candidates are also potentially less costly and 
quicker to develop since, in the absence of concern for intussusception, the vaccine can be tested in 
clinical trials with fewer than 10,000 infants at a substantially lower cost. However, inactivated RV 
vaccines could not provide endogenously synthesized proteins and generally do not elicit cytotoxic 
T cell responses that may be important in resolution of RV infections [83]. In addition, they often 
need toxic adjuvants for boosting their protective immune response [85]. 
2.6.3. Subunit vaccines 
Subunit vaccines are non-living and containing clearly defined and carefully controlled antigens or 
antigenic subunit domains. They pose no risk of reversion to a virulent state and antigen 
competition typical of complex live vaccines can be minimized when subunit vaccines are used 
[86]. The subunit vaccines against RV may range from recombinant peptides, recombinant fusion 
and soluble proteins, RLPs and chimeric VLPs.  
2.6.3.1. Recombinant peptides and proteins 
Several studies demonstrated the immunogenicity of some recombinant RV structural and non-
structural proteins and recombinant peptides derived from RV proteins in different animals, in 
naturally-infected children and adults, and in vaccinated children [5,48,87]. The major proteins with 
high potential for vaccine development are VP6, NSP4, VP7 and VP4 [66].  
VP6 is the most immunogenic and conserved RV protein [5]. It contains several highly conserved 
group-reactive epitopes.  A study of VP6 epitopes has been conducted using pools of synthetic 
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overlapping peptides representing the entire antigen sequence, particularly those peptides 
overlapping  with the amino acid sequences of the carboxyl terminal half of the VP6 protein of the 
murine RV strain [88,89] and human RV G1P[8]A strain [90,91]. A highly conserved and 
protective CD4+ T cell epitopes were identified from VP6 protein of porcine RV YM, simian RV 
SA11 strains [92], murine RV (Epizootic Diarrhoea of Infant Mice (EDIM)) strain [88,89,93], 
G1P[8] human RV infected rhesus macaque [90]. Major histocompatibility complex (MHC)-class I-
restricted CD8+ T cell-binding epitopes were also identified from RV VP6 protein [89,91,94]. Some 
of these CD8+ T cell epitopes were partially protective in H-2b C57B1/6 mice model [89,94]. 
The identification of highly conserved and protective or partially protective T-cell epitopes from 
VP6 has ignited efforts to develop subunit vaccines containing VP6 and/or peptides derived from 
VP6.  Several promising candidate VP6-based subunit vaccines have been produced from E. coli 
[95-97], transgenic plants [98,99] and the milk of transgenic rabbits [100]. Intranasal administration 
of E. coli-expressed chimeric VP6 protein along with the mutant E. coli heat-labile enterotoxin 
[LT(R192G)] adjuvant has consistently resulted in approximately 99% reductions in RV shedding 
after subsequent EDIM challenge [95-97]. Passively immunized mouse pups born from dams 
immunized with plant-expressed chimeric VP6 exhibited reduced diarrheal symptoms compared 
with the non-immunized ones following challenge with virulent RV strains [98,99].  Studies 
revealed that vaccines-based on VP6 protein generated RV specific faecal secretory IgA, systemic 
IgG and IgA and a RV-specific Th1 response [94,100,101]. Non-neutralizing anti-VP6 antibodies 
are highly cross-reactive among all group A RVs and inducing heterotypic protection [96,98,99]. 
Anti-VP6 IgA was able to confer protection by inhibiting viral transcription at the start of the 
intracellular phase of the viral replication cycle [98,99,102]. Moreover, immunization with VP6 
might prime the immune system for enhanced production of neutralizing antibodies against the 
outer capsid proteins VP4 and VP7 upon challenge with homotypic or heterotypic viruses [98,99]. 
A study also demonstrated that the protection elicited in neonatal mice after VP6/LT(R192G) 
immunization was associated with T cell responses, particularly those cells that were stimulated to 
produce Th1- and ThIL-17 specific cytokines [103]. 
NSP4 is another highly conserved protein with high potential for vaccine development against 
group A RVs infecting mammalian species [104]. Hyser et al. [105] identified four B-cell epitopes 
from the RV SA11 NSP4 cytoplasmic tail by use of monoclonal antibodies and epitope-specific 
antibodies. All of these epitopes were considered to be linear epitopes as the antibodies were able to 
detect denatured wild-type NSP4. Among these epitopes, NSP4aa114-135 is highly conserved and two 
of the critical residues E120 and E122 are 100% conserved in all reported sequences [105]. 
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Moreover, previous study on immunization with the synthetic peptide, NSP4aa114-135 demonstrated 
the generation of protective antibody against RV induced diarrhoea [34]. 
NSP4 is the first described viral enterotoxin [31]. It induces dose-and age-dependent diarrhoea in 
neonatal mice without causing histological alterations [32,35,106]. An antibody directed against 
NSP4 may protect the host from NSP4- and RV-induced diarrhoea like that of antibody responses 
directed solely against the secreted bacterial enterotoxins protect the host against many of the 
bacterial infections [34]. Studies have demonstrated that both humoral and cellular immune 
responses stimulated against a  recombinant NSP4 or a synthetic NSP4aa114-135 peptide  in different 
animals, in naturally infected children and adults, and in vaccinated children [48,87,107,108].  
In addition to their role as immunogens, NSP4 and peptides derived from NSP4 can function as an 
adjuvant to enhance immune responses for a co-administered antigen. Intranasal co-administration 
of keyhole limpet hemocyanin, tetanus toxoid, ovalbumin or double layer (VP2/VP6) RLPs with 
either the full length simian RV SA11 NSP4 or its cleavage product, NSP4aa112-175, significantly 
enhanced antigen-specific systemic and mucosal immune responses in mice [106]. The influenza 
M2e-antigen fused with the NSP4 coiled-coil region (NSP4aa98-135) fragment also showed an 
increased immunogenicity and protective efficacy of the M2e-antigen. Most importantly, 
vaccination with M2e-NSP4aa98-135 caused a significant decrease in lung virus load early after 
challenge with influenza A virus and maintained its efficacy against a lethal challenge even at a 
very low vaccine doses [109].  
The structural proteins of the RV outer capsid, VP7 and VP4, are also the main targets for vaccine 
discovery and development. They independently induce neutralizing antibodies to the virus 
[66,110,111] and targets for homotypic or heterotypic protective antibodies [111,112]. The 
glycoprotein, VP7 forms the smooth shell of the virion, while the non-glycosylated VP4 forms the 
spikes of RV that extend from the viral particle surface (Fig. 2-6A) [113]. Trypsin cleavage of VP4 
into VP8 (28 kDa) and VP5 (60 kDa) is required for high-level of viral infectivity and stabilization 
of the spikes [9]. The VP8 domain binds to cell surface receptors at the early stage of cell-entry and 
the VP5 facilitates subsequent membrane penetration [3,4]. The trypsin cleavage products remain 
associated in the virion and consist of a projection with obvious 2-fold symmetry and a trimeric 
base.  The first 26 amino acids of VP8 form  α-helix structure, and the N-terminal helices of three 
subunits (yellow coloured) make up a three-chain coiled-coil which inserts into the foot of the spike 
contained three VP5 C-terminal domains (green coloured) (Fig. 2-6B and C) [9]. The lectin-like, 
globular domain of VP8, residues 65-231, forms the distal head of the spike (Fig. 2-6C). The two 
lectin-like domains at the distal end of the spike are linked to the N-terminal helices by the 
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segments of residues 27-64 [9,113]. The N-terminal α-helices domain of VP8 contain a linear B-cell 
epitope [8]. The epitope contains residues 1-10 of VP8, and is highly conserved among different 
strains of human RVs [8,114]. Three tandem copies of RV10, expressed as a thioredoxin and a 
universal tetanus toxin T-cell epitope (P2) fusion protein, induced the production of anti-RV10 
specific and human RV-neutralizing antibodies in mice [114]. 
Residues 65-224 of the lectin-like domain of VP8, designated VP8* (Fig. 2-6C), is the distally 
located domain of the RV spike protein. This domain is essential for initial cell attachment of RV 
via interactions with specific cellular glycans [9,115,116]. Although many RV strains bind to 
terminal sialic acid-containing receptors, such as GM3, they can switch between entirely different 
classes of glycans, such as histo-blood group antigens, via a small changes in the VP8* receptor-
binding pocket [117]. Since interference with initial binding of RV with glycans is likely to prevent 
viral infection, the interactions of cellular-glycans and VP8* can serve as targets for drug discovery 
or vaccine development. VP8* (18 kDa) is a large and conformational antigenic domain of VP8, 
and the antibody directed against VP8* blocks binding of the viral particle to the host cell receptors 
and prevents release of RV DLPs into the cytoplasm of host cells (Fig. 2-6D) [115]. Thus, VP8* 
has been considered as the best candidate for RV vaccine development.  
 Several studies have demonstrated the successful induction of RV-neutralizing antibodies using 
VP8* and VP8-based subunit vaccines [8,114,118,119]. Chickens vaccinated with  E. coli-
expressed VP8* elicited anti-VP8*-specific antibodies which displayed high neutralization activity 
against the Wa strain of human RV [120]. VP8* antigen expressed in  glycosylation deficient 
Saccharomyces cerevisiae induced a strong immune response in female mice that conferred passive 
protection to their offspring [121]. Wen et al. [122]  also generated recombinant VP8*  protein of 
human RV strains Wa P[8], DS-1 P[4] and 1076 P[6] in E. coli and reported observations of high 
levels of homotypic and variable levels of heterotypic neutralizing antibodies against each of the 
antigens when administered to guinea pigs intramuscularly. Their findings indicated that the VP8* 
proteins may be a plausible additional candidate for new parenteral RV vaccines. In another study, a 
recombinant VP8* antigen expressed in tobacco transplastomic plants induced protective immunity 
against bovine rotavirus infection in a suckling mouse model [118]. More recently, the inclusion of 
a universal tetanus toxoid CD4+ T cell epitope P2 significantly enhanced the immunogenicity of a 
recombinant RV VP8* subunit parenteral vaccine [123]. In addition, two other truncated VP8 
proteins, VP8-1 (VP8aa26-231) and VP8-2 (VP8aa51-231), were expressed in E. coli and evaluated for 
their immunogenicity and protective efficacy. VP8-1 subunit vaccine showed better yield, 
homogeneity and high protective efficacy [113]. Favacho et al. [111] attempted to produce a high 
quantity of recombinant bovine RV VP8ext (the extended VP8-including the entire trypsin cleavage 
43 
 
region) in E. coli for studying the structure-function relationship of the VP8 fragment in order to 
understand its role in cell attachment and RV tropism. Although recombinant VP8-based proteins or 
peptides as subunit vaccines have several advantages over live vaccines, most of them are poorly 
immunogenic and need toxic adjuvants to boost their immune response. Moreover, their yield from 
different heterologous expression systems is low for commercial exploitation of the vaccine 
antigens [96,111,113,114,118,122]. Interestingly, and probably due to the size and conformational 
sensitivity of VP8*, it has not previously been arrayed on a VLP able to undergo in vitro self-
assembly. 
 
Figure 2-6. Structure of a RV VP4 spike protein and its VP8 subunit domain. (A) Structure of a RV triple layer particle 
with VP4 spike. (B) The bar representation of domains of VP4. The amino acid residues of different domains of VP4 
were labelled above the coloured bar. α : the N-terminal α-helix of VP8 with residues 1-26;  residues 27-64 without 
well resolved structure; lectin: the lectin-like, globular domain of VP8 with residues 65-231;  β-sheet: the antigenic 
domain of VP5 with residues 248-479;  the three-chain coiled coil with residues 480-509; and the C-terminal of VP4 
with residues 510-776. Tryptic cleavage of VP4 results in VP8 (residues 1-231) and VP5 (residues 248-776) with 
excision residues 232-247. (C) The ribbon representation of the atomic structure of VP4. The morphology of the spikes 
in the mature virion described as head, body, stalk and foot. The head contains the lectin-like domain. The β-sheet of 
the two subunits form the body and that of the third subunit forms the stalk. The foot contains the N-terminus of VP8, 
the α-domain and the C-terminus of VP5. (D) Interaction of the VP8* subunit domain of VP4 with host cell receptors 
for viral infectivity. The figure was adapted with slight modifications from Clarke et al. [115](Figure 2-6 A and D) and 
Xue et al.[113](Figure 2-6 B and C). 
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2.6.3.2. Rotavirus-like particles 
VLPs are highly organized multimeric protein complexes that self-assemble from viral structural 
protein(s) and mimic the morphological structure of the corresponding native virus particles without 
the viral genome, other structural protein(s) and non-structural viral protein(s) [124]. They are 
produced by the recombinant expression of structural protein(s) in different heterologous expression 
host cells from bacterial expression systems to various mammalian cell lines [125]. VLPs are 
undergoing research as tools for vaccination, gene therapy, drug delivery, diagnostics, 
nanomaterials and for protein interaction and cell interaction studies [124,125]. Particularly, their 
application in the field of vaccinology has increased interest because of their high safety and 
efficacy profile, their repetitive and high density native display of epitopes or their self-adjuvanting 
property, their ability to present foreign epitopes on their surface,  their particulate and multivalent 
nature  and their stability compared with soluble antigens [124,126]. They are generally more 
immunogenic than other subunit vaccines such as recombinant peptide and/or protein immunogens 
and are able to induce strong humoral and cellular immune responses even without adjuvants 
[124,126]. Currently, three VLPs, VLP-based hepatitis B virus surface antigen, the human 
papillomavirus capsid protein L1 and the recombinant VLP-based vaccine Hecolin®, are 
commercialized for human use against hepatitis B virus infection, human papillomavirus-induced 
cervical cancer and hepatitis E virus infection respectively [124-126]. Numerous VLP- and 
chimeric VLP-based vaccines against many infectious agents such as  influenza virus, parvovirus, 
Norwalk, norovirus, Group A streptococcus, RV etc. have shown promising results under clinical 
trials and pre-clinical evaluations using small animal models [124].  
RLPs can be safe and effective alternative candidate vaccines to live-attenuated oral vaccines. It has 
been also shown that the immunogenic response is higher when the viral proteins are associated into 
particles than when they exist in linear, soluble form [127]. Studies in different animal models have 
shown that the different RLPs including double layer (VP2/VP6)-, triple layer (VP2/VP6/VP7)- and 
complete (VP2/VP4/VP6/VP7)-RLPs showed different better levels of protection after challenge 
although the protective efficacy depends upon composition of proteins in RLPs, route of 
administration, the type of the adjuvants and the species of the animals used [127,128]. RLPs are 
synthetic mimics of the virus. They are produced by simultaneous expression of different 
recombinant structural proteins in a eukaryotic expression system, such as the insect cell-
baculovirus expression vector system [129] and/or yeast expression system [130].   
The production of RLPs using the insect cell-baculovirus expression vector system is a highly 
complex system. The process involves first the expression of the four RV structural proteins, VP2, 
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VP6, VP7 and VP4, and their subsequent assembly in to RLPs as shown in figure 1-3 (Chapter 1). 
The process is not completely efficient and unassembled monomers, single-layered and double-
layered RLPs are also found in production processes aimed at producing double-layered- or triple-
layered-RLPs [131]. This makes the downstream processing and quantification of the desired RLPs 
so complex and expensive. The yield is very low and scale up also seems infeasible [129,131,132]. 
Rodriguez-Limas et al. [130] have also produced triple-layered RLPs using the yeast, 
Saccharomyces cervisiae, as expression host cell. However, the concentration of the desired RLPs 
produced inside the yeast cells was very low compared to other expression platforms.  
In another study, a RV vaccine candidate using a VLP subunit platform has been reported, based on 
the combination of truncated VP8* (aa65-aa223) from the RV spike protein with the protrusion (P) 
domain of the norovirus capsid protein. The resulting chimeric VLP was highly immunogenic 
although the limitations of yield and scalability can be the challenge of the system as it was made 
inside a cell, and then purified using low-throughput SEC [133]. Production of VLPs or chimeric 
VLPs inside the expression host cell is efficient in most cases. However, it is not suitable for a 
large-scale bioprocessing because of possible contamination of the product with nucleic acids and 
the formation of heterogeneous VLPs that lead to much more complex downstream processing 
[134]. Such historical approach to VLP manufacture via in vivo assembly of expressed structural 
proteins inside the expression host cells is very challenging for mass scale production of quality 
VLPs as vaccines for use in the developing world.  
An alternative and now proven approach for VLP assembly via cell-free in vitro processing has 
been developed over a decade for low-cost production of highly purified and quality VLPs [135-
139]. Professor Anton Middelberg and Dr Linda Lua, and their groups at The University of 
Queensland, have devised a scalable and transformational microbial platform technology. Under 
this approach the murine polyomavirus VP1 and truncated VP1 are produced as soluble 
recombinant proteins at gram-per-liter levels using E. coli cells and followed by purification of 
capsomeres using chromatographic [138-140] or non-chromatographic methods [141] and/or 
optional in vitro assembly of capsomeres to form VLPs in a cell free reactor. Such platform offers 
an efficient, homogenous, stable, highly immunogenic product, and significantly reducing scaling-
up time and complexity [136-139]. The VP1 capsomere and VLP platforms can serve as a carrier 
for presentation of immunologically relevant RV antigens for low-cost production of capsomeres 
and VLPs in a modular format.  
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2.7. Murine polyomavirus VP1 vaccine platforms 
Polyomaviruses are ubiquitous members of the Polyomavirdae family that infect both mammalian 
and avian hosts [142]. They are non-enveloped particles containing a circular, double-stranded 
DNA genome.  The murine polyomavirus is one of the best-characterized species of mammalian 
polyomaviruses [142,143]. Its genome codes six proteins of which three are structural proteins, 
which are designated as VP1, VP2 and VP3 [144,145]. The murine polyomavirus VP1 has a 
molecular mass of 43 kDa and its primary structure contains sequences of 384 amino acids [145]. It 
is the major capsid protein comprising  approximately 80% of the protein found in the capsid of the 
wild-type virion [146].  
Capsids of the murine polyomavirus consist of 360 copies of VP1, that assemble into T= 7 dextro 
(T, triangulation number) icosahedral shells. Each capsid shell comprised of 72 pentameric capsid 
subunits, termed capsomeres, which are arranged in an icosahedral lattice with a diameter of 
approximately 45 to 50 nm [146,147]. The capsomeres of each capsid are set up in sixty hexavalent 
and twelve pentavalent capsomeres. Each pentavalent capsomere is encircled by further five 
capsomeres, whereas each hexavalent capsomeres by further six capsomeres. The carboxy-terminal 
arms of VP1 stabilize the pentameric capsomeres among each other, whereupon the N-terminus of 
the VP1 protein contains the viral DNA-binding domain and a nuclear localization sequence 
[147,148]. The native murine ployomavirus also contains the minor capsid proteins VP2 and VP3 
[149].  The VP1 capsomeres are also able to assemble into VLPs in vitro in the presence of calcium 
and specific pH conditions, with a size and morphology similar to the native murine polyomavirus 
capsids containing the viral genome and minor capsid proteins VP2 and VP3 [150].  
DNA-free murine polyomavirus VP1 VLPs  have shown promising potentials as vectors for 
immunotherapy, targeted gene and drug delivery, and as vaccines against viral infections and cancer 
[134]. As candidate vaccines, VP1-VLPs have shown dramatic effectiveness as they mimic the 
overall structure of authentic virus particles and present viral antigens in a more authentic 
conformation than other subunit vaccines [149,151-153]. For a VP1-VLP to be a realistic vaccine 
candidate and/or delivery vehicle, it needs to be produced in a safe expression system that is 
amenable to large-scale production [136,151]. For VP1- VLP manufacture, VP1 can be produced 
using  a baculovirus insect cell,  a yeast or an E. coli expression system [134,136]. Despite the 
success of the eukaryotic cells in VLP production for a wide variety of viruses, a major limitation 
with this route occurs because of nucleic acid contamination and the formation of heterogeneous 
VLPs. In terms of large-scale bioprocessing, these problems may lead to batch-to-batch product 
variability, making the downstream process much more complex and expensive [134]. To overcome 
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such limitations, alternative approaches based on microbial transformational platforms have been 
reported. Using this approach, the murine polyomavirus major capsid protein, VP1 is produced as 
soluble recombinant glutathione-S-transferase (GST) fusion proteins in E. coli cells. Enzyme-
mediated release of the GST tag followed by purification and separation by SEC resulted in large 
amounts of pentameric VP1 capsomeres [136,139]. In vitro assembly of highly purified VP1 
capsomeres has resulted in formation of quality VLPs through addition of specific agents in a cell-
free bioreactor [135,137,139,150].  
The N- and C-terminal of VP1 domains are involved in the formation of VLPs [154]. Exclusion of 
either C-terminal domain or both the N-and C-terminal domains prevented assembly of VP1 
capsomeres into VLPs [138,140]. These capsomeres are more stable, and can be used as cheap 
alternative vaccines to their corresponding VLPs. Both VP1 VLPs and capsomeres can serve as as 
carrier vaccine platforms for the display of foreign epitopes [138,140,155].  
2.7.1. The VLP vaccine platform 
Insertion of immunologically relevant vaccine antigens  to the viral structural proteins  at the DNA 
level through polymerase chain reaction or gene construction have resulted in  modular  VLPs 
[125,156]. Such viral structural proteins, produced at low cost and high yields, able to display the 
foreign epitopes on their surface, are currently promising alternative vaccine candidates for a 
number of  different diseases [124]. The murine polyomavirus VLPs, which are formed from 
overexpressed major capsid protein VP1, are among the promising VLP platforms for development 
of modular VLPs for vaccination [157]. They have high capacity for insertion of peptide epitopes 
[137,145,157] and have demonstrated huge potential as carrier platforms for the display of foreign 
epitopes and antigens on the surface in a modular architecture [137,157].  
VP1 has two surface exposed loops, S1 loop at amino acid 86 and S4 loop at position 293 (Fig. 2-7) 
for insertion of foreign antigenic modules [138,145].  Unlike S1 loop, S4 loop has shown high 
tolerance and capacity for insertion of peptide epitopes [138]. The S4 loop was engineered to 
contain AfeI restriction enzyme sites for molecular insertion of heterologous modules [138]. 
Insertion of a single module [138] or two tandem modules [155,158] of J8-peptide from the M-
protein of Group A streptococcus at S4 loop have resulted in modular VP1 that forms modular VP1 
capsomeres when expressed in E. coli. Purified modular capsomeres assembled into modular VLPs 
in vitro using a cell-free bioreactor. The modular VLPs showed clear immunogenicity in mice 
[138,158]. The produced J8-peptide-specific antibodies exerted in vitro bactericidal activity [138], 
and showed protective efficacy in mice [155].  
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Figure 2-7. The two surface exposed loops of murine polyomavirus VP1. 
The VP1 VLP vaccine platform technology summarized in Fig. 2-8 offers an efficient, 
homogenous, stable, highly immunogenic product, and significantly reducing scaling-up time and 
complexity [135-139,150]. Its simplicity and ease of scalable will make the VLP vaccine platform 
an ideal technology in low-and middle-income countries of Africa, Asia and Latin America. It can 
be used for production of modular vaccine candidates for prevention of various target diseases at 
low-cost in the developing world.  
 
49 
 
 
Figure 2-8. Bioprocessing of modular VLPs using the VLP vaccine platform. Insertion of a synthetic gene encoding a 
target antigen from various pathogens at surface exposed S4 loop of VP1 results a modular construct. The modular 
construct expresses GST-tagged modular proteins that form pentameric modular capsomeres in E. coli. Cell lysis by 
sonication or homogenization brings proteins into the extracellular environment. GST-tagged proteins can be captured 
by affinity chromatography. Enzyme-mediated release of the GST tag followed by purification by gel filtration and 
endotoxin removal result in highly purified capsomeres. Pure capsomeres can be assembled in vitro into VLPs and VLP 
formulation can be tested in animals for its immunogenicity and protective efficacy. This figure was produced based on 
the information available in Middelberg et al. [138]. 
2.7.2. The capsomere vaccine platform 
The N-and C-terminal domains of VP1 are involved in VLP formation [154]. Exclusion of the last 
63 amino acid residues from the C-terminal, and the first 28 amino acids from the N-terminal and 
63 amino acids from the C- terminal of VP1 result in truncated VP1 (Fig. 2-9C and D). 
Recombinant expression of truncated VP1 variants in E. coli has resulted in the formation of  stable 
pentameric capsomeres that do not assemble in vitro into VLPs [138,140]. The capsomeres with 
engineered insertion sites at their exposed surface loops and C-terminus (Fig. 2-9C) [138] or at their 
surface exposed loops, N-terminus and C-terminus (Fig. 2-9D) [140] can serve as carrier platforms 
for heterologous modules in a modular architecture. For example, insertion of a single [138] or 
multiple [140] modules of M2e- antigen from influenza (A/California/04/ 2009/H1N1) at 
engineered N (position 28), S4 loop (Position 293) and C (Position 320) of truncated VP1 according 
to the VP1 amino acid sequence has resulted in expression of modular capsomeres that did not form 
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VLPs via in vitro assembly. Formulation of these modular capsomeres with safe and effective 
adjuvants showed clear immunogenicity [138,155] and protective efficacy [159] in mice. 
  
 
Figure 2-9. Murine polyomavirus VP1 and truncated variants with module insertion sites. (A) The murine polyomavirus 
VP1 with its surface exposed loops, N-and C-terminal domains. (B) The murine polyomavirus VP1 with its surface 
exposed loops and sites of truncation for N-and C-terminal domains. (C) Exclusion of the last 63 amino acid residues 
from the C-terminal resulted in VP1ΔC63. (D) Exclusion of the first 28 amino acid residues from the N-terminal and 
the last 63 amino acid residues from the C-terminal resulted in VP1ΔN28ΔC63. This figure was produced based on the 
information available in Middelberg et al. [138]and Wibowo et al. [140]. 
 Modular capsomeres have been produced in high yields from low-cost bacterial expression systems 
[138,140]. The capsomere platform has received increased interest recently because of its simple, 
technically less difficult and cheap manufacturing processes (Fig. 2-10) compared to manufacturing 
of the corresponding modular VLPs (Fig. 2-8). Manufacturability using simple, cheap and efficient 
processes, and their biological efficacy [159] will make modular capsomeres alternative second-
generation cheap vaccines to the corresponding modular VLPs. The manufacturing and processing 
costs have been decreased further using easily scalable non-chromatographic unit operations, 
particularly for manufacturing modular capsomere vaccine for veterinary applications [141]. 
Simplification of technical manufacturing difficulties, improved process efficiency, and 
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minimization of manufacturing and processing costs often enables low-resource countries to 
participate in manufacturing processes and/or to use the final product with affordable costs. 
 
 
Figure 2-10. Bioprocessing of modular capsomeres using the capsomere vaccine platform. Insertion of a synthetic gene 
encoding a target antigen from various pathogens at N-terminus, surface exposed S4 loop and/or C-terminus insertion 
site(s) of truncated VP1 results a modular construct. The modular construct expresses GST-tagged modular proteins 
that form pentameric modular capsomeres in E. coli. Cell lysis by sonication or homogenization brings proteins into the 
extracellular environment. GST-tagged proteins can be captured by affinity chromatography. Enzyme-mediated release 
of the GST tag followed by purification by gel filtration and endotoxin removal result in highly purified capsomeres. 
Formulation of pure capsomeres can be tested in animals for its immunogenicity and protective efficacy. This figure 
was produced based on the information available in Wibowo et al. [140]. 
Modularization of an effective and easily made part of antigenic modules into the capsomere and 
VLP platforms can be well tolerated [138,140,155]; however success depends on the 
physicochemical properties, size, density of the inserted modules. Thus, modularization may require 
optimization of bioprocessing conditions, specific design principles using synthetic biology 
methods and/or reducing the density of modules to express soluble target modular proteins and to 
maintain the stability of modular vaccine candidates.  
2.8. Strategies for expression of soluble modular proteins and enhanced stability of modular 
capsomeres and VLPs 
Modularization of capsomeres and VLPs may alter protein characteristics such as isoelectric point, 
hydrophilic-hydrophobic property, secondary structure, three-dimensional structure, the structural 
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features of protein-protein interfaces and the nature of their interactions, and the interaction of 
amino acid residues and subdomains of proteins with solvent molecules.  Most of these 
characteristics may depend upon the amino acid composition of the protein, the amino acid 
sequences and sizes of the inserted modules. It has been widely accepted that the amino acid 
sequence of a protein determines its three-dimensional structure, dynamics, structural stability and, 
ultimately, its biological function [160].  Combination of hydrophobic and hydrophilic amino acids 
is essential for formation and stabilization of protein secondary structure [161]. The capacity and 
tolerance of VP1 insertion sites for inserting heterologous antigenic modules may also responsible 
for changes in structural features and physicochemical properties of the proteins. A study 
demonstrated that large antigens inserted at surface exposed S4 loop of VP1 caused structural 
perturbations of VLPs [162]. On the other hand insertion of highly hydrophobic antigenic modules 
on the surface exposed loops may result in high surface hydrophobicity of proteins, which is often 
associated with changes in protein conformations  and related to the ease with which a protein 
unfolds [163]. Although protein hydrophobicity is very essential for maintaining a protein`s folded 
structural integrity in cooperative with electrostatic interactions, hydrogen bonds, van der Waals 
forces and covalent disulphide bonds [164], high surface hydrophobicity due to  solvent exposed 
hydrophobic patches on protein surface may negatively affect expression of soluble proteins in E. 
coli and their stability during expression in vivo and/or during downstream processing in vitro. 
Producing soluble proteins for purification and manufacturing of stable proteins is a major concern, 
particularly for the field of vaccination, where lower efficacy can be a result of poor vaccine 
stability [165]. A number of approaches for successful expression of soluble proteins and 
stabilization of the proteins at different stages of processing are described in the literature [166]. 
Some of these strategies are described below. 
2.8.1. Tailoring expression and bioprocessing conditions 
Production of recombinant proteins using heterologous expression hosts, such as E. coli, is a 
complex process involving optimization of multiple factors in parallel to obtain soluble, stable and 
functional proteins [139]. Depending on the physicochemical properties or size specific to each 
heterologous module, modular constructs may not express target proteins at all or in substantial 
amount, or express as inclusion bodies, or express soluble protein that form undesired forms, such 
as protein aggregates, during downstream processing. Insertion of large antigens on a VLP surface 
caused structural perturbations and resulted in expression of modular proteins that did not form 
VLPs [162] whereas constructs containing hydrophobic modules often fail to express the target 
proteins in E. coli. Highly hydrophobic proteins may be harmful to recombinant expression host 
cells and, thus prematurely terminated polypeptides, trapped folding intermediates and partially 
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folded proteins may be consistently targeted for degradation to avoid their accumulation in cells 
[167].  
Proteolytic degradation of a protein must be prevented to improve the level of its expression. 
Targeted expression of proteins as inclusion bodies in E. coli is one of the methods, gaining 
considerable success to avoid proteolytic degradation of proteins. It can be achieved using fusion 
partners specifically designed to enhance over expression of proteins as insoluble inclusion bodies 
[168]. Particularly, this approach is suitable for the mass scale production of short peptides and 
inherently disordered proteins. But, other proteins forming inclusion bodies need solubilisation and 
in vitro refolding procedures to obtain a functional protein [169]. Refolding procedures are 
generally complicated and expensive, and yields are usually low due to re-aggregation of the 
solubilized polypeptide chains during the refolding process [170]. The in vitro refolding may not 
usually work successfully for all target classes, particularly; recovery of proteins in their pentameric 
form following refolding procedures may become a challenging and a daunting task for 
manufacturing of capsomere- and/or VLP-based vaccines. Thus, obtaining soluble proteins, which 
can maintain their colloidal stability both in vivo and in vitro, directly from the expression host cells 
is highly desirable. 
The production of soluble proteins in E. coli is affected by several factors. Optimization of 
environmental factors, such as inducer concentration and induction temperature [139,166], 
induction time [166], growth media components and additives [171-173], can provide dramatic 
improvements in expression of soluble proteins. Optimization of genetic factors (including E. coli 
strains and expression vectors) [139,174] and other factors, such as lysis buffers and their additives 
[166], can also tackle protein solubility problems. The attachment of target proteins with fusion tags 
such as  thioredoxin, GST, maltose binding protein, N-utilization substance A and small ubiquitin-
like modifier  has been commonly used to prevent degradation, promote proper folding and enhance 
expression of soluble proteins in E. coli  [175,176]. Some of the fusion partners are also serving as 
tags for affinity purification to capture soluble fusion proteins [176]. In most cases, release and 
removal of the tag proteins, particularly, the large fusion tags,  are essential to characterize  target 
proteins using size-limited analytical tools [174] and to use the target proteins for in vivo 
application [140,174] or to use the target proteins as a starting material for manufacturing functional 
materials such VLPs for in vivo application [138,140]. Tag release needs protease treatment, which 
often adds to the cost and complexity of the process [177]. Moreover, some target proteins may 
form aggregates in solution due to their low solubility following release of the fusion tag [178].  
Proteins also form aggregates during processing or upon storage because of many intrinsic or 
extrinsic factors [179].  
54 
 
Protein aggregation is one of the major causes of physical instability of proteins and it is a challenge 
common to biological systems, experimental research, medical and industrial applications 
[179,180]. It is one of the major obstacles in development and commercialization of protein-based 
biopharmaceuticals for the purpose of prophylactic, therapeutic and diagnostic medicine [180]. The 
aggregates usually exhibit undesirable characteristics that may lead to   reduced or no biological 
activity, immunotoxicity or other undesired side effects [179]. Thus stabilizations of proteins 
against aggregation remain one of the most intensive research areas in development of proteins for 
pharmaceutical, medical and commercial applications. A number of approaches for stabilization of 
proteins at different stages of processing are described in the literature [181,182]. Among those the 
simplest and the most common method is tailoring the environment surrounding the proteins [182]. 
This can be achieved by optimizing solution conditions such as pH, ionic strength [182,183] or by 
adding stabilizing additives [183]. Several additives [165,184-189] have been studied for their 
potential to stabilize proteins at different stages of processing, formulation or upon storage. 
The stability of proteins against aggregation in different buffer conditions can be monitored using 
different analytical tools and assay methods such as SEC, light scattering methods, high-throughput 
ultracentrifugation dispersity sedimentation assay-coupled with sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) analysis, filtration coupled with SDS-PAGE or 
western blotting, turbidity assay, asymmetric flow field-flow fractionation (AF4), fluorescence 
microscopy, circular dichroism, fluorescence and fluorescence lifetime spectroscopy [188,190-194]. 
In practice, however, there is no ideal and universal analytical tool to monitor accurately and 
reliably the aggregation status of a given protein of interest. Identification of the most effective 
additive, pH or ionic strength from a large experimental space for each target protein is laborious 
and time-consuming using analytical methods with low-throughput capacity [195,196]. Therefore, 
the use of HTS techniques may provide opportunities for simple and rapid screening for the most 
effective solution conditions. HTS techniques have become a valuable tool for speeding up process 
development at various stages of processing biopharmaceuticals [197,198]. Usually, for HTS of the 
buffer conditions, the analytical methods require short analysis time, low sample consumption, and 
compatibility with a wide range of buffer components, such as buffering agents, salts and additives 
[188,193]. For example, DLS measurement, which provides in situ analysis within short period of 
time, has been used for miniaturized HTS of VLP formulation conditions that can be further refined 
by using AF4 with high resolution but with a low throughput [188]. 
DLS, also known as photon correlation spectroscopy or quasi-elastic light scattering spectroscopy, 
is a non-invasive diagnostic tool for particle sizing and determination of particle size distribution of 
proteins or other polymers in solutions or colloidal dispersions [199-201]. The DLS technique (Fig. 
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2-11) enables for the direct determinations of the translational diffusion coefficient of scattering 
units from analysis of time-dependent fluctuations of scattered light intensity arising from particles 
undergoing random Brownian motion [188,201]. The hydrodynamic radius or the Z-average radius 
(or cumulant mean) of particles can be calculated from the molecular diffusion coefficient using the 
Stokes-Einstein equation [201]. Despite its low resolution capacity and high sensitivity to the 
presence of large particles such as soluble aggregates, DLS provides in situ analysis with in short 
period of time and is suitable for HTS of various solution conditions for enhancing the stability of 
proteins at different stages during protein manufacturing and processing [188].  
 
 
Figure 2-11: The basic working principle of DLS for obtaining diffusion coefficient and particle size information. The 
sample is illuminated by a laser beam and the fluctuations of the scattered light are detected at a known scattering 
angle, Ɵ, by a fast photon detector. Diffusion coefficient and particle size information is obtained from the correlator. 
This figure was produced with slight modification based on the information available in Li et al. [200]. 
2.8.2. Synthetic biology design strategies 
The advances in DNA synthesis, assembly and sequencing have increased interests in using 
synthetic biology for the design and/or redesign of individual proteins, protein residues and subunit 
domains, genes, promoters, operators, terminators, vector replication elements and other core parts 
of synthetic biology circuits [202]. Using synthetic biology approaches, improved expression 
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plasmids and, robust and genetically stable expression strains have been developed for production 
of high yields and titres of target molecules [203,204]. Synthetic biology has the potential to 
influence various aspects of global health through cheaper drug production, identification and 
manipulation of host drug targets, manipulation of microbes  and their vectors, and developing a 
range of multivalent vaccines against various target diseases [203]. Synthetic biology tools can 
enable redesigning of existing biological systems, novel proteins, natural proteins, protein subunit 
domains and their parts, and synthesizing new ones to deal with specific problems. For example, 
with the advance of synthetic biology, non-conventional yeasts can be redesigned to expand their 
role as industrial expression hosts [204]. Conventional expression organisms, such as E. coli strains, 
can be redesigned to facilitate and ease the downstream processing of the target small molecules 
and proteins [203]. Modular constructs or their modules can be also redesigned to improve protein 
expression level, expression of soluble protein and to enhance protein stability during expression, 
purification, formulation and/or storage. 
In the design and redesign of modular constructs or their modules for expression of modular murine 
polyomavirus VP1, the size, physicochemical properties, or number of heterologous modules can be 
tailored using synthetic biology tools to enhance level of protein expression, protein solubility and 
stability. Lua et al., [162] demonstrated presentation of an 18 kDa RV VP8* large antigen on the 
surface of VLP using longer linkers. The study revealed that insertion of the longer linkers could 
ensure structural separation and independence and alleviate structural perturbations of VLPs 
following insertion of VP8* antigen.  
 Linkers have played various important roles in recombinant fusion protein production [205]. 
Flexible linkers are incorporated in fusion protein design to allow interaction between domains or to 
increase spatial separation between domains whereas rigid linkers are crucial to maintain distance 
between domains. Cleavable inkers allow in vivo separation of protein domains [205]. Linkers 
showed profound impact on the stability of fusion proteins during expression, processing and 
storage [206,207]. They are improving protein folding, facilitating protein expression and 
increasing protein yield [205,208]. They are also modulating the biodistribution and 
pharmacokinetic profiles of fusion proteins to increase their desired biological activity [205]. G4S is 
one of the most commonly used flexible linker that is used to maintain inter-domain interactions 
[155,205]. Longer flexible linkers  are able to separate  different moieties of fusion proteins 
spatially in order to alleviate structural perturbation of moieties, which often compromises the 
stability and activity of fusion proteins [162,206]. Linkers containing polar or charged amino acids 
often improve solubility of proteins [205]. 
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For modular proteins with high hydrophobic characteristics because of inserted hydrophobic 
modules, synthetic biology tools enable redesign of the modules to reduce the hydrophobic 
characteristics of the modules and/or modular proteins that may affect protein expression, solubility 
and stability. The stability of proteins often depends on hydrophobic interactions, electrostatic 
interactions, hydrogen bonding and, other intra- and inter-molecular forces between protein 
molecules and/or protein and solvent molecules [164]. These interactions can be systematically 
balanced and kept optimum by introducing additional hydrogen bonds on the surface, reducing 
surface hydrophobicity or through optimization of surface charge or by adding polar or charged 
amino acids in the sequence of surface exposed residues. A study showed that glutamic acid, 
aspartic acid and serine contribute most favourably to protein solubility at high net charge [209]. 
Insertion of double aspartic acid residues into a hydrophobic module enhanced expression of 
soluble modular murine polyomavirus VP1 proteins [210]. Incorporation of glutamic acid residues 
(E4) in module design as ionic flanking elements has improved expression of soluble modular VP1 
protein inserted with a hydrophobic module from influenza A virus [211].  Stubenrauch et al. [212] 
inserted an octa-glutamic acid peptide as a purification tag in a surface exposed loop of pentameric 
VP1 of polyomavirus. The polyionic tag was efficiently used to capture pentameric VP1 by ion 
exchange chromatography and did not inhibit in vitro assembly of VP1 pentamers into VLPs. 
Incorporation of poly ionic peptides into hydrophobic modules may counteract the effect of high 
surface hydrophobicity on protein solubility, as well as stability against aggregation.  
2.8.3. Protein co-expression 
Numerous proteins exist in the form of a protein complex containing only two or three to multiple-
subunits [213,214]. Most of their subunits exert their functions through formation of active and 
stable protein complexes, and protein-protein interactions [213]. Traditionally, multi-protein 
complexes are produced by overexpression and purification of each subunit protein separately using 
the bacterial, yeast, insect or mammalian host expression system, followed by in vitro reconstitution 
of partner subunit proteins [215,216]. This approach has been successfully used to produce many 
protein complexes [215]. However, in vitro reconstitution often requires refolding procedures at 
least for one-subunit of the complex and it also suffers from protein aggregation that affects the 
yield and functionality of the protein complexes or their subunits [215,216]. Protein co-expression 
technology using either a prokaryotic or eukaryotic expression hosts has become an important 
strategy for producing a variety of protein complexes for biochemical, biophysical, functional, 
structural, and high throughput screening studies [215,217]. Unlike the in vitro reconstitution or 
refolding of the individually expressed partners, co-expression usually overcomes solubility 
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problems of individually expressed subunits and allows their proper folding into their native form, 
and leads formation of a soluble complex in vivo [216,218]. 
Many protein co-expression systems are available for simultaneous expression of two or more 
proteins in eukaryotic and prokaryotic cells [219,220]. Protein co-expression in eukaryotic cells 
may be favoured in case of proteins or their complexes that require post translational modifications 
for their function and/or stability [216]. Despite the advantages of the eukaryotic systems, co-
expression strategies in E. coli remain one of the most powerful and the primary systems of choice 
for production of protein complexes [216,220]. E. coli co-expression system has the benefit of 
obtaining large quantities of target proteins at low-cost and short time due to ease of its 
manipulation and rapid growth [216,219,220]. Moreover, some successful efforts in enhancing the 
ability of E. coli to secrete proteins to the extracellular environment, efforts in developing 
antibiotics-free plasmid systems with other alternative methods for selections, and engineering 
glycosylation and other post-translational modification in to the E. coli expression/co-expression 
systems have born fruits in practical sense for low-cost manufacturing of proteins [221]. For 
example, Sommer et al. [222] demonstrated efficient production of extracellular proteins, such as 
alkaline phosphatase and β-lactamase, by means of optimized co-expression of bacteriocin release 
proteins in E. coli. A study also showed overexpression of post-translationally modified peptides in 
E. coli by co-expression with modifying enzymes [223]. 
Protein co-expression has also got potential applications for productions of toxic, membrane or 
hydrophobic proteins, which often requires the presence of their binding-partner protein(s) to ensure 
their expression, and their correct folding and stability [213]. Co-expression membrane proteins 
with folding modulators and chaperones  have resulted in production of membrane proteins in large 
quantities in vivo [224]. Studies demonstrated that co-expression of appropriate folding accessory 
proteins have significantly improved the productivity of active form of proteins in E. coli [225,226]. 
Co-expression of proteins with molecular chaperones have reduced the aggregation of proteins, 
increased their expression as soluble proteins and activity [227], and improved conformational 
quality of recombinant proteins in E. coli [228]. Protein co-expression has offered an important 
strategy for improving the yield, activity and stability of different enzymes for structural studies 
[229], for industrial [218,230,231] and therapeutic applications [217]. Co-expression of structural 
proteins of complex viruses, such as rotavirus, in eukaryotic cells [129,130] has resulted in the 
formation of VLPs.  
Protein co-expression in E. coli and eukaryotic cells can be achieved using either multiple or single 
expression vector strategies [216,219]. Multiple vector strategy utilizes two or more plasmids, each 
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carrying the gene(s) expressing one or two component proteins [213,215]. This strategy often 
requires less cloning steps and provides flexibility when many combinations of individual 
constructs need to be tested [217]. The expression constructs for each component can be generated 
in parallel, and used in expression trial and expression optimization individually or in combination 
[215]. For successful co-expression of proteins in E .coli via multiple vector strategy, ideally each 
vector should contain a different antibiotic selection marker as well as a different origin of 
replication, in order to stably maintain the plasmids in the host cells [215-217]. However, plasmids 
with the same origin of replication but with different antibiotic selection markers could co-exist in 
the cells by simply using higher concentrations of antibiotics [215,217]. For example, commercially 
available Novagen Duet vectors are used for co-expression of proteins using multiple vector 
strategy. These vector systems utilize more than two plasmids, each with a different combination of 
a compatible replicon and an antibiotic selection marker, or simply utilize plasmids with identical, 
incompatible replicons and different antibiotic selection markers [232]. On the other hand, protein 
co-expression from a single vector system in E. coli can be achieved via either a single expression 
cassette or multiple expression cassettes, where an expression cassette consists of a single 
transcriptional unit with “promoter-open reading frame(s) (ORF(s))-terminator sequence elements 
[215]. With the single-cassette approach, an unrestricted number of genes are inserted into a 
plasmid to form a single transcriptional unit with either two translational units (bicistronic) or 
multiple translational units (polycistronic) [213,215,233]. These operon-like constructs have been 
successfully used for co-expression of two or more proteins under the control of a single promoter 
[217,232]. The single-cassette approach is the method of choice in cases where strict control of 
stoichiometry is essential to form a functional protein subunit [213]. Usually, the upstream ORFs 
are expressed more efficiently than the downstream ones, resulting in sub-stoichiometric 
arrangement of the resultant complex [215,233]. The second approach for co-expression of proteins 
using a single vector system relies on tandem coding regions involving multiple expression 
cassettes [215,217].  Using this approach, individual genes/ORFs are expressed separately under the 
control of multiple expression cassettes carried by a single plasmid, where in general the number of 
cassettes is the same as the number of genes transcribed [215,217,233]. This co-expression 
approach might offer better yield of protein-protein complexes compared to co-expression using 
multiple vector system and single vector system with a single expression cassette [217,233]. 
However, it also might lead to an imbalanced ratio of expressed protein products because of 
uncoupled transcription of the genes, differences in the rate of transcription, translation, 
translocation, and the stability of RNA and protein products [215,217].  
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A variety of single co-expression vectors are available commercially for co-expression of proteins 
using both E. coli and eukaryotic cells [215]. Construction of single co-expression constructs 
usually requires laborious and time-consuming cloning steps to avoid unintended restriction 
digestion during sub-cloning [215,232]. It is also difficult to change the combination of targeted 
proteins after generation of a certain plasmid for single vector co-expression strategy [232]. Despite 
the sequential steps needed for single vector construction, expression of all component proteins 
from a single co-expression construct often facilitates easy establishment of expression strains and 
ensures expression of component proteins in the same host cell [215,217,232]. It can also be used 
for titrating down the ratio of one or more than one components in a protein complex to achieve the 
desired physicochemical properties of the protein complex that is essential for its physical, chemical 
and structural stability and biological activity. For example, Lua et al. [162] developed a 
baculovirus-insect cell bicistronic expression system that co-expresses unmodified murine 
polyomavirus VP1 and modular VP1 presenting an 18 kDa RV VP8* large antigen from a single 
plasmid. This approach was able to overcome steric hindrance to VLP formation by titrating down 
the ratio of modular VP1 during co-expression and reducing the amount of the large VP8* antigen 
on the VLP surface. Due to the shortcomings of manufacturing of VLPs from eukaryotic expression 
systems, VLP manufacturing via in vitro assembly of VLP subunits in a cell-free bioreactor has got 
huge potential for reduction of manufacturing and processing costs [234]. Chapter 5 addresses 
extrapolation of the baculovirus-insect cell bicistronic expression system to the bacterial expression 
system for low-cost production of modular capsomeres, which can be used as alternative vaccine 
candidates to VLPs or as starting subunits for in vitro VLP assembly using a cell-free bioreactor.   
2.9. Assessing the immunogenicity and efficacy of RV subunit vaccine candidates in vivo  
Development of an effective vaccine against RV hinges on an improved understanding of the host 
immune response to RV. An ideal subunit vaccine candidate should be able to stimulate the 
appropriate arm of the immune system with concomitant generation of the memory cells. Despite 
tremendous progress in understanding the structural features [39], the replication cycle [20], 
mechanisms of rotavirus pathogenesis [33] and immunity [39], full correlation of immune response 
with protective immunity against RV infection and diarrhoea is not well understood. Understanding 
the nature of protective immunity against RV will increase the success of developing effective 
vaccines.  
New vaccine development involves a multistep process. The pre-clinical studies are the earliest 
phases of new vaccine development that entail investigation of candidate vaccines both in vitro in 
laboratories and in vivo in animals [235]. In vitro studies comprise assessment of quality control of 
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the manufacturing process and validation of in vitro immunogenicity assays to be used in 
subsequent preclinical and clinical trials. In vitro studies are also fundamental components of 
vaccine design. For example, neutralization assays are employed for identification of the serotype 
of the most prevalent circulating viral strains, which in turn affects vaccine design and vaccine 
formulation [235].  As part of the in vitro studies in developing non-replicating vaccine candidates 
against RV, various subunit vaccines containing RV VP4, VP7, VP6 or NSP4 peptides and proteins 
[5,6,88,113,114], RLPs [129] or modular VLPs containing RV antigens [133,162] have been 
produced using  prokaryotic and/or eukaryotic expression systems.  
In vivo studies are designed during pre-clinical evaluation to assess safety and immunogenicity of 
RV subunit vaccine candidates. Such studies have relied on the use of appropriate animal models to 
generate valuable safety and immunogenicity data to select high ranking and potential vaccine 
candidates for clinical evaluation in humans.  The role of various animal models for preliminary 
evaluation of the immunogenicity of new RV subunit vaccine candidates is again an unanswered 
question, as high immunogenicity in any of these animals provides no assurance of protection either 
in animals or in humans. Among others, mice, rat, rabbit, piglet, calf, lamb, non-human primates 
have been used for assessing the safety, immunogenicity and efficacy of RV vaccines [44,236,237]. 
Mice are extensively used for studying the immunogenicity of different RV subunit vaccine 
candidates [237]. They are preferred to other animal species because of simplicity of keeping, 
breeding and reproducing them [238], their small size, low cost, availability of a large collection of 
inbred, outbred, immunologically deficient and genetically altered RV naïve mice strains, as well as 
broad accessibility of research immunological reagents [239]. In pre-clinical studies, the outcomes 
from preliminary immunogenicity assessments are typically viewed as tests of biological concepts 
for selecting a potential candidate for further clinical studies. Immunogenicity endpoints must be 
determined in consideration of various factors, such as host and vaccine factors, the type of the 
desired immune responses-humoral, cellular, or mucosal- and the time points when the immune 
responses are measured [235,240]. Antigen-specific antibody response usually constitutes the 
primary immunogenicity endpoint during preclinical study. A qualitative assay such as the dot 
blotting analysis [241] or a quantitative assay such as the enzyme-linked immunosorbent assay is 
employed to detect or to measure antibody response [235,242]. Depending on the type of epitopes 
present in each vaccine candidate, consideration of the cell-mediated immune responses during the 
early pre-clinical evaluations is also equally important for selecting potential vaccine candidates 
that can induce protective immunity against RV. 
Vaccine candidates with valuable safety and immunogenicity data based on the outcomes from the 
pre-clinical studies can be used for further efficacy study using different animal models. The adult 
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mice and rabbit RV infectious models, the gnotobiotic piglet RV disease model, and neonatal mice 
and calves passive protection models have been used to evaluate protective efficacy of RV subunit 
vaccine candidates [243]. Studies using the neonatal mice and calf models demonstrated passive 
protective immunity in mouse pups and calves [244,245]. Efficacy studies of various RV subunit 
vaccines in adult mice [95,246] and rabbit [44,100,247] models also showed complete or significant 
partial protection against RV infection, but not against diarrhoea.  In comparison, the neonatal 
gnotobiotic piglet’s model presents a number of advantages for evaluating vaccine efficacy. For 
example, the gnotobiotic pigs closely resemble humans in gastrointestinal physiology and in the 
development of mucosal immunity, and susceptible up to at least 8 weeks of age to infection and 
diarrhoea with many human RV strains [236]. Different RV subunit vaccines showed protective 
efficacy during preclinical studies using the neonatal gnotobiotic piglet’s infection and disease 
model [44,51,128]. Generally, evaluation of the immunogenicity, safety and efficacy of vaccine 
candidates during preclinical studies helps selection of potential vaccine candidates for further 
phase I, phase II and phase III clinical studies. Particularly, the efficacy data obtained using 
neonatal gnotobiotic piglet’s model offers information that may be more relevant for the 
development of RV vaccines for humans. However, the use of the neonatal gnotobiotic piglet’s 
model has been limited in early preclinical studies because of high cost and the need for specialized 
equipment, facilities and staff [243]. Thus, the mouse model remains as a simple and cost effective 
choice in the earliest phase of vaccine development. In vivo study using the mouse model is 
particularly suited for preliminary assessment of the immunogenicity of new vaccine candidates. 
More recently, the mouse model has been used successfully to obtain relevant immunogenicity and 
protective efficacy data for murine polyomavirus VP1 modular capsomeres and VLPs presenting 
M2e- and J8-peptide modules, respectively [138,140,155,159].  Despite the presence of a strong 
pre-existing anti-VP1 antibody, high levels J8i-specific antibody titer was obtained from mice 
immunized by modular VLPs presenting J8i-peptide modules [158]. These results and the findings 
in Chapter 5 and Appendix B strengthen the use of the mouse model in the earliest phases of new 
vaccine development.  
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Abstract  
Virus-like particles (VLPs) and capsomere subunits have been developed as safe and effective 
vaccine candidates in the fight against infectious diseases. These bioengineered structures are 
suitable platforms for repetitive high density presentation of foreign epitope modules. However, due 
to the module’s diverse physicochemical properties, modularisation of capsomeres and VLPs 
requires tailoring of the physicochemical environment specific to each module to maintain protein 
stability against aggregation. Here we report a high-throughput technique for screening buffer 
components to stabilize capsomeres, based on light scattering analysis.  This screening method was 
applied to modular capsomeres presenting peptide epitopes from the rotavirus spike protein VP8 
subunit domain, engineered as a next-generation rotavirus vaccine candidate. Among various 
additives tested, non-ionic detergents, such as Triton X-100, Tween-80 and Tween-20, were able to 
stabilize modular capsomeres, either alone or in combination with L-arginine, as confirmed with 
high-resolution size exclusion chromatography. Results demonstrate that tailoring the nature of the 
environment surrounding self-assembling proteins using small organic molecules can enhance the 
bioprocessing of modular vaccine capsomeres. The developed screening method potentially 
provides a powerful approach for rapid tailoring of processing conditions specific to antigenic 
modules displayed on next-generation recombinant capsomere and VLP vaccines, for low-cost 
vaccine delivery at global scale. 
Key words: virus-like particles, capsomeres, protein, aggregation, downstream processing, protein 
recovery.  
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3.1. Introduction 
Virus-like particles (VLPs) are macromolecular assemblies of the viral structural protein(s) that 
retain antigenic features of the authentic virus without the viral genome [1-3]. VLPs  have come 
into focus for their promising application in vaccination [4-7] because of their high safety and 
efficacy profile [8]; their repetitive and high density native display of epitopes leading to their self-
adjuvanting property; their ability to present foreign epitopes on the surface; and their stability 
compared with soluble antigens [9-12]. So far, three VLP-based vaccines have been 
commercialized for human use against hepatitis B virus infection, human papillomavirus-induced 
cervical cancer and hepatitis E virus infection [4,13]. Numerous other VLP-based vaccines against 
many infectious agents have shown promising results under pre-clinical evaluation using small-
animal models and in clinical trials [12,14-16]. Moreover, assembly-incompetent VLP sub-units, 
termed capsomeres, have recently gained attention for their potential as alternative low-cost second-
generation vaccine candidates to VLPs [15,17-19]. Although most capsomeres showed less 
immunogenic response compared with the corresponding VLPs,  their reduced efficacy was 
significantly compensated by using effective and safe adjuvants [20]. Some capsomeres could 
induce almost the same level of immune response as the corresponding VLPs when formulated with 
safe adjuvants [15,18,19].  
Despite the significant benefits of the marketed VLP-based vaccines and the promising potential of 
those in the developmental pipeline, many will likely remain unaffordable for resource-poor 
countries due to their high manufacturing and processing costs from eukaryotic expression systems 
[7,17,21]. Minimizing production costs has been the focus of several developments to enable low-
resource countries to use the final product with affordable cost [22]. The ability to manufacture 
VLPs from microbially-expressed sub-units via in vitro assembly in a cell-free reactor, under 
engineering controls, suggests huge potential for cost reduction [23]. Low-cost bacterial expression 
systems have been used for production of the VLP sub-units resulting in high yields 
[7,15,21,24,25]. For example, the murine polyomavirus major capsid protein, VP1, has been 
produced as a GST-VP1 fusion protein at gram-per-liter levels in Escherichia coli (E. coli) [7,21]. 
Enzyme-mediated cleavage of the GST tag followed by purification and separation by size 
exclusion chromatography (SEC) results in pure VP1 capsomeres that have been assembled in vitro 
to form VP1 VLPs in cell-free reactors [24,26]. The production of assembly-incompetent VP1 
capsomeres using prokaryotic expression has also been reported [15,18]. Current research focuses 
on the modularization of foreign antigenic epitopes into VLPs or capsomeres to target specific 
diseases. Middelberg et al. [15] have developed VP1 VLPs that were able to display J8-peptide 
from the M-protein of Group A streptococcus; such antigen-loaded modular VLPs showed 
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protection in a mouse model following unadjuvanted nasal delivery [15,27]. The modular 
capsomeres containing single [15,18] or multiple modules [18] of influenza M2e peptide antigen 
gave protection in mice when formulated with Alhydrogel® [28].  
The insertion of modules into the VLP subunits can be well tolerated, [15,18,27]; however results 
can be dependent on the physicochemical properties of modules. Thus, modularization may require 
tailoring of the processing conditions specific to each module to maintain protein colloidal stability. 
The stability of proteins is a major concern, particularly for the field of vaccination, where lower 
efficacy can be a result of poor vaccine stability [29]. A number of approaches for stabilization of 
proteins at different stages of processing are described in the literature [30,31]. Among those the 
simplest and the most common method is tailoring the environment surrounding the proteins [31]. 
This can be achieved by optimizing solution conditions such as pH, ionic strength [31,32] or by 
adding stabilizing additives [32]. Several additives [29,33-40] have been studied for their potential 
to stabilize proteins at different stages of processing, formulation or upon storage.  
Despite the availability of various stabilizing additives, identification of the most effective additive 
from a large experimental space for each target protein is laborious and time-consuming using 
analytical methods with low-throughput capacity [41,42]. Therefore, the use of high-throughput 
screening (HTS) techniques may provide opportunities for simple and rapid screening for the most 
effective additives. HTS techniques have become a valuable tool for speeding up process 
development at various stages of processing biopharmaceuticals [43,44]. They have been used 
effectively for rapid identification and selection of conditions for precipitation [45] and separation 
[46] of monoclonal antibodies from host cell proteins; for determining protein solubility [41,43] and 
rapid assessment of the dependence of colloidal stability on complex parameter interactions [41]; 
and for development of production processes [47] and quantification [48] of polysaccharide vaccine 
candidates. Mohr et al. [40] demonstrated a miniaturized HTS methodology for VLP formulation 
by integrating dynamic light scattering (DLS) and asymmetrical flow field-flow fractionation. DLS 
measurement with high-throughput capacity provides in situ analysis within short time periods 
using small amounts of protein. Although the DLS technique is a low resolution method with 
limitations and high sensitivity to the presence of large particles [40], it can be effectively used for 
HTS of protein processing conditions, particularly in cases when the size difference between 
different species, such as between capsomeres and soluble aggregates, is high.  
The present study describes the development of a rapid, simple and effective HTS method to 
identify optimal processing conditions for stabilization of modular capsomeres. The method, based 
on DLS analysis, was used for rapid screening of subsets of buffer additives that could enhance the 
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stability of modular capsomeres (RvVP1), presenting an antigenic module derived from the VP8 
subunit domain of the rotavirus spike protein. The potential of the superior additives based on DLS 
analysis in stabilizing RvVP1 was further confirmed with high-resolution SEC. The screening 
methodology developed in this study can be applied for tailoring the physicochemical environment 
of modular capsomeres and VLPs that incorporate antigenic modules having diverse 
physicochemical properties. The identification of protein-stabilizing buffer additives in this manner 
highlights the need to tailor the physicochemical environment specific to each module for 
processing and manufacture of stable modular capsomeres and VLPs in a fast and economical way. 
In this regard, the method can be used as a powerful tool for further advancing the platform and 
adding to the speed of manufacturing of quality modular capsomeres and VLPs for low-cost vaccine 
delivery at global scale. 
3.2. Materials and methods 
3.2.1. Chemicals 
The following details the reagents used as additives and their source.  All additives were of 
analytical grade: L-arginine (L-Arg) (MP Biomedicals, LLC Solon, Ohio, USA); L-glutamic acid 
(L-Glu), α-cyclodextrin, β-cyclodextrin, Ƴ-cyclodextrin, methyl-β-cyclodextrin, tween-80 (TW-80), 
triton X-100 (TX-100), and bovine serum albumin (BSA) (Sigma–Aldrich, MO, USA); 
biotechnology grade phosphate buffered saline (PBS), and isopropyl-β-D-thiogalactoside (IPTG) 
(Astral Scientific Pty. Ltd., Gymea NSW, Australia); Tween-20 (TW-20) (Ajax Finechem, VIC, 
Australia).  
3.2.2. Plasmid construction 
Vector pGEX-4T-1 (GE Healthcare Biosciences, Chalfont St. Giles, UK) with inserted murine 
polyomavirus VP1 sequence (pGEXVP1) was generously provided by Professor Robert Garcea 
(University of Colorado, CO, USA). Plasmid, pGEXVP1-S4, encoding the protein, VP1, was 
created previously by inserting AfeI restriction enzyme site at position 293 of VP1 [15]. Plasmid, 
pGEXVP1-S4-VP8aa1-10, encoding RvVP1 was prepared from pGEXVP1-S4; RvVP1 is the 
protein VP1 but containing the amino acid sequence (EMASLIYRQLLESEMASLIYRQLLESEM 
ASLIYRQLLES) at position 293. The amino acid insert, VP8aa1-10, corresponds to tandem copies 
of residues 1-10 (MASLIYRQLL) of the VP8 subunit domain of the human rotavirus spike protein, 
with spacer amino acids. DNA sequence of the insert was prepared by PCR-based gene synthesis 
from a set of oligos (5´gagatggcgagcctcatct 3´, 5´cgctttcgaggagttggcgatagatgaggctcgccatctc3´, 5´gcc 
aactcctcgaaagcgaaatggcctctctgatctaccg3´, 5´atttcagactccagcagctggcggtagatcagagaggcca3´, 5´cagctg 
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ctggagtctgaaatggcgtccctgatttaccgtc3´and 5´ggattcgagcagttgacggtaaatcagggacgc3´), generated from 
DNAWorks (http: //helixweb.nih.gov/dnaworks/). Correct insertion of the desired gene sequence 
was verified by DNA sequencing at the Australian Genome Research Facility (Brisbane, Australia).  
3.2.3. Protein expression and purification 
pGEXVP1-S4 and pGEXVP1-S4-VP8aa1-10 were transformed into separate E. coli RosettaTM (DE3) 
pLysS chemically competent cells (Novagen, San Diego, CA, USA). Bacterial expression of 
glutathione-S-transferase (GST) tagged proteins, GST-VP1 and GST-RvVP1, was as previously 
described [7,21] except cell cultures were induced with 0.1 mM  IPTG at 20oC for expression of 
GST-RvVP1. GST-tagged proteins were captured by GST affinity chromatography (GSTrapTM HP 
5 ml column) (GE Healthcare) as described previously for purification of GST-VP1 [7,21,49]. All 
protein concentrations were determined using the Coomassie (Bradford) Protein Assay Kit (Pierce, 
IL, USA) microplate assay protocol. BSA was used as the standard and PBS was used to dilute the 
stock solution to achieve the standard concentrations in the assay.  
3.2.4. Enzyme-mediated release of the GST tag 
Thrombin-mediated cleavage to release the GST tag and purification of VP1 capsomeres was as 
previously reported [18,49]. For this process, purified GST-RvVP1 underwent thrombin proteolytic 
cleavage in a buffer containing different additives as summarized in Table 1. Briefly, concentrated 
stock solutions of additives listed in Table 1 were made in a buffer containing 40 mM tris-base, 1 
mM ethylenediaminetetra-acetic acid (EDTA) disodium and 5% (v/v) glycerol. The additives were 
dissolved completely and filtered through 0.22 µm filter membrane [50]. The buffer was adjusted to 
pH 8.0 using aqueous solution of hydrochloric acid (32% (v/v)) and dithiothreitol (DTT) at a final 
concentration of 5 mM was added prior to use. Twenty-five microliters of freeze-thawed GST-
RvVP1 aliquot at a concentration of 3.5 mg mL-1 in L buffer [200 mM NaCl, 40 mM tris (pH 8.0), 1 
mM EDTA disodium, 5% (v/v) glycerol and 5 mM DTT], twenty-five microliters of buffer 
containing each additive (Table 1) and one microliter of thrombin (40 U/mL) (GE Healthcare) were 
mixed in 1.5 mL polypropylene Eppendorf tubes (Sarstedt, Australia). The concentration of each of 
the additives was adjusted to their target final concentration mentioned in Table 1, prior to mixing 
with the protein samples. The reaction mixtures were vortexed for 2 s, spun down using Wealtec E-
centrifuge (Pathtech Pty Ltd, VIC, Australia) and then incubated at room temperature for 2 h. The 
reaction mixtures were then centrifuged at 22000g, 4°C, for 5.0 min, and the soluble fractions were 
analysed by SDS-PAGE and DLS measurements.  
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Table 3-1. List of buffer additives and their final concentrations for stabilization of modular capsomeres against 
aggregation  
Additives 1-27 Additives 28-54 
1 200 mM NaCl 28 400 mM NaCl, 100 mM Trehalose 
2 200 mM NaCl, 50 mM L-Arg 29 600 mM NaCl, 50 mM Trehalose 
3 200 mM NaCl, 100 mM L-Arg 30 600 mM NaCl, 100 mM Trehalose 
4 200 mM NaCl, 150 mM L-Arg 31 200 mM NaCl, 50 mM L-Arg, 50 mM L-Glu 
5 200 mM NaCl, 200 mM L-Arg 32 200 mM NaCl, 10 mM α-cyclodextrin 
6 200 mM NaCl, 250 mM L-Arg 33 200 mM NaCl, 10 mM β-cyclodextrin 
7 150 mM NaCl 34 200 mM NaCl, 10 mM γ-cyclodextrin 
8 150 mM NaCl, 50 mM L-Arg 35 200 mM NaCl, 10 mM Methyl-β-cyclodextrin 
9 150 mM NaCl, 100 mM L-Arg 36 200 mM NaCl, 0.1% (v/v) TX-100 
10 150 mM NaCl, 150 mM L-Arg 37 200 mM NaCl, 0.05% (v/v) TX-100 
11 150 mM NaCl, 200 mM L-Arg 38 200 mM NaCl, 0.013% (v/v) TX-100 
12 150 mM NaCl, 250 mM L-Arg 39 200 mM NaCl, 0.1% (v/v) TX-100, 25 mM L-Arg 
13 100 mM NaCl 40 200 mM NaCl, 0.05% (v/v) TX-100, 25 mM L-Arg 
14 100 mM NaCl, 50 mM L-Arg 41 200 mM NaCl, 0.013% (v/v) TX-100, 25 mM L-Arg 
15 100 mM NaCl, 100 mM L-Arg 42 200 mM NaCl, 0.05% (v/v) TW-80 
16 100 mM NaCl, 150 mM L-Arg 43 200 mM NaCl, 0.005% (v/v) TW-80 
17 100 mM NaCl, 200 mM L-Arg 44 200 mM NaCl, 0.0013% (v/v) TW-80 
18 100 mM NaCl, 250 mM L-Arg 45 200 mM NaCl, 0.05% (v/v) TW-80, 25 mM L-Arg 
19 400 mM NaCl 46 200 mM NaCl, 0.005% (v/v) TW-80, 25 mM L-Arg 
20 400 mM NaCl, 50 mM L-Arg 47 200 mM NaCl, 0.0013% (v/v) TW-80, 25 mM L-Arg 
21 600 mM NaCl 48 200 mM NaCl, 0.05% (v/v) TW-20 
22 600 mM NaCl, 50 mM L-Arg 49 200 mM NaCl, 0.023 % (v/v) TW-20 
23 100 mM NaCl, 50 mM Trehalose 50 200 mM NaCl, 0.006% (v/v) TW-20 
24 100 mM NaCl, 100 mM Trehalose 51 200 mM NaCl, 0.05% (v/v) TW-20, 25 mM L-Arg 
25 200 mM NaCl, 50 mM Trehalose 52 200 mM NaCl, 0.023% (v/v) TW-20, 25 mM L-Arg 
26 200 mM NaCl, 100 mM Trehalose 53 200 mM NaCl, 0.006% (v/v) TW-20, 25 mM L-Arg 
27 400 mM NaCl, 50 mM Trehalose 54 200 mM NaCl, 25 mM L-Arg 
 
3.2.5. Analysis of the cleavage products by SDS-PAGE 
SDS-PAGE was performed using 10% SDS-PAGE gel as reported previously [11]. Gels were 
destained using 45% (v/v) methanol and 10% (v/v) acetic acid solution.  
3.2.6. Dynamic light scattering (DLS) measurements  
Soluble VP1 capsomere aggregates, VP1 capsomeres and GST were separated and purified by SEC 
as previously reported [18,49]. The fractions corresponding to the soluble VP1 aggregate peak were 
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pooled together and concentrated by ultracentrifugation at 5000g, 4°C for 5 min using Amicon® 
ultra-0.5 mL 10K membrane (Millipore Ireland Ltd, Tullagreen, Co. Cork, Ireland). The 
concentration of the protein was determined by Bradford microplate assay (Pierce, IL, USA). 
Similarly, the protein concentrations were determined for VP1 capsomere and GST peak fractions. 
The concentration of each sample was adjusted to 450 µg mL-1 by dilution with L buffer. Fifty 
microliters of solution mixtures were prepared by mixing solutions of pure VP1 capsomere 
aggregates (450 µg mL-1), VP1 capsomeres (450 µg mL-1) and GST (450 µg mL-1) in 1.5 mL 
polypropylene microtubes (Sarstedt, Australia). All solution mixtures contained 50% (v/v) GST 
solution, and from 0% - 50% (v/v) VP1 capsomere and aggregate solutions. Pure solutions of VP1 
capsomere aggregates (450 µg mL-1), VP1 capsomeres (450 µg mL-1) and GST (450 µg mL-1), and 
their mixtures were subjected to analysis by DLS for particle size and size distribution in order to 
validate DLS analysis method using a 384-well microplate. Briefly, 20 µL of the mixtures were 
transferred in duplicates in to a 384-well Corning® polystyrene plate (Corning, NY, USA), and 
centrifuged to remove trapped air bubbles at 1000g, 4oC, for 4 min. Analyses were performed by 
using a Dynapro® plate reader (Wyatt Technology Corporation, CA, USA) equipped with an 830 
nm laser and a temperature control module. The Dynamics® software (Version 7.0.3.12, Wyatt 
Technology Corporation) was used for scheduled data acquisition and analysis. Ten 5 s 
measurements were taken for each well, resulting in 20 measurements for each mixture at 25°C. 
Data analysis was performed using the Dynals algorithm bundled with the Dynamics® software. 
The DLS method that was validated in this manner was applied to HTS of buffer additives for their 
potential to stabilize RvVP1 capsomeres following thrombin-mediated release of the GST tag in the 
presence of additives summarized in Table 1.  
3.2.7. Analysis by size exclusion chromatography 
Separation and purification of  VP1 capsomeres by SEC was performed as previously described 
[18,21]. Purification of RvVP1 capsomeres followed similar approaches. Briefly, GST-RvVP1 was 
diluted to 1.75 mg mL-1 with L buffer or L buffer containing TX-100, TW-80, or TW-20, alone or 
in combination with 25 mM L-Arg at final concentrations as described in Table 1 and subjected to 
thrombin-mediated release of GST tag at room temperature for 2 h. The cleavage products were 
centrifuged (22,000g, 4°C, 5 min) and RvVP1 capsomeres were recovered from 500 µL of the 
supernatant with a Superdex 200 30/100 GL column (GE Healthcare Biosciences) operated with an 
AKTAexplorerTM10 (GE Healthcare Biosciences) liquid chromatography system. The column was 
pre-equilibrated with L buffer or L buffer containing each of the additives at a flow rate of 0.5 mL 
min-1. Proteins were detected and visualized with SDS-PAGE from elution fractions corresponding 
to the aggregate and capsomere peaks of SEC chromatograms. 
92 
 
3.3. Results and Discussion 
3.3.1. Expression and purification of GST-VP1 and GST-RvVP1 
Expression of GST fusion proteins by E. coli Rosetta (DE3) pLysS cells transformed with the 
relevant expression vectors was confirmed by SDS-PAGE (Fig. 3-1A). No basal expression of the 
target recombinant GST fusion proteins was observed from the cultures harvested before induction 
with IPTG.  Target proteins were found in the soluble fractions of the cell lysates of induced 
cultures.  Purification by GST affinity chromatography resulted in a good recovery of target GST 
fusion protein (Fig. 3-1B). 
GST-VP1 and GST-RvVP1 were subjected to enzymatic cleavage with thrombin as reported 
previously [7,21]. SDS-PAGE analysis of the soluble fraction following cleavage (Fig. 3-2A) 
showed that the enzyme was able to release the tag completely. Cleavage product mixtures were 
subjected to SEC for separation and purification of capsomeres, soluble capsomere aggregates and 
GST for both VP1 and RvVP1 (Fig. 3-2B). The lanes in Fig. 3-2A demonstrate that the majority of 
soluble VP1 protein (Lane 3) remains as capsomeres (Lane 4); whereas for RvVP1 the majority of 
the soluble protein (Lane 6) is lost in the aggregate peak (Lane 7) and barely any remains as 
capsomeres (Lane 8). This observation demonstrates that RvVP1 capsomeres were not stable when 
the stability buffer optimized for VP1 capsomere [21] was used for downstream processing of 
RvVP1. The specific causes for poor stability of RvVP1 capsomeres are unknown. It is speculated 
that instability of the capsomeres may be driven by hydrophobic interactions. Thus, modularization 
of capsomeres can necessitate re-optimisation of the buffer conditions to maintain the colloidal 
stability of the new protein that results from modularisation. 
 
 
 
 
93 
 
 
Figure 3-1. Expression profile of GST-VP1 and GST-RvVP1 in E. coli Rosetta (DE3) pLysS cells. (A) The target 
proteins were visualized by SDS-PAGE from un-induced (U) cultures, total cell lysate (T), soluble fraction (S) and 
insoluble fraction (I) of induced cultures. Novex® Sharp Pre-stained Protein marker (M) was used as ladder. (B) The 
target GST fusion proteins (Lane 1: Protein marker; Lane 2: GST-VP1 and; Lane 3: GST-RvVP1) were purified from 
the soluble fractions of the cell lysates by GST affinity chromatography and visualized by SDS-PAGE. 
 
 
Figure 3-2. Relative solubility of VP1 and RvVP1 capsomere in L-buffer optimised for VP1. (A) SDS-PAGE analysis of 
the target proteins (Lane 1: Protein marker; Lane 2: GST-VP1; Lane 3: Total soluble protein after cleavage of GST-
VP1; Lane 4: VP1 capsomere peak fraction; Lane 5: GST-RvVP1; Lane 6: Total soluble protein after cleavage of GST-
RvVP1; Lane 7: RvVP1 aggregate peak fraction and; Lane 8: RvVP1 capsomere peak fraction) during downstream 
processing. (B) Size exclusion chromatogram of VP1 and RvVP1 capsomeres following thrombin mediated cleavage of 
the GST tag in L-buffer.  
3.3.2. DLS analysis for HTS of buffer additives for enhanced stability of modular capsomeres  
3.3.2.1. Validation of the DLS method 
DLS is a non-invasive diagnostic tool for particle sizing and determination of particle size 
distribution in solutions or colloidal dispersions [50]. From DLS measurements, diffusion 
coefficient can be obtained from analysis of time-dependent fluctuations of scattered light intensity 
arising from particles undergoing random Brownian motion [40,51]. The hydrodynamic radius or 
the Z-average radius (or cumulant mean) of particles can be calculated from the molecular diffusion 
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coefficient using the Stokes-Einstein equation [51].  However, due to  DLS particle sizing´s  higher 
sensitivity to the presence of  large particles, such as soluble aggregates [40], accurate interpretation 
of the DLS data is very challenging. The presence of trace amounts of large particles may mask 
contributions of small particles on the over-all hydrodynamic property of solutions. Thus validation 
of DLS analysis using well characterized materials can minimize errors and avoid a false negative 
or false-positive conclusion. 
Solutions of pure VP1 capsomeres, VP1 capsomere aggregates and GST, purified by SEC and 
quantified by Bradford microplate assay, and their solution mixtures [section 2.5] were used to 
validate the DLS measurement, using a 384-well plate.  Mixtures of VP1 capsomeres, VP1 
aggregates and GST solutions were used to simulate the thrombin cleavage products of GST-
RvVP1 in the presence of various additives (Table 1). Fig. 3-3A shows the change in the Z-average 
radius of particles dependent on the ratio of capsomere and aggregate particles in solution. As % 
(v/v) of capsomere solution increased from 0 to 50%, the Z-average radius decreased. As expected, 
the Z-average radius was highest for the solution containing pure capsomere aggregates and the 
lowest for the solution of pure GST. The Z-average radius is a preferred parameter for particle size 
analysis by DLS since its calculation is mathematically stable and the Z-average result is less 
sensitive to noise [52,53].  
Fig. 3B shows the intensity autocorrelation curve for pure VP1 capsomere, VP1 capsomere 
aggregate and GST solutions, and solution mixtures. The autocorrelation curves at 100%, 50% and 
45% (v/v) of VP1 capsomeres show a smooth and continuous exponential decay, indicative of low 
sample polydispersity. The decay time for particles in the mixture extended when the % (v/v) of the 
capsomere solution decreased from 50% to 40% or the % (v/v) of capsomere aggregate solution 
increased from 0 to 10%. The extended decay time might be due to the greater sample 
polydispersity. Moreover, diffusion of particles might be slowed down due to inter-particle 
interactions of small and large particles at some critical number of particles, creating an optimum 
surface area for maximum interaction to occur,  affecting the hydrodynamic properties of the 
particles [54]. The DLS analysis method, which was validated using artificial mixtures of purified 
VP1 capsomeres, VP1 capsomere aggregates and GST, was applied to HTS of buffer additives for 
their potential to enhance the stability of RvVP1 capsomeres.  
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Figure 3-3. Validation of the DLS method using solution mixtures of pure VP1capsomeres, VP1 capsomere aggregates 
and the GST. (A) Plot of the Z-average radius of particles in the mixture against % (v/v) of VP1 capsomeres, 
aggregates and GST respectively in solution mixtures. The Z-Average radius expressed as mean of two values. The 
coloured bars, dark green ( ), light green ( ) and orange ( ), present good, slightly good and bad conditions 
respectively. (B) DLS showing the intensity autocorrelation of the mixtures with time. The good conditions are indicated 
by . 
3.3.2.2. HTS of buffer additives for enhanced stability of modular capsomeres 
Buffer additives (Table 1) including NaCl at different concentrations, L-Arg, equimolar mixture of 
L-Arg and L-Glu, trehalose, cyclodextrins, the non-ionic detergents, TX-100, TW-80 and TW-20, 
and combinations of L-Arg and non-ionic detergents were examined for their potential to enhance 
stability of RvVP1 capsomeres. The concentration of the additives was fixed based on their use in 
the literature as stabilizing agents at various stages of protein processing, formulation or upon 
storage [30,33,40,55] and in consideration of their compatibility with the activity of thrombin and 
the DLS measurement. The additives were added to the protein solution before release of the GST 
tag using thrombin. Successful cleavage of the tag was assessed by SDS-PAGE. It was observed 
that L-Arg at a concentration of 100, 150, 200 and 250 mM, and equimolar mixtures of L-Arg and 
L-Glu at 50 mM, decreased the enzymatic cleavage activity of thrombin (data not shown). In a 
previous study it was speculated that L-Arg and L-Glu may act as strong competitive inhibitors of 
proteases or that binding of L-Arg and L-Glu to the surface of the protein may mask the protease 
recognition site [30]. All other additives did not interfere with the action of the enzyme for GST tag 
release under the conditions tested. 
HTS technologies are based on fast analysis and low sample volume [42,43] meaning that a large 
number of conditions can be quickly tested using a relatively small amount of materials [40,42]. 
Here we have developed a DLS-based method that allows quick screening of relatively low sample 
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volume (20 µL) to monitor the stability of RvVP1 capsomeres in the presence of additives listed in 
Table 1. According to the DLS method validation (Fig. 3-3) reduction in the Z-average radii of 
particles (less than 40 nm) indicates the ability of theses additives to enhance the stability of 
modular capsomeres (size ~ 10 nm) and inhibit the formation of large aggregates (size > 40 nm). 
The results of the DLS analysis of the additive screen are summarized in Fig. 3-4, which depicts the 
Z-average radius of particles in cleavage product solutions plotted against processing conditions 
categorized into 17 subgroups based on the type or concentration of additives. The Z-average radii 
of particles were greater than 40 nm for most of the conditions tested in this study; however, the 
evaluation of the 54 conditions (Table 1) demonstrated better performance of eight conditions (Fig. 
3-4). These conditions contained non-ionic detergents, 0.1% (v/v) TX-100, 0.05% (v/v) TX-100, 
TW-80 and TW-20 as additives either alone or in combination with 25 mM L-Arg. It is common for 
buffers to be augmented with detergents to increase solubility and to maintain stability during 
isolation and purification of hydrophobic proteins [56,57]. Among the different types of detergents, 
the use of non-ionic detergents to stabilize proteins, suppress aggregation and assist protein 
refolding has been well documented in the literature [31,55,57-60]. Their amphiphilic nature makes 
them good competitors with proteins for surfaces and interfaces and thus prevent adsorption 
induced denaturation and aggregation of proteins [31,60]. In addition, non-ionic surfactants may 
directly interact with hydrophobic regions in protein molecules and reduce their tendency to 
aggregate [61,62]. They can also prevent aggregation by serving as chaperones assisting protein 
folding and refolding [62].  
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Figure 3-4. DLS-based HTS of buffer additives for enhanced stability of modular RvVP1 capsomeres. The Z-average 
radius of particles in solutions of the cleavage product mixtures plotted against the cleavage buffer additives. The Z-
average radius expressed as mean of two values. The values of Z-average radii of particles in the presence of promising 
additives indicated by green ball ( ) and the orange ball ( ) represents the values in the presence of less performing 
additives.  
The potential of TX-100, TW-80 and TW-20 either alone or in combination with L-Arg to increase 
the stability of RvVP1 capsomeres was further confirmed with high-resolution SEC. Following 
thrombin-mediated cleavage to release the GST tag in the presence of TX-100 (0.1% and 0.05% 
(v/v) alone or in combination with 25 mM L-Arg, SEC showed that the detergent was able to 
increase the stability of modular capsomeres (Fig. 3-5) compared with downstream processing 
without the additives (Fig. 3-2B). Similarly, TW-80 and TW-20 (0.05% (v/v)) alone or in 
combination with 25 mM L-Arg could also increase stability of modular capsomeres (Fig. 3-5). L-
Arg alone was not able to enhance stability of modular capsomeres (data not shown) and there were 
no clear differences between the mAU UV absorbance values of the peaks corresponding to RvVP1 
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capsomere fractions when detergents were used alone and in combination with L-Arg as stabilizing 
additives (Fig. 3-5). These results indicate that enhanced stability of modular capsomeres was 
mainly due to the non-ionic detergents, and the use of L-Arg in combination with detergents did not 
result in additive or synergistic effect to enhance the stability of RvVP1 capsomeres. The presence 
of L-Arg can greatly influence the stability of a protein in solution. L-Arg is one of the most widely 
used aggregation-suppressing additives during protein refolding and purification [63-67]. However, 
it may not work well for all proteins and its effect depends on protein-additive or intra-additive 
interactions determined by the concentration of the additive [68].  
 
 
Figure 3-5. Size exclusion chromatogram of RvVP1 capsomeres following thrombin mediated cleavage of the GST tag 
in L-buffer with TX-100, Tween and L-Arg additives. P1, P2 and P3 represent the aggregate, capsomere and GST peaks 
respectively. 
To ensure the improved capsomere stability observed in SEC traces was not an artefact of the buffer 
itself, the RvVP1 protein was visualized with SDS-PAGE (Fig. 3-6) from the cleavage product 
mixtures and from purified SEC fractions. As shown in Fig. 3-6 A, the use of non-ionic detergent 
(TX-100, TW-80 or TW-20) as buffer additive during downstream processing could increase the 
stability of RvVP1 capsomeres compared with processing in buffer conditions optimized for VP1 
capsomeres (Fig. 3-2 A, lanes 7 and 8). Concentration (C) of RvVP1 protein from capsomere peak 
fractions (Fig. 3-5) was determined using Bradford microplate assay. The result showed that there 
was no clear difference in protein concentration when modular capsomeres were processed using 
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TX-100 [C = 0.206 mg/mL), TW-80 [C = 0.184 mg/mL] or TW-20 [C = 0.192 mg/mL] as 
stabilizing additive. Despite its application in enhancing stability of proteins and their elution from 
chromatographic resins during purification [65,69], use of L-Arg in combination with non-ionic 
detergents did not increase the yield of purified modular capsomeres as the concentration of the 
protein was almost the same as proteins purified using non-ionic detergents as the sole additives. 
Generally, the high-resolution SEC and subsequent analyses were in agreement with the results 
obtained from the HTS approach using DLS; improved capsomere yield means a higher population 
of particles in capsomere size range, which is reflected in the DLS Z-average size. Thus, there is 
agreement between the results obtained from DLS analysis and SEC, confirming the validity of this 
approach. The HTS method demonstrated in this study is simple, rapid and effective approach for 
identifying suitable buffer additives to increase stability of modular capsomeres. While the method 
demonstrated here was limited in the use of lab scale facilities, the process itself could be utilized in 
larger scale, higher throughput facilities, thus justifying it as a high-throughput screen. Here it could 
identify eight potential processing conditions to enhance stability of RvVP1 capsomeres out of 54 
conditions in less than two hours. Moreover, such a method saves substantial amount of protein 
sample and buffers compared to an iterative trial and error approach of process optimization using 
analytical tools having low-throughput capacity. 
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Figure 3-6. SDS-PAGE analysis of the target proteins (marker protein (M), GST-RvVP1 (G), total soluble protein after 
cleavage (S), total insoluble protein after cleavage (I), aggregate peak fraction (A) and capsomere peak fraction (C))  
throughout the downstream processing steps using: (A) non-ionic detergents as buffer additives; and (B) combination of 
L-Arg and non-ionic detergents as buffer additives. 
3.4. Conclusion 
Our aim was to develop a HTS method for rapid identification of buffer additives to increase 
stability of modular capsomeres during downstream processing. The method, based on a high-
throughput DLS analysis, has identified small organic molecules that could increase stability of 
RvVP1 capsomere, which was used as a model protein in this study. The method is simple and 
effective, requiring little analysis time and low protein consumption. Using this strategy, 54 
processing conditions in the presence of various additives were screened for their potential to 
enhance stability of RvVP1 capsomeres.  Eight conditions were successfully identified as effective 
stabilisers, from which the additives, 0.1% (v/v) TX-100, 0.05% (v/v) TX-100, TW-80 and TW-20 
were able to increase stability of RvVP1 modular capsomeres. The potential of these subsets of 
additives for enhancing stability of modular capsomeres during purification was further confirmed 
with a high-resolution SEC. Non-ionic detergents are very mild chemical compounds that do not 
denature proteins and they increase stability of proteins by inhibiting hydrophobic interactions 
between proteins or by coating interfaces to modulate adsorption loss and aggregation. The results 
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in this study demonstrate that tailoring the nature of the physicochemical environment surrounding 
the proteins using small organic molecules could stabilize RvVP1 modular capsomeres. The 
developed screening method provides a powerful approach for rapid tailoring of processing 
conditions specific to the antigenic modules on modular capsomeres. It can also eliminate time-
consuming and laborious trial and error approaches to optimize processing conditions for other 
proteins at all stages of purification. 
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Abstract  
Virus-like particles (VLPs) and capsomere subunits have shown promising potential as safe and 
effective vaccine candidates. They can serve as platforms for the display of foreign epitopes on their 
surfaces in a modular architecture. Depending on the physicochemical properties of the antigenic 
modules, modularization may affect the expression, solubility and stability of capsomeres, and VLP 
assembly. In this study, three module designs of a rotavirus hydrophobic peptide (RV10) were 
synthesized using synthetic biology. Among the three synthetic modules, modularization of the 
murine polyomavirus VP1 with a single copy of RV10 flanked by long linkers and charged residues 
resulted in the expression of stable modular capsomeres. Further employing the approach of module 
titration of RV10 modules on each capsomere via E. coli co-expression of unmodified VP1 and 
modular VP1-RV10 successfully translated purified modular capomeres into modular VLPs when 
assembled in vitro. Our results demonstrate that tailoring the physicochemical properties of 
modules to enhance modular capsomeres stability is achievable through synthetic biology designs. 
Combined with module titration strategy to avoid steric hindrance to inter-capsomere interactions, 
this allows bioprocessing of bacterially-produced in vitro assembled modular VLPs.  
Keywords: rotavirus, synthetic biology, linkers, module titration, co-expression, Escherichia coli 
4.1. Introduction 
Virus-like particles (VLPs) are highly organized multimeric protein complexes that self-assemble 
from viral structural protein(s) without the viral genome. VLPs are undergoing research as tools for 
vaccination, gene therapy, drug delivery, diagnostics, nanomaterials and immune therapy [1,2]. 
Particularly, their application in the field of vaccinology increased interest following the successful 
development and approval of three VLP-based vaccines for human use against hepatitis B virus 
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infection [3,4], human papillomavirus-induced cervical cancer [5] and hepatitis E virus infection 
[6]. Numerous other VLP-based vaccines against many infectious diseases have shown promising 
results under pre-clinical and clinical studies [7].  
VLP subunits, termed capsomeres, have also gained attention for their potential as alternative 
second-generation cheap vaccines to VLPs [8-13]. A human papillomavirus 16/18 L1 capsomere 
vaccine is currently undergoing a phase II clinical trial [14]. Under pre-clinical studies, human 
papillomavirus L1/L2 capsomeres [11,15-17] and modular murine polyomavirus VP1 capsomeres 
[8,10,18] have shown promising immunogenicity and protective efficacy results in different animal 
models.  
Both VLPs and capsomeres can serve as platforms for surface display of foreign epitopes or 
antigens in a modular architecture [8,10]. The murine polyomavirus major capsid protein VP1 has 
been used for presentation of a single or multiple modules of M2e-peptide epitope from influenza A 
virus [8,10] and J8i-peptide epitope from group A streptococcus M1 protein [8,19], respectively. 
These modular architectures were produced using a low-cost E. coli expression system and purified 
in high yields using both chromatographic [8,10,19-21] and non-chromatographic methods [22]. 
Purified modular VP1 capsomeres can form VLPs via in vitro assembly in a cell-free bioreactor 
[8,23]. This approach reduces VLP manufacturing and processing costs often linked to eukaryotic 
expression systems [24] and thus enables low-resource countries to use the final product at 
affordable costs [13]. However, the production of a modular capsomere from E. coli and the in vitro 
modular VLP assembly can highly be dependent on the physicochemical properties of the inserted 
modules. As previously observed, hydrophobic modules at the surface-exposed loop affected the 
capsomere stability during downstream processing [25,26]. 
Although nature employs hydrophobicity for its role in protein-protein interactions [27] and in 
stabilization of proteins [28-30], inserting hydrophobic modules into the surface-exposed loop of 
viral capsid protein can significantly change protein surface hydrophobicity. The surface 
hydrophobicity is often associated with changes in protein conformations [31] and related to the 
ease with which a protein unfolds [32]. Engineering surface-exposed hydrophobic modules is 
highly desirable to promote correct protein folding during expression and to maintain the solubility 
and stability of modular capsomeres, thus allowing the formation of modular VLPs via in vitro 
assembly. Insertion of negatively charged residues at both ends of hydrophobic protein domains has 
shown to enhance the stability of proteins [26,33]. Polar and/or charged amino acids, particularly, 
glutamic acid, aspartic acid and serine, have contributed most favourably to protein solubility at 
high net charge [34].  
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Linkers are the other important elements that have gained considerable success in construct design 
for the production of proteins [35]. Linkers can improve protein stability [36,37], folding, 
expression and purification yield [35,38], and for targeting fusion proteins to specific sites in vivo to 
increase their desired biological activity [35]. Linkers are used to separate different moieties of 
fusion proteins spatially in order to alleviate structural perturbation to moieties [36,39]. More 
recently, Lua et al. [39] designed longer linkers to ensure structural separation and independence 
between a rotavirus (RV) 18 kDa VP8* antigenic module and the base VLP. Alleviating structural 
perturbations via incorporation of longer linkers and eliminating steric barrier by VP8* module 
titration using a baculovirus-insect cell co-expression strategy have facilitated VLP assembly in 
vivo.  
In this study, we described three specific module designs containing hydrophobic RV10 peptide 
from a RV VP8 subunit protein, [40] to address the effect of hydrophobic modules on the stability 
and in vitro assembly of VLPs. In addition, we demonstrated that module titration approach using 
E. coli co-expression strategy is feasible, and necessary for the production of in vitro assembled 
modular VLP displaying hydrophobic RV10. A synthetic biology-based module design and E. coli 
co-expression strategy developed in this study can further enable a rapid and a low-cost processing 
of modular capsomeres and VLPs presenting modules with adverse physicochemical properties for 
low-cost vaccine delivery against target diseases at a global scale. 
4.2. Materials and methods 
4.2.1. Plasmid construction 
pGEX-4T-1 plasmid (GE Healthcare Biosciences, Chalfont St. Giles, UK) with inserted murine 
polyomavirus VP1 sequence (M34958) was generously provided by Professor Robert Garcea 
(University of Colorado, CO, USA). This construct was designated as GST-VP1 and used for 
expression of GST-tagged wild-type murine polyomavirus VP1 protein. Plasmid GST-VP1-S4 (Fig. 
1A) was generated previously by inserting AfeI restriction enzyme site at position 293 of VP1 [8]. 
Construct GST-ΔVP1 was generated previously by excluding the first 28 amino acids from the N-
terminus and the last 63 amino acids from the C-terminus of VP1 sequence, and inserting PmlI, 
NaeI, AfeI, and SnaBI restriction enzyme sites at positions 28 (N-terminus), 85 (loop S1), 293 (loop 
S4), and 380 (C-terminus) of VP1 positions, respectively [10].  
DNA sequences encoding three tandem copies of residues 1-10 (MASLIYRQLL, RV10) from the 
human RV spike protein VP8 subunit domain [MASLIYRQLLMASLIYRQLLMA SLIYRQLL, 
(RV10)3], was prepared by annealing of complementary oligos (5´atggcaagcctaatatacagacaactac 
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taatggcaagcctaatatacagacaactactaatggcaagcctaatatacagacaactacta3´). The prepared gene insert was 
ligated into AfeI-linearized GST-VP1-S4 vector (Fig 1A), and into PmlI-, AfeI-, or SnaBI-linearized 
GST-ΔVP1 vector (Fig. 1C) sequentially to generate modular constructs VLP-(RV10)3 (Fig. 1B) 
and Cap(RV10)3 (Fig. 1D), respectively. The gene insert encoding three tandem copies of RV10 
with ESE residues inserted between the RV10 peptides, and flanked by E and ES 
[EMASLIYRQLLESEMASLIYRQLLESEMASLIYRQL LES, (RV10)3ESE] was prepared by 
annealing complementary oligos (5´gagatggcgagcctcatctatcgccaactcctcgaaagcgaaatggcctctctgatcta 
ccgccagctgctggagtctgaaatggcgtccctgatttaccgtcaactgctcgaatcc3´). The prepared gene insert was 
cloned into AfeI-linearized GST-VP1-S4 vector, and into PmlI-, AfeI-, or SnaBI-linearized GST-
ΔVP1 vector sequentially to generate modular constructs VLP-(RV10)3ESE (Fig. 1B) and 
Cap(RV10)3ESE (Fig. 1D), respectively. 
Similarly, gene insert encoding E4-RV10-E4, a module comprising RV10 with tetra glutamic acid 
residues (EEEE or E4), was prepared by assembling a set of oligos (5´tataatgggctggagagttacaa3’, 
5´gatgaggctcgccatctcttcctcttcgcttcttgtaactctccagcccattata3’, 5´agagatggcgagcctcatctatcgccaactcctcg 
aagaagaggaagcttatgat3´, 5’gccctctccagtgatggacatcataagcttcctcttcttcga3´) generated from DNAWork 
s (http://helixweb.nih,gov/dnaworks/). Linker sequences, G4S-Q25 (residues GGGGSQGVSDLV 
GLPNQICLQKTTSTILKP) and P6-G4S (residues PAQCSE-GGGGS), were inserted into the N-
and C-terminus of E4-RV10-E4 sequence, respectively, at the DNA level using PCR-based gene 
assembly, annealing and amplification. The prepared gene insert encoding module, G4S-Q25-E4-
RV10-E4-P6-G4S, was cloned into AfeI-linearized GST-VP1-S4 vector by homologous 
recombination to generate construct VLP-RV10 (Fig. 1B).  
pETDuet-1 vector with multiple cloning sites (MCS1 and MCS2) was purchased from Novagen 
(Madison, Wisconsin, USA). VP1 gene was cloned into MCS1 of pETDuet-1 vector between EcoRI 
and SalI restriction sites. This vector was designated as pET-VP1 and used for expression of VP1 
without a tag.  Another construct, designated as pET-VP1-RV10 (Fig. 1E), was generated to carry 
both VP1 and VP1-RV10 gene inserts for co-expression of the proteins. The NaeI restriction 
enzyme site was inserted into construct VLP-RV10 at position 86 of VP1 as described previously 
[39]. The VP1-RV10 gene insert with RV10 flanking linkers G4S-Q25-E4 and E4-P6-G4S was 
amplified from construct VLP-RV10 and cloned into MSC2 of pET-VP1 construct between NedI 
and PacI restriction sites, to generate construct pET-VP1-RV10. All cloned constructs were verified 
by DNA sequencing at the Australian Genome Research Facility (Brisbane, Australia). 
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4.2.2. Protein expression 
Constructs GST-VP1, GST-ΔVP1, VLP-(RV10)3, VLP-(RV10)3ESE, VLP-RV10, Cap(RV10)3 and 
Cap(RV10)3ESE were transformed into E. coli RosettaTM(DE3) pLysS chemically competent cells 
(Novagen, San Diego, CA, USA), separately. Bacterial expression of all GST-tagged proteins were 
as previously described [20,21], except cultures were induced with 0.1 mM IPTG (Astra Scientific 
Pty. Ltd., Gymea NSW, Australia) at 20 ºC for 16 h. Constructs pET-VP1 and pET-VP1-RV10 
were transformed into chemically competent E. coli Rosetta 2 (DE3) cells (Novagen, San Diego, 
CA, USA). The transformed cells  were grown separately at 37 ºC to an OD600 of 0.5 using Luria 
Bertani (LB) broth containing 50 µg mL-1 ampicillin (aMResco®, Solon Ohio, USA) and 34 µg mL-
1 chloramphenicol (Astral Scientific Pty. Ltd., Gymea NSW, Australia). Expression of non-tagged 
VP1 and co-expression of VP1 and modular VP1-RV10 were induced with 0.5 mM IPTG at 26 ºC 
for 16 h. The expression level and solubility of the target proteins were detected using SDS-PAGE 
that was performed using 10% gel as reported previously [41]. 
4.2.3. Purification of capsomeres from GST-tagged constructs 
Purification of GST-tagged proteins was performed as described previously for purification of GST-
tagged wild-type VP1 [20,21,42]. Release of GST from GST-tagged wild-type VP1 (GST-VP1) 
using thrombin-mediated cleavage and VP1 capsomere purification was carried out as previously 
reported [10,42]. Tobacco etch virus protease (TEVp) was produced from a recombinant E. coli and 
purified by immobilized metal ion affinity chromatography as reported previously [43]. The pure 
enzyme was used for release of GST from all other GST-tagged proteins. TEVp-mediated release of 
the tag protein was performed at 25:1 ratio (w/w) for 2 h at room temperature. The cleavage 
products were centrifuged (22,000 g, 5 min, 4ºC) and the capsomeres were recovered from 1.0 mL 
of supernatants for each protein with a Superdex 200 10/300 GL column (GE Healthcare 
Biosciences) operated with an AKTAexplorerTM10 (GE Healthcare Biosciences) liquid 
chromatography system. The column was pre-equilibrated with L-buffer [40 mM Tris (pH 8.5), 500 
mM NaCl, 1mM ethylenediaminetetra-acetic acid (EDTA) disodium, 5% (v/v) glycerol and 5 mM 
dithiothreitol (DTT)] at a flow rate of 0.5 mL min-1. The column was also pre-equilibrated with L-
buffer containing 0.5% (v/v) triton x-100 (TX-100) at a flow rate of 0.5 mL min-1 for purification of 
VLP-(RV10)3ESE capsomeres after TEVp-mediated release of the GST tag in the presence of 
0.05% (v/v) TX-100. The Unicorn software (Version 7.0) (GE Healthcare) was used for monitoring 
sample runs and for analysis and evaluation of the chromatogram data. Target proteins were 
detected with SDS-PAGE in elution fractions corresponding to the aggregate and capsomere peak 
fractions of SEC chromatograms. 
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4.2.4. Purification of capsomeres from non-tagged constructs 
Soluble cell lysates were prepared as described previously [20,21,42], except cell pellets were 
resuspended in L-buffer containing 500 mM NaCl. Capsomeres from constructs pET-VP1 and pET-
VP1-RV10 were purified from soluble cell lysate by selective salting-out precipitation for 2 h at 4 
ºC using 1 M Na2SO4. The protein pellets were collected by centrifugation (22,000 g, 5 min at 4 ºC) 
and resuspended in L-buffer. The soluble portion of the resuspension was separated from the 
insoluble fraction by centrifugation (22,000 g, 5 min at 4 ºC). The capsomeres were further purified 
by SEC through a Superdex 200 10/300 GL column that was pre-equilibrated with L-buffer at a 
flow rate of 0.5 mL min-1.  
4.2.5. Static light scattering 
Molecular weight (MW) of modular capsomere VLP-RV10 was estimated on multi-angled 
detectors DAWN®EOSTM (Wyatt Technology Corporation) light scattering instrument connected to 
a high-performance liquid chromatography system (Agilent Technology System). The molecular 
weight of VP1 capsomeres was estimated under the same conditions as a control. Protein solutions 
of VP1 and VLP-RV10 (V = 100 µL, C = 10.0-15.0 mg mL-1) after release of GST by enzyme-
mediated cleavage were loaded on a Superdex 200 10/300 GL column and eluted with L-buffer at a 
flow rate of 0.5 mL min-1. The 90º light scattering and UV absorbance at 280 nm of the eluting 
materials were recorded on a computer and analyzed with the Astra® software supplied by Wyatt 
Technology Corporation. The 90º light scattering detector was calibrated using bovine serum 
albumin [100 µL at 2.0 mg mL-1, MW: 66 kDa] as a standard. 
4.2.6. VLP assembly and characterization 
In vitro assembly of stable modular capsomeres into modular VLPs was as previously described [8], 
except  dialysis was performed for 24 h at room temperature and for 16  h at 4 ºC against assembly 
buffer GL1 and PBS, respectively. Assembled products were analysed using Asymmetric Flow 
Field-Flow Fractionation (AF4) coupled with multi-angle light scattering as described previously 
[44]. Visualization of VLPs with transmission electron microscope (TEM) from in vitro assembly 
was performed as previously reported [44]. 
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4.3. Results and discussion  
4.3.1. Module designs 
Murine polyomavirus VP1 was engineered to present heterologous antigenic modules on its surface 
loops [8]. The surface loop S4, position 293 of VP1, contains an AfeI site to allow molecular 
insertion of foreign sequences (Fig. 4-1A). This is a VLP forming platform. For the capsomere 
platform (Fig. 4-1C), the first 28 and the last 63 amino acid residues of VP1 were excluded. ΔVP1 
contains engineered PmlI-, NaeI-, AfeI- and SnaBI-restriction enzyme sites at positions 28 (N-
terminus), 86 (S1 loop), 293 (S4 loop) and 380 (C-terminus) of VP1 positions, respectively, for 
insertion of foreign modules.  Previous studies have demonstrated good tolerance of heterologous 
peptide module insertions on both VLP and capsomere platforms [8,10,19]. The physicochemical 
properties of modules for insertion, such as hydrophobicity and charge, can affect the expression, 
solubility and stability of modular proteins [25,26].  
The RV10 peptide comprises amino acid residues 1-10 of the RV VP8 subunit protein, and is one of 
the linear B-cell epitopes involved in human RV neutralization [40,45]. RV10, a hydrophobic 
peptide, is a highly conserved epitope among human and animal RV strains [40]. In this work, three 
different designs of module RV10 [(RV10)3, (RV10)3ESE and G4S-Q25-E4-RV10-E4-P6-G4S] 
were synthesized at the DNA level using synthetic biology strategies, with the aim to generate 
modular constructs for production of stable modular capsomeres and VLPs. 
(RV10)3 is a module containing three tandem copies of RV10. Insertion of (RV10)3 at the DNA 
level into the VLP and capsomere platforms produced constructs VLP-(RV10)3 and Cap(RV10)3, as 
illustrated in Fig. 4-1. Module (RV10)3ESE contains three tandem copies of RV10 with additional 
E, ESE and ES residues. Constructs VLP-(RV10)3ESE (Fig. 4-1B) and Cap(RV10)3ESE (Fig. 4-
1D) were designed to investigate if the addition of polar and/or charged amino acids to the element 
(RV10)3 can reduce module hydrophobicity, thus enhance the expression of soluble modular 
proteins. Previous studies have demonstrated that substitution or incorporation of polar and/or 
charged amino acids into the sequence of surface exposed residues contribute most favourably to 
protein solubility [34,46,47] and suppress protein aggregation [26,33].  
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Figure 4-1. Construct designs for modular capsomeres. (A) VLP platform with engineered insertion site at VP1 surface-
exposed S4 loop [8],  with VP1 protein expressed as GST fusion protein. (B) Modular constructs VLP-(RV10)3, VLP-
(RV10)3ESE and VLP-RV10 with inserted modules (RV10)3, (RV10)3ESE and G4S-Q25-E4-RV10-E4-P6-G4S at S4 
loop of VP1, respectively. (C) Capsomere platform with engineered N-terminus, S1 loop, S4 loop and C-terminus 
insertion sites on truncated VP1 [10], expressed as GST fusion protein. (D) Modular constructs Cap(RV10)3 and 
Cap(RV10)3ESE with inserted modules (RV10)3 and (RV10)3ESE, respectively, at N-terminus, S4 loop and C-terminus 
insertion sites of truncated VP1. (E) Dual expression construct, pET-VP1-RV10, carrying both wild-type VP1 and 
modular VP1-G4S-Q25-E4-RV10-E4-P6-G4S sequence. 
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Module G4S-Q25-E4-RV10-E4-P6-G4S was synthesized by incorporating a single element of 
RV10 and ionic linkers to shorten the hydrophobic stretch in comparison to (RV10)3 and 
(RV10)3ESE. Insertion of G4S-Q25-E4-RV10-E4-P6-G4S into the VLP platform at the DNA level 
produced construct VLP-RV10 (Fig. 4-1B). Longer flanking linkers, G4S-Q25 and G4S-P6, were 
used for spatial separation of the module from the carrier to alleviate potential structural 
perturbation, as observed in another study displaying VP8* protein domain on VLP [39].  
4.3.2. Module density 
Fig. 4-1E illustrates the construct pET-VP1-RV10 designed for dual expression of unmodified VP1 
and modular VP1 inserted with G4S-Q25-E4-RV10-P6-G4S module, in E. coli co-expression. High 
surface density of G4S-Q25-E4-RV10-E4-P6-G4S modules on each capsomere (5 copies per 
capsomere) may cause a steric barrier to inter-capsomere interactions, resulting in poor VLP 
assembly. This construct was designed to allow titration of module density on the surface of 
capsomere by co-expressing both VP1 and modular VP1 in a single bacterial cell. The resulting 
capsomeres may contain a mixture of 5VP1, 4VP1:1VP1-RV10, 3VP1:2VP1-RV10, 2VP1:3VP1-
RV10, 1VP1:4VP1-RV10 and 5VP1-RV10. We hypothesized stable capsomeres with reduced 
module density will lead to in vitro assembled VLPs. This co-expression strategy for the reduction 
of module density on the surface of carrier protein is adopted from the success of a baculovirus-
insect cell co-expression system in reducing the surface density of VP8* module to avoid steric 
barrier to VLP formation [39]. 
4.3.3. Effect of module hydrophobicity and charge  
The expression and solubility of glutathione-S-transferase (GST) fusion modular proteins in 
comparison with GST fusion VP1 and ΔVP1 were analyzed using SDS-PAGE (Fig. 4-2). No basal 
expression of the target GST fusion proteins was observed from the cultures harvested before 
induction with isopropyl-β-D-thiogalactoside (IPTG). The expression and solubility of GST fusion 
VP1 and ΔVP1 were as previously reported [8,10]. VLP-(RV10)3 was poorly expressed and no 
expression was detected for Cap(RV10)3. Modularization of the hydrophobic (RV10)3 modules 
likely increased the hydrophobicity of the modular proteins, thus resulting in poor or no target 
protein expression. Low level expression in E. coli was previously reported for a protein with its 
highly hydrophobic characteristics [48]. Highly hydrophobic proteins may have adverse effect on 
host cells, thus prematurely terminated polypeptides, trapped folding intermediates and partially 
folded proteins may be consistently targeted for degradation to avoid their accumulation in cells 
[48,49]. 
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The addition of charge residues to RV10 element resulted in soluble expression of modular 
construct VLP-(RV10)3ESE (Fig. 4-2, Lane 10). Total expression level of modular VLP-
(RV10)3ESE and Cap(RV10)3ESE improved significantly in comparison to VLP-(RV10)3 and 
Cap(RV10)3 (Fig. 4-2). Addition of ESE, E and ES residues to (RV10)3 has enhanced the total 
protein expression, consistent with previous studies [26,33,34,46,47].  
 
 
Figure 4-2. Expression and protein solubility of GST fusion target proteins. The target proteins were detected and 
visualized by SDS-PAGE from un-induced cultures (U), total cell lysate (T) and soluble fraction (S) of induced cultures. 
Novex® Sharp Pre-stained Protein marker (M) was used as a ladder. Arrows indicate the GST-tagged target proteins. 
GST-tagged VLP-(RV10)3ESE was first purified with GST affinity chromatography, followed by 
TEVp-mediated release of the GST tag and purification of capsomeres by SEC. Both SEC 
chromatograms (Fig. 4-3A) and SDS-PAGE analysis (Fig. 4-3B) show that mostly soluble 
aggregates were obtained post removal of GST tag from construct VLP-(RV10)3ESE. This suggests 
that VLP-(RV10)3ESE modular capsomeres were not stable and prone to aggregation in L-buffer.  
Modular VLP-(RV10)3ESE capsomeres purified in the presence of TX-100 as stabilizing additive in 
L-buffer did not form modular VLPs via in vitro assembly (Fig. 4-4B). When analyzed on AF4 post 
VLP assembly, only unassembled capsomeres and soluble aggregates were detected. The specific 
causes preventing modular VLP assembly for construct VLP-(RV10)3ESE are unknown. One 
possibility is the hydrophobic-hydrophobic interactions between surface exposed RV10 elements, 
driving the formation of aggregates. Poor capsomere and VLP stability can also arise due to module 
insertion, causing a reduction of stabilization energy [50]. Thus, this necessitates specific design of 
RV10 modules that will maintain capsomeres stability in compatible VLP assembly buffer.  
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Figure 4-3. Downstream processing of capsomeres. (A) Size exclusion chromatograms of modular capsomeres 
following TEVp-mediated release of GST tag. P1, P2 and P3 represent the aggregate, capsomere and GST peaks, 
respectively. (B) SDS-PAGE analysis on downstream processing of capsomeres. Marker protein (M), GST-tagged 
soluble protein after GST affinity purification (S), TEVp-mediated tag cleavage (D), P1 aggregate peak fraction (A) and 
P2 capsomere peak fraction (C).  
4.3.4. Flanking linker and charged element for surface display of hydrophobic peptide 
Construct VLP-RV10 contains module G4S-Q25-E4-RV10-P6-G4S and was expressed as soluble 
GST fusion target proteins (Fig. 4-2B, Lane 13). Using a single copy of RV10 element with 
additional surface charged E4 residues likely decreased the hydrophobicity of modular proteins and 
resulted in good expression level of soluble proteins. Previously, insertion of E4 residues as ionic 
flanking elements has enhanced expression of soluble modular VP1 containing a hydrophobic H190 
module from influenza virus [51]. Studies have demonstrated positive correlation of decreasing 
hydrophobicity with high protein expression and solubility levels [52,53].  
In addition to high level of soluble proteins with construct VLP-RV10, stable capsomeres were 
obtained post release of GST tag (Fig. 4-3). The SEC chromatogram suggests a more compact 
capsomere structure for VLP-RV10 as the capsomeres eluted later than unmodified VP1 
capsomeres. The MW of VP1 and modular VLP-RV10 capsomeres analyzed by static light 
scattering were 219.2 kDa and 270.2 kDa, respectively, confirming their pentameric structure forms 
(Fig. 4-4A). Despite obtaining stable VLP-RV10 capsomeres, no VLP was detected after in vitro 
VLP assembly (Fig. 4-4B). 
Decreasing module hydrophobicity by reducing elements of RV10 in a module can minimize 
hydrophobic interaction forces that drive protein aggregation [54]. The E4 ionic linkers increased 
the surface charge of the module; consequently the electrostatic repulsive forces between protein 
molecules can counteract the hydrophobic interaction forces, enhancing the stability of modular 
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capsomeres. Introduction of longer flanking linkers G4S-Q25 and P6-G4S might have alleviated 
structural perturbation of capsomeres. We speculate that the lack of VLP assembly is caused by 
either strong electrostatic-repulsive interactions or steric hindrance between modular capsomeres 
due to high module density on capsomere surface. 
 
Figure 4-4. Characterization of capsomeres and in vitro assembled products. (A) SEC-HPLC/LS analysis of VP1 and 
VLP-RV10 capsomeres following TEVp-mediated release of GST tag. P1, P2 and P3 represent peaks for VP1 
capsomeres, VLP-RV10 capsomeres and GST dimers, respectively. (B) AF4 fractograms of in vitro assembled products 
of VP1, VLP-(RV10)3ESE and VLP-RV10. P1, P2 and P3 represent peaks for non-assembled proteins, assembled VLPs 
and aggregates, respectively. 
4.3.5. Module titration for in vitro assembly of VLP 
As shown in Fig. 4-5A, soluble VP1 and VP1-RV10 proteins were expressed in E. coli without 
GST tag. When both proteins were co-expressed in a dual expression system, VP1-RV10 was 
expressed at higher level than VP1. Co-expression of two or more genes from a single expression 
vector might lead to imbalance ratio of expressed proteins due to differences in the rates of 
translation [55], transcription, translocation, and the stability of RNA and protein products [56,57]. 
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Figure 4-5. Co-expression strategy for bacterially-produced stable modular capsomeres and in vitro assembled 
modular VLPs presenting module RV10.  (A) Detection and visualization of non-tagged target proteins of pET-VP1 and 
pET-VP1-RV10 from cell lysates. (B) Size exclusion chromatograms of pET-VP1 and pET-VP1-RV10 capsomeres 
following purification by selective salting-out precipitation. P1, P2 and P3 represent the aggregate, capsomere, and co-
precipitated E. coli protein peaks, respectively. (C) SDS-PAGE analysis of the target proteins. Marker protein (M), 
purified protein by selective salting-out precipitation (P), P1 aggregate peak fraction (A) and P2 capsomere peak 
fraction (C). (D) AF4 fractograms and TEM micrographs of assembled products (i) VP1VLP and (ii) RV10VLP. P1, P2 
and P3 represent peaks for non-assembled proteins, assembled VLPs and aggregates, respectively. 
Capsomeres of pET-VP1 (CapVP1) and pET-VP1-RV10 (CapRV10) were purified from clarified 
cell lysates by selective salting-out precipitation followed by a further polishing SEC step. Fig. 4-
5B and 4-5C show that stable modular capsomeres were obtained after purification. Co-precipitated 
E. coli proteins, in the aggregated fractions, were separated from the capsomeres during the SEC 
polishing step (Fig. 4-5C). After in vitro assembly, modular VLPs (RV10VLP) comprising VP1 and 
VP1-RV10 capsomeres were obtained, as analyzed on AF4 and TEM (Fig. 4-5D). A small peak of 
unassembled proteins was detected on AF4 with a VLP peak detected at 18 to 21 min elution time. 
The average root-mean-square (r.m.s) radius for the RV10VLP was 21.4 nm, similar to the size 
distribution of unmodified VP1VLP (r.m.s radius 22.5 nm). Under TEM, RV10VLP was similar in 
morphology to the unmodified VP1VLP (Fig. 4-5D). This co-expression strategy of both VP1 and 
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VP1-RV10 proteins to reduce the RV10 module density per capsomere was a successful approach 
to obtain stable RV10VLPs. Reducing the density of modules on the surface of capsomeres 
potentially minimize hydrophobic interactions, electrostatic repulsive interactions and overcome 
steric hindrance of modules to the formation of modular VLPs. Here, we have demonstrated that co-
expression strategy to reduce module density is feasible for bacterially-produced modular 
capsomeres displaying hydrophobic peptide RV10. 
4.4. Conclusion 
Using synthetic biology, hydrophobic RV10 peptide epitope of RV VP8 spike protein was 
modularized on murine polyomavirus VP1 capsid protein. The hydrophobicity of element RV10 
deters the tandem copies display strategy to increase the ratio of antigenic module to base protein 
VP1. Flanking hydrophobic element with charged glutamic acid (E4) can reduce hydrophobicity, to 
prevent hydrophobic-interaction driven protein aggregation. However, the addition of long flanking 
linkers (G4S-Q25 and P6-G4S) potentially displays the module away from base protein VP1, thus 
avoid structural perturbation by the module. The module design G4S-Q25-E4-RV10-E4-P6-G4S 
yielded high expression of modular proteins and stable modular capsomeres after purification. 
Attempts to assemble these stable modular capsomeres via in vitro VLP assembly were not 
successful. The results suggest that titrating module density down by applying co-expression 
strategy of both unmodified VP1 and modular VP1 in a single bacterial cell allows an optimal ratio 
of VP1:VP1-RV10 capsomere formation, which then lead to VLP assembly. Module titration can 
minimize hydrophobic interactions, electrostatic repulsive interactions or prevent steric barrier to 
modular VLP assembly. The strategies employed in this study provide a powerful approach for 
modularization of VLP and capsomere with various hydrophobic antigenic modules, such as T-cell 
epitopes, that are potentially challenging due to their physiochemical properties. The design 
strategies can also be used to modulate the hydrophobic domains of other proteins for enhanced 
expression of soluble and stable proteins using a low-cost prokaryotic expression system. 
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Abstract  
A high global burden of rotavirus disease and the unresolved challenges with the marketed rotavirus 
vaccines, particularly in the developing world, have ignited efforts to develop virus-like particle 
(VLP) vaccines for rotavirus. While rotavirus-like particles comprising multiple viral proteins can 
be difficult to process, modular VLPs presenting rotavirus antigenic modules are promising 
alternatives in reducing process complexity and cost. In this study, integrated molecular and 
bioprocess engineering approaches were used to simplify the production of modular murine 
polyomavirus capsomeres and VLPs presenting a rotavirus 18 kDa VP8* antigen. A single 
construct was generated for dual expression of non-tagged murine polyomavirus capsid protein VP1 
and modular VP1 inserted with VP8*, for co-expression in Escherichia coli. Co-expressed proteins 
assembled into pentameric capsomeres in E. coli. A selective salting-out precipitation and a 
polishing size exclusion chromatography step allowed the recovery of stable modular capsomeres 
from cell lysates at high purity, and modular capsomeres were successfully translated into modular 
VLPs when assembled in vitro. Immunogenicity study in mice showed that modular capsomeres 
and VLPs induced high levels of VP8*-specific antibodies. Our results demonstrate that a 
multipronged synthetic biology approach combining molecular and bioprocess engineering enabled 
simple and low-cost production of highly immunogenic modular capsomeres and VLPs presenting 
conformational VP8* antigenic modules. This strategy potentially provides a cost-effective 
production route for modular capsomere and VLP vaccines against rotavirus, highly suitable to 
manufacturing economics for the developing world. 
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5. 1. Introduction  
Rotavirus (RV) is the major enteric pathogen causing severe diarrhoea in children under 5 years of 
age worldwide [1]. It caused nearly 500,000 deaths of children worldwide in 2008 in which 90% of 
the deaths occurred in low-income developing countries in Africa and Asia [2]. The situation still 
remains unacceptably worse in most developing countries [3]. Despite the high mortality and 
morbidity rate of the disease, no RV-specific drugs are available to date. Limited information on 
therapeutic targets have impeded efforts for RV-specific drug discovery and development [4]. Thus, 
vaccination remains the primary prophylactic strategy to reduce the disease burden of RV [5,6].  
The use of two live-attenuated oral RV vaccines, RotaTeq® (Merck) and RotarixTM 
(GlaxoSmithKline), has reduced childhood mortality rate in developed countries [7,8]. Some 
developing countries have included the vaccines into their childhood immunization program. 
However, the vaccines are less effective [9], too costly and logistically prohibitive for use in the 
developing world [10]. Both RotarixTM (US$ 2.50 per dose) and RotaTeq® (US$ 3.50 per dose) are 
still too expensive for low-income developing countries [10]. They also come with possible risk of 
reversion and intussusception [11]. The high disease burden of RV and the challenges associated 
with current vaccines, particularly in developing countries, have ignited efforts to develop next-
generation low-cost, effective and safe vaccine candidates. These vaccine candidates under 
development include non-replicating subunits such as synthetic peptides, proteins and virus-like 
particles (VLPs) [12,13].  
Several studies have demonstrated the role of the VP8 subunit domain of RV spike protein and its 
potential as a vaccine [14-16]. Particularly, the lectin-like domain of VP8 (residues 64-223), known 
as VP8*, has been shown to induce RV neutralizing antibodies [12,17-20]. However, effectiveness 
of VP8* is highly dependent on the co-administration of adjuvants that are not approved for use in 
human vaccination [14,21,22].   
Rotavirus-like particles (RLPs) are an effective and potentially safe alternative vaccine candidate to 
soluble proteins and live-attenuated oral vaccines [23]. They are synthetic mimics of the virus [24], 
with proven immunogenicity and protection efficacy in animal studies [13,23]. As rotavirus is a 
complex virus, production of RLPs via co-expression of two or more structural proteins inside 
eukaryotic cells is also highly complex [25-27]. Process complexity often reduces yield and 
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increases cost [27]. Consequently, RLPs may be highly expensive vaccine candidates, limiting 
applicability for use in the developing world. 
Minimizing the cost of bioprocessing has become a focus of many developments to produce safe 
and effective vaccine candidates at affordable cost for use in the developing world [28]. The use of 
synthetic biology for vaccine design is one of the strategies that have gained attention for 
addressing manufacturing and processing gaps of vaccine candidates. With the aid of synthetic 
biology and computational tools [29,30], full length, or truncated proteins or small peptide epitopes 
have been molecularly inserted into viral structural proteins to generate a new class of 
bioengineered  modular VLP vaccines [31,32]. Insertion of a RV 18 kDa VP8* antigen into the 
protrusion (P) domain of the norovirus capsid protein produced a highly immunogenic modular 
VLP subunit vaccine against RVs inside E. coli cells [33]. Lua et al. (2015) have designed a stable 
modular murine polyomavirus VLP vaccine candidate presenting VP8* using purposefully designed 
linkers and module titration via a baculovirus-insect cell co-expression strategy. However, VLP 
production in vivo has limitations on yield and scalability, and the high operating costs associated 
with VLP recovery from cells [30,33]. 
An alternative and proven approach for VLP production is cell-free in vitro assembly of VLP, 
which has been developed for low-cost production of highly purified and high quality VLPs using 
murine polyomavirus VP1 VLP vaccine platform [34,35]. This platform has shown great potential 
for mass-scale production of highly immunogenic and protective modular VLPs presenting J8-
peptide module from group A streptococcus [35,36]. The existing VLP platform uses glutathione-S-
transferase (GST) fusion partner as a solubility and affinity tag for the expression and purification 
of GST fusion VP1 proteins. The use of GST tag comes with major drawbacks, such as poor 
binding affinity of GST fusion proteins to affinity chromatography media, formation of 
macromolecular soluble aggregates and high-priced affinity chromatography media [37]. 
Subsequent enzyme-mediated release of the GST tag also adds complexity and cost to the 
bioprocess [38,39]. Process complexity and high operating costs due to the use of GST tag 
rationalized the need for non-tagged protein expression for simple and low-cost recovery of 
capsomeres for in vitro VLP assembly. The concept of tag-free VP1 expression in E. coli has been 
proven with high expression yield of VP1 after optimization of expression parameters [40,41].  
The present study describes a combination of molecular and bioprocessing engineering approaches 
for simplified production of bacterially-produced and in vitro assembled modular VLPs presenting a 
RV 18 kDa VP8* module. A module titration strategy allowed correct presentation of 
conformational VP8* module on the surface of E. coli produced capsomeres and VLPs. In addition, 
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we demonstrated that expression of non-tagged proteins in E. coli and protein recovery using 
selective salting-out precipitation simplify the bioprocessing of modular capsomeres for subsequent 
production of in vitro assembled modular VLPs with high purity, stability and immunogenicity. The 
new strategy based on integrated molecular and bioprocess engineering approaches in this study 
provide an efficient and powerful approach for low-cost production of highly immunogenic 
modular capsomere and VLP vaccine candidates readied for further translation against RV in the 
developing world.   
5.2. Materials and Methods 
5.2.1. Plasmid construction 
Murine polyomavirus VP1 sequence (M34958) was cloned into the first multiple cloning sites 
(MCS1) of pETDuet-1 (Novagen, Madison, Wisconsin, USA) between EcoRI and SalI restriction 
sites. This construct was designated as VP1 and used for the expression of wild-type VP1 proteins. 
Another construct, designated as VP1-VP8*, was generated to carry both VP1 (at MCS1) and VP1-
VP8* (at MCS2) gene inserts for co-expression of the proteins. The VP1-VP8* gene insert with 
VP8* flanking linkers G4S-Q25 and P6-G4S was amplified from construct pBAC-VP1-Q25-VP8*-
P6 [30], and cloned into MSC2 of VP1 construct between NdeI and PacI restriction sites. All 
cloned constructs were verified by DNA sequencing at the Australian Genome Research Facility 
(Brisbane, Australia).  
5.2.2. Protein expression 
Constructs VP1 and VP1-VP8* were transformed separately into chemically competent E. coli 
Rosetta 2 (DE3) cells (Novagen, San Diego, CA, USA). VP1 and VP1-VP8* transformed E. coli 
Rosetta 2 (DE3) cells were grown separately at 37 ºC to an OD600 of 0.5 using Luria Bertani (LB) 
broth containing 50 µg mL-1 ampicillin (aMResco®, Solon Ohio, USA) and 34 µg mL-1 
chloramphenicol (Astral Scientific Pty. Ltd., Gymea NSW, Australia). Cultures were induced with 
0.5 mM isopropyl-β-D-thiogalactoside (IPTG) (Astra Scientific Pty. Ltd., Gymea NSW, Australia) 
at 26 ºC for 16 h for protein expression.   
5.2.3. Capsomeres purification 
Cell pellets from each of 200 mL cultures of VP1 and VP1-VP8* were re-suspended separately in 
20 mL L-buffer [40 mM Tris, 500 mM NaCl, 1 mM ethylenediaminetetra-acetic acid (EDTA) 
disodium, 5% (v/v) glycerol, 5 mM dithiothreitol (DTT), pH 8.5]. Cells were lysed by sonication 
and cell lysates were clarified by centrifugation as previously described [42]. Target proteins were 
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precipitated from the cell lysates using 1 M Na2SO4 for 2 h at 4 ºC. The precipitates were collected 
by centrifugation (22,000 g, 5 min at 4 ºC) and re-suspended in 2 mL of L-buffer. The soluble 
portion of the re-suspension was separated from the insoluble fraction by centrifugation (22,000 g, 5 
min at 4 ºC). VP1 and VP1-VP8* capsomeres, designated wild-type capsomere (wtCap) and 
CapVP8*, respectively, were recovered from supernatants by size exclusion chromatography (SEC) 
through a Superdex 200 10/300 GL column (GE Healthcare, UK). The column was pre-equilibrated 
with either L1-buffer [40 mM Tris, 300 mM, pH 8.5) or L2-buffer [40 mM Tris, 300 mM NaCl, 1 
mM EDTA disodium, 5% (v/v) glycerol, 5 mM DTT, pH 8.5] at a flow rate of 0.5 mL min-1. 
Bacterial endotoxin was removed from capsomere fractions with an anion exchanger as described 
previously [35].  
5.2.4. Characterization and formulation of capsomeres 
Qualitative analysis of all protein samples, for detection and visualization of protein purity from 
capsomere fractions, was performed by SDS-PAGE gel electrophoresis using 10% gel as reported 
previously [43]. All protein concentrations were determined at 280 nm, based on the Beer-Lambert 
Law [44]. Theoretical molecular weight and extinction coefficient of each protein was obtained 
from ProtParam [45]. The concentration of capsomere solutions was adjusted to 1.0 mg mL-1 by 
ultracentrifugal filtration using Amicon®Ultra-4.0 ml 30K membrane (Merck Millipore Ltd 
Tullagreen, Co. Cork, Ireland) (5,000 g, 10 min at 4°C).  Endotoxin levels of wtCap and CapVP8* 
were measured using LAL-based assay Endosafe PTSTM -2005 (Charles River Laboratory, MA, 
USA). Formulations of CapVP8* in L1-buffer were stored at -80 ºC whereas wtCap and CapVP8* 
in L2-buffer were used for in vitro VLP assembly. 
5.2.5. VLP assembly and characterization 
In vitro assembly of wtCap and CapVP8* into VLPs was as previously described [35] except 
dialysis was performed for 24 h. VLP size distribution was analyzed by  Asymmetric Flow Field-
Flow Fractionation (AF4) coupled with multi-angle light scattering as described previously [46]. 
Visualization of VLPs with transmission electron microscope (TEM) was also performed as 
previously reported [46].  
5.2.6. VP8* protein preparation 
Construct GST-TEVp-VP8* was generated by the Protein Expression Facility (The University of 
Queensland, Australia). The expression vector was transformed into chemically competent E. coli 
RosettaTM (DE3) pLysS cells (Novagen, San Diego, CA, USA). Expression of GST-tagged VP8* 
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was as previously described for expression of GST-tagged VP1 [35] except cultures were induced 
with 0.1 mM IPTG at 20 ºC for 16 h. Purification of GST-tagged VP8* by affinity chromatography 
and enzymatic release of the GST tag were performed using published protocols for purification of 
GST-tagged VP1 [35,39].  After release of GST tag, VP8* protein was recovered from 1.0 mL 
protein solution with Superdex 75 10/300 GL column (GE Healthcare Biosciences) operated with 
an AKTAexplorerTM 10 (GE Healthcare Biosciences) liquid chromatography system. The column 
was pre-equilibrated with PBS at a flow rate of 0.5 mL min-1. Prior to in vivo study, endotoxin was 
removed from protein solution (< 2.5 EU per dose) with anion exchanger as described previously 
[35].  
5.2.7. Dot blotting, immunogold labeling and densitometric analysis  
Dot blotting and immunogold labeling were carried out for detection of VP8* antigens from 
CapVP8* and VLP-VP8* formulations according to the methods reported previously [30] using 
mouse anti-VP8* monoclonal antibody (RV-5:2) [47]. Proteins were detected and visualized with 
SDS-PAGE from CapVP8* and VLP- VP8* formulations. Densitometric analysis of the protein 
bands corresponding to VP1 and modular VP1-VP8* proteins was performed using the BioRad 
Image lab software version 4.0.1.   
5.2.8. Immunization  
Four groups of eight female Balb/c mice, aged 6-8 weeks, were obtained from Animal Resources 
Centre (Murdoch, WA, Australia) and cared for humanely in accordance with the University of 
Queensland Animal Ethics Committee guidelines. All animal experimental work was reviewed and 
approved by the University of Queensland Animal Ethics Committee (AIBN/136/15/SMART). 
All groups of mice received primary immunizations subcutaneously on Day 0. The first and second 
booster immunizations were administered subcutaneously 21 and 42 days following primary 
immunization, respectively. Blood was collected on Days 0, 14, 35 and 56; serum was separated 
and stored at -20 ºC. Group 1 received 50 µg of unmodified VP1VLP as negative control, Group 2 
received 50 µg of CapVP8*/AH adjuvanted with aluminium hydroxide (AH; Alhydrogel®, 
Brenntag, Germany), Group 3 received 50 µg VLP-VP8*, and Group 4 received 10 µg VP8*/AH as 
a positive control. The injection volume was 100 µL for all formulations. Adjuvanted formulations 
were prepared by mixing components together in a 1:1 volume ratio of protein to AH solution and 
incubation at room temperature for 1 h prior to immunization. 
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5.2.9. Enzyme-linked immunosorbent assay (ELISA) 
Measurement of VP8*- and VP1-specific serum IgG titres by ELISA was as previously described 
[42] except  the 96-well Nunc-ImmunoTM MaxiSorpTM plates (NUN442404; Thermo Fisher 
Scientific, MA, USA) were coated with VP8* or unmodified VP1 VLP antigen at 3.0 µg mL-1, and 
incubated with CapVP8*/AH and VLP-VP8*, VP8*/AH and unmodified VLP mouse sera initially 
at 100, 200 and 400-fold dilutions, respectively, followed by four-fold dilutions.   
5.2.10. Statistical analysis 
Statistical analysis was carried out using GraphPad Prism Version 6.00 (GraphPad Software Inc., 
CA, USA). Comparison between two groups was performed with unpaired two-tailed t test. Groups 
were considered significantly different (*) at p < 0.05.  
5.3. Results and Discussion 
5.3.1. Molecular and bioprocess engineering for modular VLPs 
Murine polyomavirus VP1 was previously engineered to present small peptide antigenic modules 
on its surface. A modular capsomere is produced from self-assembly of five modular VP1 
monomers in vivo in E. coli, and a modular VLP is obtained from in vitro self-assembly of 72 
capsomeres in a controlled cell-free reactor [35,36]. Insertion of a 18 kDa VP8* module derived 
from human rotavirus outer capsid protein [48] disrupted the structure of capsomeres (unpublished 
data), suggesting the need to optimize the previously established process and re-design the 
presentation of large antigenic modules with this murine polyomavirus VLP platform. Insertion of 
longer linkers and module titration allowed the formation of an insect cell-produced and in vivo 
assembled VLP presenting conformational VP8* module on its surface [30]. A combination of 
molecular and bioprocess engineering approaches was used here for low-cost production of 
bacterially-produced and in vitro assembled modular VLP-VP8*.  
Fig. 5-1 illustrates the molecular engineering of modular capsomere to display a RV 18 kDa VP8* 
module and its production using low-cost microbial cell factories. A single construct carrying both 
VP1 and modular VP1-VP8* genes can co-express the proteins in E. coli, with the possibility of 
forming mixtures of non-tagged capsomeres comprising 5VP1, 4VP1:1VP1-VP8*, 3VP1:2VP1-
VP8*, 2VP1:3VP1-VP8*, 1VP1:4VP1-VP8* and 5VP1-VP8*. Overexpression of unmodified VP1 
decreases the surface density of VP8* module on each pentameric capsomere, thus potentially 
eliminates steric hindrance to the formation of stable capsomeres. These capsomeres are 
subsequently extracted and purified to homogeneity for VLP production via in vitro assembly. 
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Figure 5-1. Engineering modular capsomere to display a rotavirus 18 kDa VP8* module for Escherichia coli 
production. (A) A single expression construct for module titration via dual expression of VP1 and modular VP1-VP8* 
proteins. (B) A mixture of modular capsomeres, made up of VP1 and VP1-VP8* proteins, were obtained via co-
expression in Escherichia coli. (C) Recovery of non-tagged modular capsomeres away from Escherichia coli host 
proteins. 
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Figure 5-2. Bioprocessing steps for preparation of murine polyomavirus modular virus-like particles (VLPs). (A) 
Expression and purification of GST-tagged VP1 proteins for production of modular VP1 capsomeres and VLPs using 
Escherichia coli. (B) A simplified bioprocess for production of non-tagged modular capsomeres and VLPs. Modular 
VP1 capsomeres were selectively precipitated from Escherichia coli cell lysate for VLP in vitro assembly. 
Fig. 5-2 compares the previously established bioprocess with the new simplified bioprocess, for 
production of murine polyomavirus VP1 VLPs using E. coli. To reduce process complexity during 
modular VP1 protein recovery, the use of GST tag to increase target protein solubility and as 
purification affinity tag was eliminated. A simple selective salting-out precipitation approach to 
recover tag-free modular capsomeres from E. coli cell lysate was developed in this study (Fig. 5-
2B). This approach eliminates affinity chromatography and subsequent enzyme-mediated release of 
the tag used in the previous process (Fig. 5-2A). Processing of GST-tagged capsomeres adds 
complexity to the downstream process due to the multimerization effects of GST protein, poor 
binding affinity and high cost of affinity chromatography media [37]. Release of the GST tag 
requires treatment with proteases, which adds further cost to the bioprocess [39]. A process 
simulation study demonstrated that the downstream processing section using chromatography steps 
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contributed more than two-thirds of total operating cost for capsomere and VLP vaccine production 
at 10 kL-bioreactor scale [28]. Replacing the chromatography steps with simpler non-
chromatographic approaches can reduce process complexity and production cost, and increase the 
speed and economic benefits of the process [28,42]. Non-chromatographic approaches, such as 
selective salting-out precipitation, are simple, scalable and amenable to continuous flow operation 
[42,49]. It can be easily optimized to increase the purity of capsomeres, or coupled with different 
membrane-based filtration processes [50] to avoid post precipitation polishing chromatographic 
steps. By employing both molecular and bioprocess engineering, the strategy used in this study has 
the potential to simplify process complexity and reduce production cost for modular capsomeres 
and VLPs. This could be particularly attractive to the developing world to get access to safe and 
effective vaccines at affordable cost, with calculations showing vaccine production at a cost less 
than 1 cent per dose [28].  
5.3.2. Production of stable CapVP8* 
Fig. 5-3A shows the co-expression of VP1 and modular VP1-VP8* proteins. The expression of VP1 
(42.5 kDa) and VP1-VP8* (64.5 kDa) proteins was detected post-induction. VP1 was 
overexpressed when co-expressed with VP1-VP8* in E. coli. Selective salting-out precipitation of 
target proteins from E. coli cell lysates, with a polishing SEC step (Fig. 5-3B), resulted in the 
separation of stable modular capsomeres, CapVP8*, from most host cell protein contaminants. As 
shown by SDS-PAGE analysis (Fig. 5-3C), CapVP8* capsomere peak fraction (Fig. 5-3B, P2) 
contained mainly the target proteins, VP1 and VP1-VP8*. The aggregate peak fractions (Fig 5-3B, 
P1) contained mainly the E. coli host proteins.  Purified CapVP8* was greater than 90% in purity 
(Fig. 5-3C). Endotoxin removal was conducted on the capsomere samples. Capsomeres with the 
endotoxin level less than 2.5 EU per dose were ready for injection or for in vitro VLP assembly in 
endotoxin-free environment.   
Overexpression of VP1 in comparison to modular VP1-VP8* decreased the number of VP8* 
modules per capsomere and this may eliminate the steric barrier to the formation of modular VLPs 
(VLP-VP8*) via in vivo assembly [30]. In E. coli, higher VP1 expression resulted in the formation 
of stable CapVP8* with less surface density of VP8* modules. Besides titrating module density on 
CapVP8*, protein co-expression can enhance solubility of modular VP1-VP8* by enabling proper 
folding of each protein subunit, thus leading to the formation of soluble and stable complexes, a 
phenomenon observed for production of protein complexes [51].  
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Figure 5-3.  Analysis on expression and purification of modular capsomeres. (A) SDS-PAGE analysis on the expression 
of non-tagged VP1 and modular VP1-VP8* in Escherichia coli. Marker protein (M), un-induced cultures (U), total cell 
lysate (T) and soluble fraction (S) of induced cultures. (B) Size exclusion chromatograms of capsomeres following 
selective salting-out precipitation of target proteins. P1 and P2 represent the aggregate and capsomere peaks, 
respectively. (C) SDS-PAGE analysis on downstream processing of capsomeres. Marker protein (M), purified by 
selective salting-out precipitation (P), aggregate peak fraction P1 (A) and capsomere peak fraction P2 (C). 
5.3.3. In vitro assembly of VLP-VP8* and characterization  
Purified modular CapVP8* capsomeres were assembled into VLPs as described in Section 2.5. Fig. 
5-4 shows the AF4 fractograms and TEM micrographs of the assembled VLPs, unmodified VP1 
VLP (Fig. 5-4A) and VLP-VP8* (Fig. 5-4B). The average root-mean-square (r.m.s) radius for VLP-
VP8* was 21.5 nm, almost the same as the radius of unmodified VP1 VLP. The VLPs were stable 
against aggregation, and they are similar in size distribution and morphology with the 
corresponding VLPs produced previously [30,35,46]. 
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Figure 5-4. Characterization of in vitro assembled VLPs. AF4 fractograms and TEM micrographs of (A) unmodified 
VLP, and (B) modular VLP-VP8*. P1, P2 and P3 represent peaks for unassembled proteins, VLPs and aggregates, 
respectively. 
Both immunogold labelling of VLP-VP8* (Fig. 5-5B) and dot blot analysis of CapVP8* and VLP-
VP8* (Fig. 5-5C) with anti-VP8* monoclonal antibodies confirmed that modularized VP8* is 
conformational on the surface of purified CapVP8* and in vitro assembled VLP-VP8*. These 
results are in agreement with the results obtained for modular VLP-VP8* produced in vivo using a 
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baculovirus-insect cell co-expression system [30]. Densitometric analysis of the protein bands 
corresponding to VP1 and VP1-VP8* proteins of CapVP8* and VLP-VP8* samples (Fig. 5-5D) 
showed that the stoichiometric ratios of VP1 to VP1-VP8* was 4.5:0.5. However, this ratio likely 
varies between each capsomere and VLP because of the mixed populations of VP1:VP1-VP8* (Fig. 
5-1B). While further work is needed to strive for a controlled ratio of VP1 and VP1-VP8* in each 
capsomere or VLP particle, our results demonstrate the feasibility of module titration using an E. 
coli co-expression strategy for modularization of VLPs with large antigens. 
 
 
Figure 5-5. Detection of VP8* modules on CapVP8* and VLP-VP8*. (A) TEM micrographs of in vitro assembled VLP-
VP8*. (B) Immunogold labelling with anti-VP8* antibodies detected VP8* modules on the surface of in vitro assembled 
VLP-VP8* (arrows). (C) Dot blot analysis with anti-VP8* antibodies detected VP8* modules in CapVP8* and VLP-
VP8* samples. (D) SDS-PAGE analysis of purified CapVP8* and assembled VLP-VP8*, showing the ratio of VP1 and 
modular VP1-VP8* proteins. Lanes: (M) Marker protein; (1) Purified CapVP8*; (2) In vitro assembled VLP-VP8*. 
5.3.4. Immunogenicity of modular CapVP8* and VLP-VP8* 
Modular CapVP8* and VLP-VP8* were evaluated for their immunogenicity in mice. Immunization 
with 3 doses of CapVP8*/AH and VLP-VP8* each containing approximately 1.5 µg of VP8* 
antigen per dose elicited high and comparable (P = 0.6730) VP8*-specific IgG titers (~105) 
compared to unmodified VLP (Fig. 5-6A). A strong VP1-specific antibody titre obtained with 
CapVP8*/AH and VLP-VP8* (Fig. 5-6B) did not interfere with induction of VP8*-specific 
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antibody. This result is in agreement with the previous study [52,53], indicating that a pre-existing 
anti-VP1 antibody response does not suppress module-specific immune response. Immunization 
with 3 doses of VP8*/AH as a positive control produced significantly higher VP8*-specific IgG 
titre than those elicited by CapVP8*/AH (P < 0.05) and VLP-VP8* (P < 0.01) (Fig. 5-6A). 
Production of high levels of VP8*-specific antibody with group immunized with VP8*/AH is likely 
due to the higher dose of VP8* (10 µg in each dose) in comparison to 1.5 µg of VP8* in each dose 
of CapVP8*/AH and VLP-VP8*.  
 
 
Figure 5-6. VP8*- and VP1-specific total IgG titres. (A) VP8*-specific IgG titres induced in mice following three 
subcutaneous immunizations with CapVP8*/AH, VLP-VP8*, unmodified VLP (as a negative control) and VP8*/AH (as 
a positive control), separately. (B) VP1-specific IgG titres induced in mice following three subcutaneous immunizations 
with unmodified VLP, CapVP8*/AH and VLP-VP8*, separately. Statistical analysis of antibody titres after the third 
immunization (or boost 2) is presented.  *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 indicate significant 
difference between the antibody titres of groups, ns indicates no significant differences. 
Production of comparable level of VP8*-specific antibodies against CapVP8* and VLP-VP8* 
suggested the potential of CapVP8*/AH formulation as alterative cheap vaccine candidate to VLP-
VP8*. Previous studies demonstrated that adjuvanted modular murine polyomavirus VP1 
capsomeres and human papillomavirus type 16 capsomeres induced almost the same level of 
immune response as their corresponding VLPs [35,54]. High level of VP8*-specific antibody 
elicited by VLP-VP8* without adjuvants and previously published results [36] demonstrate the 
known self-adjuvanting property of VLPs. In addition, the known thermostabilization of VLPs 
using simple excipients demonstrated for VLPs comprising VP1 [55], also opens the opportunity 
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for cold-chain elimination and potentially allows low-cost delivery of vaccines for use in the 
developing world. 
5.4. Conclusion 
Our aim is to use integrated molecular and bioprocess engineering to simplify production of 
bacterially-produced modular VLP vaccine candidate against RV, for use in the developing world. 
Using E. coli co-expression strategy of unmodified VP1 and modular VP1, a RV 18 kDa VP8* 
antigenic module was modularized on murine polyomavirus VP1 capsid protein. Module titration 
decreased the number of VP8* module on each capsomere, potentially maintaining the stability of 
modular capsomeres and eliminating steric barrier to VLP assembly. The modular capsomeres, 
purified from E. coli cell lysates by selective salting-out precipitation followed by SEC polishing, 
formed modular VLPs presenting conformational VP8* modules when assembled in vitro. The 
modular capsomeres (CapVP8*) and VLPs (VLP-VP8*) induced high levels of VP8*-specific 
antibodies in mice. The results in this study demonstrate that integrating molecular engineering of 
capsomeres with a simple bioprocessing route allowed the production of highly stable and 
immunogenic modular capsomeres and in vitro assembled modular VLPs using microbial cell 
factories. This microbial-based VLP vaccine platform can potentially empower the developing 
world to participate in the development and production of vaccines against RV and other target 
diseases at affordable cost. 
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Chapter 6 
Conclusions and Future Work 
6.1. Summary of key research findings 
Childhood mortality estimates consistently find diarrhoeal diseases due to RV among the leading 
causes of deaths [1]. The use of oral live-attenuated RV vaccines (RotarixTM and RotaTeq®) has 
reduced childhood mortality in high- and middle-income countries [2-6]. Yet, the burdens of RV 
and childhood mortality remain unacceptably high, particularly in world´s poorest developing 
countries because of lower efficacy of the vaccines in the region [7,8]. The use of live-attenuated 
virus also comes with risk of reversion and safety concerns [9]. In addition, current licensed 
vaccines suffer from financial and logistic challenges [2,10].  Both RotarixTM (US$2.5 per dose) 
and RotaTeq® (US$3.50 per dose) are still too expensive for  low-income developing countries even 
at greatly reduced prices offered by the manufacturing companies [10]. Implementation of RV 
vaccination in low-income developing countries is  also still facing logistic challenges due to the 
need of the cold chain system and lack of integrated and well-functioning health systems [2,10].  
The unresolved challenges with the marketed RV vaccines are the driving factors for development 
of alternative vaccines for use in the developing world. Low-income developing countries need 
product development partnerships and technology transfers to stimulate vaccine research, 
development and manufacturing locally at affordable cost. Developing a simple, efficient, low-cost, 
rapid and scalable vaccine platform technology can enable developing countries to get RV vaccines 
at affordable cost from abroad or to manufacture the vaccines locally at home. Therefore, this thesis 
aims to develop non-replicating RV vaccine candidates using the murine polyomavirus VLP and 
capsomere platforms for display of RV10 peptide epitope and an 18 kDa large VP8* antigen from a 
RV spike protein VP8 subunit domain. 
The experimental work reported in this thesis was specifically designed to explore three key aspects 
in the use of the VLP and capsomere platforms for presentation of RV antigenic modules:  
(i) Enhance the stability of modular capsomeres.  A high-throughput screening (HTS) 
method was developed to identify buffer additives for enhancing the stability of modular 
RvVP1 capsomeres presenting three tandem copies of RV10 with polar and charged 
amino acid residues. The developed screening method allowed the rapid identification of 
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additives that could enhance the stability of RvVP1 modular capsomeres during 
downstream processing (Chapter 3). 
 
(ii) Synthetic biology design strategies for RV10 modules.  This preliminary study 
investigated different design options for modules containing a single copy or three 
tandem copies of RV10, based on synthetic biology, with the aim to address the effect of 
the hydrophobicity and charge of RV10 containing modules on protein expression and 
solubility, stability of modular capsomeres, in vitro VLP assembly and stability of in 
vitro assembled modular VLPs. Additionally, the effect of reducing the density of RV10 
modules on a capsomere surface for in vitro assembly of stable modular VLPs was 
investigated (Chapter 4). The immunogenicity of modular capsomeres and modular 
VLPs presenting RV10 was also assessed using a mouse model (Appendix B). 
 
(iii) Simplified bioprocess for capsomeres and VLPs presenting a large antigen. An efficient 
and simple bioprocess was developed through re-engineering of the previously-
established bioprocessing steps of the murine polyomavirus VLP platform. The 
simplified bioprocess allowed production of stable modular CapVP8* and in vitro 
assembled VLP-VP8* presenting a RV 18 kDa VP8* antigenic modules. The preclinical 
mouse immunogenicity trial was carried out for modular CapVP8* and VLP-VP8* 
(Chapter 5). 
RV10 and VP8* were selected as model RV antigens to develop modular capsomeres and VLPs 
in this project as they are targets of neutralizing antibodies during RV infection. Previous 
studies demonstrated that formulations of a modular peptide antigen containing tandem copies 
of RV10 [11] and  VP8*-based subunit vaccines [12] with Freund´s adjuvant elicited a high 
level of virus neutralizing antibodies.  
The following sections describe key findings of this project obtained from experimental work. 
6.1.1. Enhance the stability of modular capsomeres 
Maintaining the stability of proteins against aggregation remains one of the most challenging tasks 
in development of safe and effective protein pharmaceuticals and subunit vaccines [13,14]. The 
poor stability of proteins during downstream processing of RvVP1 modular capsomeres using a 
stability buffer optimized for unmodified VP1 capsomeres (Chapter 3) was a key challenge to 
manufacture modular RV VLPs using a murine polyomavirus VLP platform. The specific causes 
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for poor stability of modular RvVP1 capsomeres are unknown. It was hypothesised that instability 
of RvVP1 capsomeres may be driven by hydrophobic interactions. Thus, maintaining the stability 
of RvVP1 capsomeres can necessitate optimization of the buffer conditions during downstream 
processing. 
A HTS method was developed for rapid identification of buffer additives to increase stability of 
RvVP1. The method, based on DLS analysis to monitor the stability of the capsomeres in the 
presence of additives, has identified additives that could enhance the stability of RvVP1 
capsomeres. Among the various additives tested, non-ionic detergents, TX-100, TW-80 and TW-20, 
either alone or in combination with L-Arg, were able to enhance the stability of RvVP1. Further 
analysis with a high-resolution SEC confirmed an improvement in the stability of modular RvVP1 
capsomeres in the presence of non-ionic detergents in comparison to those processed using a buffer 
without any of the three non-ionic detergents. The results in this study highlighted the necessity of 
tailoring the physicochemical environment specific to each antigenic module for enhanced stability 
of modular capsomeres. The developed HTS method, based on DLS analysis, is simple, fast and 
powerful for rapid identification of non-ionic detergents among various other additives able to 
enhance the stability of modular RvVP1 capsomeres during downstream processing. Non-ionic 
detergents are very mild chemical compounds that do not denature proteins and they stabilize 
proteins, suppress aggregation and assist protein refolding [15-20]. They also prevent adsorption-
induced protein denaturation and aggregation by competing with proteins for hydrophobic surfaces 
and interfaces [15,20]. In addition, they may directly interact with hydrophobic regions in protein 
molecules and reduce their tendency to aggregate [21,22].  
Despite their ability in enhancing the stability of modular RvVP1 capsomeres, the use of non-ionic 
detergents did not increase the purification yield (< 0.5 mg-per-litre of cultures) of 
RvVP1capsomeres (Chapter 3). RvVP1 capsomeres purified in the presence of TX-100, TW-80 or 
TW-20 as stabilizing additives did not form modular VLPs when assembled in vitro (Appendix A). 
The limitation of purification yield after optimization of the downstream processing conditions of 
RvVP1 capsomeres and requirement for sufficiently stable RvVP1 capsomeres for production of 
modular VLP via in vitro assembly highlight the need for an alternative strategy to improve the 
stability and purification yield of modular capsomeres. Synthetic biology design strategies of RV10 
containing modules may be a suitable approach and thus were pursued in this thesis. 
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6.1.2. Synthetic biology design strategies for modules 
Modularization of the murine polyomavirus VP1 capsomere and VLP platforms may affect 
expression and solubility of modular proteins, the stability of capsomeres and/or in vitro assembly 
of VLPs depending upon the physicochemical properties and the density of peptide modules on the 
surface of capsomeres and/or VLPs. As reported in Chapter 3, tailoring the bioprocessing 
conditions specific to the inserted module was not robust in terms of preparing high yields of 
RvVP1 capsomeres for further immunogenicity study or for production of VLPs via in vitro 
assembly. Encouraged by the results in Chapter 3, this thesis investigated synthetic biology design 
strategies for tailoring the physicochemical properties of RV10 modules with the aim of producing 
high yield of modular capsomeres and VLPs. Using synthetic biology, three modules, (RV10)3, 
(RV10)3ESE and G4S-Q25-E4-RV10-E4-P6-G4S, were designed and synthesized at the DNA level 
to examine the effect of the hydrophobicity and charge of modules on protein expression and 
solubility, stability of modular capsomeres and in vitro VLP assembly. Modularization of (RV10)3, 
(RV10)3ESE and G4S-Q25-E4-RV10-E4-P6-G4S at the DNA level for incorporation into the VLP 
platform produced VLP-(RV10)3, VLP-(RV10)3ESE and VLP-RV10 modular constructs, 
respectively. Similarly, modularization of (RV10)3 and (RV10)3ESE into the capsomere platform 
produced Cap(RV10)3 and Cap(RV10)3ESE constructs, respectively (Chapter 4). 
The results in Chapter 4 showed that VLP-(RV10)3 was poorly expressed and no protein was 
detected for Cap-(RV10)3. The total expression level of proteins from VLP-(RV10)3ESE and Cap-
(RV10)3ESE was improved significantly compared to VLP-(RV10)3 and Cap(RV10)3, indicating 
the contribution of E, ESE and ES residues in enhancing protein expression. A drop in protein 
solubility was observed for VLP-(RV10)3ESE in comparison to GST-VP1 whereas the solubility 
was extremely low for proteins from Cap-(RV10)3ESE, showing that protein expression and 
solubility may also be affected by the insertion site and number of inserted modules. Previous study 
demonstrated that both the insertion site and the number of inserted modules affected the expression 
and solubility of GST-tagged capsomeres containing an influenza virus M2e-peptide module [23]. 
Purification of VLP-(RV10)3ESE modular construct using a stability buffer optimized for 
purification VP1 capsomeres did not yield stable modular capsomeres. The use of TX-100 enhanced 
the stability of VLP-(RV10)3ESE modular capsomeres during downstream processing. However, 
the purification yield was very low and VLP-(RV10)3ESE modular capsomeres did not form 
modular VLPs via in vitro assembly (Chapter 4). The result demonstrated that incorporation of the 
polar and charged amino acid residues into the module sequence was not sufficient to reduce the 
hydrophobicity of the module to enhance the stability and purification yield of modular capsomeres. 
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In addition, the presence of TX-100 might affect inter-capsomere interactions and prevent assembly 
of capsomeres into VLPs or aggravate aggregation of in vitro assembled VLPs. 
On the other hand, construct VLP-RV10 expressed good amount of soluble proteins in E. coli and 
resulted in purification of stable modular capsomeres. The expression of soluble protein and the 
stability of modular capsomeres were improved by reducing copy number of RV10 module and 
incorporating ionic linkers. The number of RV10 modules was reduced from three tandem copies to 
one copy with the aim to reduce the stretch of the hydrophobic sequences in (RV10)3 and 
(RV10)3ESE modules. The ionic linkers, G4S-Q25-E4 and E4-P6-G4S were incorporated in order 
to reduce the hydrophobicity of the RV10 module by providing additional charges to the 
hydrophobic RV10 sequence. The longer ionic linkers might also maintain the module structure 
above the surface of capsomeres and avoid structural perturbations that may compromise the 
stability of capsomeres and VLPs.  Previous study has observed that while modular VP1 inserted 
with VP8* using a short flexible linker, G4S did not express VLP, incorporation of longer linkers, 
G4S-Q25 and P6-G4S resulted in formation of stable modular VP8*VLP in vivo using a 
baculovirus-insect cell co-expression system [24]. Structural prediction of modular capsomeres with 
homology modelling confirmed that the longer linkers were able to maintain the structure of VP8* 
module above the surface of VLPs [24]. Although high stability of modular capsomeres were 
observed from construct VLP-RV10 with longer ionic linkers (G4S-Q25-E4 and E4-P6-G4S), the 
capsomeres did not form modular VLPs via in vitro assembly in a cell-free bioreactor (Chapter 4).  
In consideration that the presence of two E4 residues in each module might cause strong 
electrostatic ionic repulsive interactions between capsomeres, preventing assembly of modular 
capsomeres into VLPs, the density of modules on the surface of capsomeres was titrated down via 
co-expression of unmodified VP1 and modular VP1-RV10 in E. coli. The construct, pET-VP1-
RV10 co-expressed soluble unmodified VP1 and modular VP1-RV10 and resulted in high yields of 
stable modular capsomeres, CapRV10. In vitro assembly of CapRV10 resulted in the formation of 
modular VLPs, RV10VLP with an average root-mean-square (r.m.s) radius of 21.4 nm. RV10VLP 
is the first bacterially-produced and in vitro assembled VLP displaying RV10. The results 
demonstrate that reducing the hydrophobicity of RV10 modules using synthetic biology design 
strategies and reducing the density of RV10 modules on the surface of capsomeres via an E. coli co-
expression strategy facilitated formation of stable RV10VLP via in vitro assembly of CapRV10.  
Prior to immunogenicity study in mice, bacterial endotoxins were removed from CapRV10 
solutions using anion exchange. The negatively-charged bacterial endotoxins were bound to a Q 
spin column resin whereas CapRV10 solutions were collected in the flow through fraction. The 
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endotoxin levels in final capsomere solutions were tested using LAL-based assay and were less than 
5 EU per dose of injection used in this study. The capsomere solutions were formulated for 
immunogenicity study and they were also used for production of RV10VLP under endotoxin-free 
conditions via in vitro assembly in a cell-free bioreactor. Endotoxin removal was carried out at the 
capsomere level to avoid encapsulation of endotoxins inside VLPs during assembly. 
Immunizations with 3 doses of 50 µg of CapRV10/AH and 50 µg of RV10VLP elicited low and 
comparable (P = 0.2236) RV10-specific IgG titers (~ 102.5 and 103 for CapRV10/AH and 
RV10VLP, respectively) and the RV10-specific IgG titre elicited by RV10VLP was significantly 
higher than that elicited by the negative control, unmodified VLP (P < 0.05) (Appendix B). Slightly 
high immunogenicity of RV10VLP in comparison to CapRV10/AH might be associated with higher 
density of RV10 modules in RV10VLP than CapRV10. Some studies showed that high epitope 
density effectively enhanced epitope-specific immune response [25] and in vivo protective 
immunity [26]. The titre of RV10-specific antibody induced by RV10VLP however was 
significantly lower than the level of antibody induced by the recombinant peptide antigen 
displaying three tandem copies of RV10 [11]. In order to induce potent immune response, 
formulation of modular capsomeres and VLPs presenting three tandem copies of RV10 might be 
required. Unfortunately, bioprocessing of  modular capsomeres and VLPs from Cap(RV10)3, 
Cap(RV10)3ESE, VLP-(RV10)3 and VLP-(RV10)3ESE became more challenging because of poor 
stability of capsomeres, low yield of capsomeres under optimized bioprocessing conditions and 
failure of these specific modular capsomeres to form VLPs via in vitro assembly. Other alternative 
approaches to improve the immunogenicity of modular capsomeres and VLPs against RV may be 
based on presentation of large conformational RV antigens on the surface of capsomeres and VLPs. 
Previous study has reported that a highly stable and immunogenic RV modular VLP vaccine 
candidate was made inside E. coli based on the combination of a RV VP8* antigen and the 
protrusion (P) domain of the norovirus capsid protein [27]. Lua et al. [24] also successfully 
presented the VP8* antigen on the surface of murine polyomavirus VP1 for production of modular 
VLP-VP8* using a baculovirus-insect cell co-expression system. However, production of modular 
VLP-VP8* inside the expression host cells often suffers from the limitations of yield and 
scalability, complex and expensive bioprocessing steps to commercialize the vaccine candidates for 
use in the developing world. Therefore, developing an alternative process for an efficient, simple 
and low-cost manufacturing of modular capsomeres and VLPs presenting VP8* might facilitate 
further development of the vaccine candidates against RV, particularly for use in the developing 
world. This idea was covered in Chapter 5. 
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6.1.3. Molecular and bioprocess engineering for simplified production of modular VLPs 
presenting a large antigen 
Chapter 4 of this thesis showed the possibility of producing stable CapRV10 and RV10VLP by 
modulating the hydrophobicity of RV10 modules by synthetic biology design strategies and by 
reducing the density of RV10 modules on the capsomere surface through protein co-expression 
strategy in E. coli. But, CapRV10/AH and RV10VLP containing a single copy of RV10 were 
weakly immunogenic (Appendix B). Presentation of large conformational antigen, such as a RV 18 
kDa VP8* antigen, on the surface of capsomere and VLPs can enhance the immune response 
directed against the inserted conformational modules. While modularization of small and relatively 
hydrophilic peptide modules into the murine polyomavirus VLP platform has been well tolerated 
[28-30], the insertion of large antigen has, to the best of our knowledge, only been recently 
achieved, via the use of synthetic biology design for incorporation of VP8* antigen with longer 
linkers [24]. However, the limitations of yield and scalability, process complexity and high cost of 
manufacturing and processing of VLP-VP8* from a baculovirus-insect cell co-expression system 
remain major challenges for further development of VLP-VP8* vaccine. This study attempted to 
use a combination of molecular and bioprocess engineering approaches for simplified production of 
modular CapVP8* and VLP-VP8* from a low-cost E. coli cell factories. CapVP8*/AH and VLP-
VP8* were evaluated for their immunogenicity in vivo in mice. 
The bioprocess used for manufacturing unmodified murine polyomavirus VLP and modular VLPs 
using the VLP platform previously [28] was re-engineered for production of  CapVP8* and VLP-
VP8*. The re-engineered bioprocess (Chapter 5), based on non GST-tagged protein co-expression 
in E. coli and purification of capsomeres using a selective salting-out precipitation and SEC, 
resulted in modular CapVP8* with high purity. This approach is simple and reduces the cost of 
bioprocessing as it does not require affinity chromatography purification and subsequent enzyme-
mediated release of the GST tag, which often add complexity and cost to the platforms used to 
recover capsomeres [31,32].  
After removal of bacterial endotoxins using anion exchange, CapVP8* was formulated as a vaccine 
candidate. It was also assembled into VLPs in vitro using a cell-free bioreactor. Analysis of the 
assembly products for particle size and particle size distribution using AF4 coupled with a multi-
angle light scattering and visualization of particles with TEM  revealed the formation of modular 
VLP-VP8* (r.m.s radius = 21.5 nm). VLP-VP8* was stable against aggregation. Detection of the 
VP8* antigen with anti-VP8* specific monoclonal antibody using dot blot analysis and 
immunogold labelling with gold-conjugated secondary antibody demonstrated presentation of 
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conformational VP8* antigen on the surface of VLP-VP8* (Chapter 5). The result was in agreement 
with the previous study that revealed presentation of conformational VP8* antigen on the surface of 
VLP-VP8* assembled in vivo using the baculovirus-insect cell co-expression system [24]. In 
addition, densitometric analysis of the protein bands corresponding to co-expressed unmodified 
VP1 and modular VP1-VP8* was able to determine the stoichiometric ratio of VP1 and modular 
VP1-VP8* from which the amount of VP8* was estimated for CapVP8* and VLP-VP8* 
formulations. The results presented in this study demonstrate that module titration using an E. coli 
co-expression strategy allowed modularization of capsomeres and VLPs with an 18 kDa VP8* 
module. Moreover, the new simplified bioprocess was simple, efficient and robust for low-cost 
production of modular CapVP8* and in vitro assembled VLP-VP8*. 
CapVP8* and VLP-VP8* were evaluated for their in vivo immunogenicity in mice compared to 
unmodified VLP and VP8* antigen as negative and positive controls, respectively. Immunization 
with 3 doses of 50 µg of CapVP8*/AH and VLP-VP8* elicited comparable (P = 0.6730) and high 
VP8*-specific IgG titres (~105). Strong VP1-specific IgG titres (~106.5) did not suppress induction 
of VP8*-specific immune response against CapVP8* and VLP-VP8* (Chapter 5). These results are 
consistent with previous study [33,34] indicating the presence of a strong pre-existing anti-VP1 
antibody did not interfere with induction of module-specific antibody by modular vaccine 
candidates. However, the VP8*-specific IgG titres elicited by CapVP8*/AH and VLP-VP8* were 
significantly lower (P < 0.05) than those elicited by VP8*/AH used as positive control. The high 
immunogenicity of VP8*/AH might be associated with the high amount of VP8* (~ 30 µg per 3 
doses) for VP8*/AH formulation that is greater than the amount of VP8* (~ 4.5 µg per 3 doses) for 
CapVP8*/AH and VLP-VP8* formulations. VLP-VP8* elicited high and comparable levels of 
VP8*-specific IgG titres like those elicited by CapVP8*/AH, indicating the self-adjuvanting 
property of VLP-VP8*. This result is in agreement with a previous study that demonstrated self-
adjuvanting property of modular VLP presenting J8-peptide modules from group A streptococcus 
[30]. The in vivo immunogenicity result for CapVP8*/AH and VLP-VP8* showed the promising 
potential of modularization of weakly immunogenic large VP8* antigen into viral capsomeres and 
VLPs for eliciting high VP8*-specific IgG titre at extremely low dose of VP8*. Interestingly, VLPs 
with self-adjuvanting property will have huge potential for delivery of adjuvant-free vaccines 
against RV and other various target diseases. 
This study introduces, to the best of our knowledge, the first bacterially-produced in vitro 
assembled and immunogenic VLP-VP8* displaying an 18 kDa large RV VP8* antigen. In addition, 
the efficiency and simplicity of the new developed bioprocess for production of CapVP8* and VLP-
VP8* will facilitate further development of CapVP8* and VLP-VP8* vaccines and other potential 
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modular vaccine candidates. It will also enable low-income developing countries to participate in 
vaccine research, development and manufacturing, and to use the final products at affordable cost. 
6.2. Overall conclusion and future work   
The high global burden of RV [35-37], the unresolved challenge with marketed live-attenuated oral 
RV vaccines, particularly in the developing regions [7,9,10,38], fluctuations in RV G/P-genotype 
that also vary by geography and season [39,40] and the emergence of unusual RV strains [39,41,42] 
have ignited efforts for the development of next-generation RV vaccines for targeting 
geographically relevant, serotype-specific as well as heterotypic protection. Among the next-
generation RV vaccine candidates under development, RLPs have received attention from various 
academic and public health organizations for their huge potential in inducing strong immune 
response and good protective efficacy [43-45]. Studies have also demonstrated development of 
highly stable modular VLPs containing a RV VP8* antigen as vaccine candidates against RV 
[24,27]. The modular VLPs have also induced strong VP8*-specific antibody response in mice [27]. 
Production of both RLPs and modular VLPs inside the expression host cell by using recombinant 
DNA techniques however remains as a major bottleneck for further development of the VLP 
vaccine candidates. It often suffers from limitations of yield and scalability, and high bioprocessing 
cost [24,27,46]. Simplifying process scalability and increasing final product yield, while 
simultaneously reducing manufacturing and processing cost, are very crucial factors for 
commercialization of VLP-based vaccines against RV, particularly in the developing world. 
Therefore, this project attempted to develop novel next-generation RV vaccine candidates using 
simple, low-cost and scalable murine polyomavirus capsomere and VLP platforms. 
The murine polyomavirus VP1 capsomere and VLP platforms have demonstrated huge potential for 
mass-scale production of modular capsomere [23,28] and modular VLP [28,30,33] vaccine 
candidates. However, depending upon the physicochemical properties, size and the surface density 
of modules, modularization may affect protein expression and solubility, the stability of capsomeres 
or in vitro VLP assembly, in a way that cannot presently be predicted. Modularization of different 
designs of hydrophobic RV10 modules into the capsomere and VLP platforms in this thesis affected 
protein expression and solubility, the stability of capsomeres or in vitro VLP assembly. The results 
in Chapter 3 concluded that tailoring of the solution conditions using non-ionic detergents as 
additives enhanced the stability of modular RvVP1 capsomeres. But, modular RvVP1 capsomeres 
did not form VLPs when assembled in vitro in the presence of non-ionic detergents as additives 
(Appendix A). The final purification yield of modular RvVP1capsomeres would also still remain 
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low to obtain sufficient capsomere materials for in vivo immunogenicity study and/or for 
manufacturing of modular VLPs via in vitro assembly. 
The use of different synthetic biology design strategies for RV10 modules in Chapter 4 enabled an 
increase the charge of RV10 module and to insert ionic linkers as flanking elements for stabilization 
of modular capsomeres and VLPs presenting RV10 modules. In addition, titrating down the density 
of RV10 modules on the surface of capsomeres via co-expression of unmodified VP1 and modular 
VP1-RV10 in E. coli resulted in highly stable CapRV10 and in vitro assembled RV10VLP. 
Immunization of mice with 3 doses of CapRV10/AH and RV10VLP elicited low and comparable 
RV10-specific antibody (Appendix B). The immunogenicity of CapRV10/AH and RV10VLP was 
significantly lower than previously published result for the peptide antigen displaying three tandem 
copies of RV10 [11]. This result suggested presentation of large conformational RV antigens to 
enhance the immune response against modular capsomeres and VLPs.  
As described in Chapter 5 of this thesis, module titration strategy using an E. coli co-expression and 
re-engineering of the bioprocessing steps of the VLP platform resulted in modular CapVP8* 
presenting a RV 18 kDa VP8* module with high purity that were able to form modular VLP-VP8* 
via in vitro assembly. The simplified new bioprocess was simple, efficient and cost-effective for 
production of modular capsomeres and VLPs. Both CapVP8*/AH and VLP-VP8* induced high 
levels of VP8*-specific antibodies. The results demonstrate the promising potential of CapVP8* 
and VLP-VP8*, with high stability, purity and immunogenicity, as viable RV vaccine candidate for 
further development. Interestingly, adjuvant-free VP8*VLP with high VP8*-specific antibody titre 
presents an ideal promise for further development of a parenterally or sublingually administered 
prophylactic vaccine against RV infection in the developing world. Before taking CapVP8*/AH 
and/or VLP-VP8* to clinical trials, further studies are needed to prove the concepts and generate 
supporting data on some of the following key aspects: 
(i) Both CapVP8*/AH and VLP-VP8* induced production of high VP8*-specific antibody 
levels, suggesting their potential virus neutralization activity and/or protective efficacy. 
The virus neutralization titres must be determined using an in vitro cell-culture-based 
fluorescent focus reduction neutralization assay. The preclinical protective efficacy of 
CapVP8*/AH and VLP-VP8* against RV infection must be determined using 
appropriate animal models.  Protection against diarrhoea should also be determined 
using the neonatal gnotobiotic pig model or the neonatal mice passive protection model. 
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(ii) An optimum formulation for CapVP8* and VLP-VP8* must be determined for best 
neutralization activity or protective efficacy and stability. Vaccines as liquid dosage 
forms are bulk, and need high cost for transportation in distribution, particularly for use 
in the developing world where there is poor infrastructure. CapVP8* and VLP-VP8* 
should be formulated as lyophilized dosage forms to eliminate the cold chain system for 
delivery of the vaccines to the developing regions. Furthermore, different delivery routes 
must be investigated. There may be potential to develop a sublingual delivery method, 
enabling simpler vaccine delivery for inducing mucosal immunity and easier 
administration of the vaccine in comparison to parenteral delivery systems.  
 
(iii) The result in Chapters 4 and 5 of this thesis demonstrated that titrating down the density 
of RV10 and VP8* modules on the surfaces of capsomeres via E. coli co-expression of 
unmodified VP1 and modular VP1-RV10 or VP1-VP8* enhanced the stability of 
modular capsomeres and facilitated in vitro assembly of modular VLPs. However, 
formation of capsomeres inside the cell from assembly of co-expressed VP1 and 
modular VP1 using a single bicistronic vector system is a random, uncontrolled and 
complex phenomenon. It often results in mixtures of VP1 capsomeres, modular VP1 
capsomeres or capsomeres containing both VP1 and modular VP1 monomers at different 
ratios. Further study on vector engineering is therefore required to reduce the diversity of 
capsomeres assembled inside the expression host cells during co-expression of 
unmodified VP1 and modular VP1. Alternatively, the capsomere with the desired 
stoichiometric ratio of unmodified VP1 and modular VP1 may be purified and separated 
from mixtures of capsomeres. This also required further study to develop a method for 
purification and separation of the desired modular capsomeres.  
 
(iv) The bioprocess developed in this thesis (Chapter 5) allowed production of highly 
immunogenic modular CapVP8* and VLP-VP8* with high purity. However, the use of 
SEC for separation of capsomeres from misfolded protein aggregates and co-purified E. 
coli proteins still makes the overall process somewhat complex and costly to adopt the 
bioprocess for manufacturing of vaccines for the developing world. Therefore, further 
study is required to optimize the selective salting-out precipitation or to develop other 
non-chromatographic methods, such as filtration, for production of high yield of pure 
capsomeres and in vitro assembled VLPs without using any chromatographic-based 
purification steps.  
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In conclusion, the experimental work in this thesis highlights the potential of tailoring of bioprocess 
conditions, biomolecular design or redesign of modules using synthetic biology, module titration 
strategy and bioprocess engineering for simple and low-cost production of stable capsomeres and 
VLPs presenting RV10 or VP8*. The experimental findings in this thesis along with the proof of 
concepts and data that will be generated from the suggested future works should be extended to 
manufacturing of modular capsomeres and VLPs presenting a wide range of RV peptide epitopes, 
RV antigens or chimeric modules containing multiple RV peptide epitopes and/or antigens. The 
candidates for future studies may include, particularly, presentation of peptide epitopes, antigens, 
chimeric peptide modules or chimeric antigenic modules derived from the RV VP4, VP7, VP6 and 
NSP4 proteins on the capsomere and VLP platforms. Such vaccine design and production strategies 
can allow delivery of safe, effective and low-cost vaccines against geographically and seasonally 
relevant RV strains at a global scale.  
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Appendix A 
Characterization of in vitro assembled products of modular RvVP1 
capsomeres 
Modular RvVP1 capsomeres were purified by SEC in the presence of non-ionic detergents as 
stabilizing additive in L-buffer described in Section 3.2.7, Chapter 3. After in vitro assembly, the 
capsomeres did not form modular VLPs, as analyzed on TEM (Fig. A2, A3 and A4).  VP1 
capsomeres were assembled in vitro into VLPs as indicated by arrows (Fig. A1). The specific 
causes preventing modular VLP assembly are unknown. One possibility is the hydrophobic-
hydrophobic interactions between surface exposed RV10 elements, driving the formation of 
aggregates. Thus, surface display of RV10 modules necessitates engineering of the hydrophobicity 
of the modules to maintain capsomeres stability in compatible VLP assembly buffer. The idea of 
engineering the hydrophobicity of RV10 modules was covered in Chapter 4 of this thesis.  
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Figure A. Characterization of in vitro assembled products of capsomeres by transmission electron microscope (TEM). 
TEM micrographs of in vitro assembled products of (1) unmodified VP1 capsomeres purified using TX-100 as buffer 
additive; (2) RvVP1 capsomeres purified using TX-100 as buffer additive; (3) RvVP1 capsomeres purified using TW-80 
as buffer additive; and (4) RvVP1 capsomeres purified using TW-20 as buffer additive.  
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Appendix B 
Immunogenicity of modular CapRV10 and RV10VLP 
Modular CapRV10 and RV10VLP produced as reported in Chapter 4 of this thesis were evaluated 
for their immunogenicity in mice. Balb/c mice immunized with 3 doses of 50 µg of CapRV10/AH 
and 50 µg of RV10VLP elicited low and comparable (P = 0.2236) RV10-specific IgG titers (~ 102.5 
and 103 for CapRV10/AH and RV10VLP, respectively). The anti-RV10-specific IgG titer elicited 
by RV10VLP was significantly higher than that elicited by unmodified VLP used as a negative 
control (P < 0.05) (Fig. B).  
 
Figure B. RV10-specific total IgG titres. RV10-specific IgG titres induced in mice following three subcutaneous 
immunizations with CapRV10/AH, RV10VLP, unmodified VLP (as a negative control), separately. Statistical analysis of 
antibody titres after the third immunization is presented.  *P < 0.05 indicates significant difference between the 
antibody titres of groups, ns indicates no significant differences. 
Previously, Kovacs et al. [1] demonstrated that the recombinant peptide displaying a single copy of 
RV10 induced significantly lower titers of RV10-specific antibody in comparison to a peptide 
antigen displaying three tandem copies of RV10. These results suggested the need to increase the 
ratio of antigen with respect to the carrier peptide. Modular capsomere and VLP displaying three 
tandem copies of RV10 were not included in this study since they were not stable against 
aggregation as described in Chapter 4. Low RV10-specific immune response against CapRV10 and 
RV10VLP might be due to low RV10 module to VP1 ratio. RV10 might be also less accessible to 
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the surface; rather it might be buried into the inner part of the protein to avoid exposure of its 
hydrophobic amino acids to the solvent and thus, the longer linkers might sterically inhibit binding 
of B-cell receptor or antibody to RV10. Slightly high immunogenicity of RV10VLP in comparison 
to CapRV10/AH might be associated with higher density of RV10 modules in RV10VLP than 
CapRV10. Studies showed that high density M2e-peptide module effectively enhanced M2e-
specific immune response [2] and in vivo protective immunity [3]. These results suggest the need to 
tandem display of the RV10 module or other large antigenic modules for effective immune response 
against RV. Thus the idea of presenting large antigenic modules is covered in Chapter 5.  
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